data_1orx_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1orx _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 121.381 0.61 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.58 24.25 67.69 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.725 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -116.9 152.02 35.38 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 115.266 -0.467 . . . . 0.0 110.608 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.405 HG21 ' O ' ' A' ' 21' ' ' PRO . 78.4 p -111.89 142.61 44.07 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.595 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.1 p -118.58 42.32 2.78 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.463 0.649 . . . . 0.0 110.403 178.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.423 HG23 ' HA ' ' A' ' 21' ' ' PRO . 25.1 t -55.58 -22.57 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.261 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.86 24.85 28.32 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.412 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.51 37.28 88.14 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.582 -0.309 . . . . 0.0 112.378 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.57 140.44 21.87 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 90.1 m -128.83 135.06 48.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.237 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -82.42 -38.13 24.49 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.602 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.495 HG22 ' SG ' ' A' ' 16' ' ' CYS . 3.1 m -66.9 114.9 20.09 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.571 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.36 -45.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.968 2.446 . . . . 0.0 113.789 -177.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.09 39.32 2.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.38 -0.914 . . . . 0.0 112.087 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.495 ' SG ' HG22 ' A' ' 13' ' ' THR . 89.6 m -143.37 131.39 21.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.128 0.489 . . . . 0.0 111.779 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.708 HG23 ' HB ' ' A' ' 24' ' ' THR . 9.2 t -89.79 -153.34 0.28 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.0 t -154.61 131.67 10.96 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.7 m -91.59 -53.24 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.625 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 178.96 -69.74 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.671 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.393 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.625 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.3 Cg_endo -97.99 11.36 0.94 Allowed 'Trans proline' 0 N--CA 1.44 -1.619 0 CA-C-N 120.546 1.231 . . . . 0.0 111.482 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.6 m -152.49 130.63 2.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.188 0.518 . . . . 0.0 111.881 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.5 m -81.47 113.39 19.5 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.708 ' HB ' HG23 ' A' ' 17' ' ' THR . 1.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.337 -178.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.492 ' SG ' HG23 ' A' ' 13' ' ' THR . 71.1 m . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 121.075 0.464 . . . . 0.0 110.36 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.01 13.07 72.32 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.245 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -98.09 151.7 20.09 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.104 -0.548 . . . . 0.0 109.748 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -105.97 143.83 33.56 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.849 0.357 . . . . 0.0 110.133 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.559 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.0 p -119.38 42.29 2.89 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.367 0.603 . . . . 0.0 110.203 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.6 t -54.94 -22.53 10.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.324 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.78 25.2 26.27 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.463 178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.94 36.74 89.35 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.524 -0.338 . . . . 0.0 112.417 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.69 140.45 21.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.2 m -127.13 132.61 50.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.162 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -81.65 -34.7 30.65 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.492 HG23 ' SG ' ' A' ' 2' ' ' CYS . 0.3 OUTLIER -76.48 115.33 46.61 Favored Pre-proline 0 N--CA 1.449 -0.476 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.914 179.318 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -62.11 -37.9 60.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 123.11 2.54 . . . . 0.0 113.858 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.99 33.93 1.47 Allowed Glycine 0 C--N 1.322 -0.202 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.801 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.0 m -150.71 140.29 21.59 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.123 0.487 . . . . 0.0 112.002 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -90.08 -149.38 0.2 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.2 t -156.82 128.37 7.07 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.051 -0.659 . . . . 0.0 112.519 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.5 m -92.13 -52.13 4.85 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 178.77 -70.04 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.703 0 CA-C-N 113.825 -1.534 . . . . 0.0 110.121 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.8 Cg_endo -97.99 11.17 0.96 Allowed 'Trans proline' 0 N--CA 1.439 -1.733 0 CA-C-N 120.632 1.261 . . . . 0.0 111.51 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 21' ' ' PRO . 3.6 m -152.54 130.73 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 CA-C-O 121.45 0.643 . . . . 0.0 112.335 -178.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.7 m -84.67 80.57 9.2 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.651 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.113 -178.402 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.536 ' SG ' HG21 ' A' ' 13' ' ' THR . 19.5 m . . . . . 0 CA--C 1.522 -0.119 0 CA-C-O 120.807 0.337 . . . . 0.0 110.343 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.74 23.85 65.75 Favored Glycine 0 C--N 1.334 0.44 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -94.71 155.35 16.88 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.717 -0.742 . . . . 0.0 110.28 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.413 HG21 ' O ' ' A' ' 21' ' ' PRO . 82.2 p -108.85 142.55 39.27 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.556 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.7 p -119.95 42.28 2.97 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.324 0.583 . . . . 0.0 110.352 178.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.514 HG21 ' HA ' ' A' ' 21' ' ' PRO . 25.5 t -54.24 -22.55 8.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.402 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.55 24.95 27.28 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.446 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.96 36.41 87.95 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.478 -0.361 . . . . 0.0 112.475 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.76 140.45 21.71 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.556 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 98.2 m -126.56 132.41 51.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.598 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -80.18 -40.06 28.0 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.776 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.536 HG21 ' SG ' ' A' ' 2' ' ' CYS . 1.5 m -76.08 116.71 58.27 Favored Pre-proline 0 N--CA 1.45 -0.451 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.171 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.1 -37.3 64.73 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 123.23 2.62 . . . . 0.0 113.734 -178.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.31 35.46 1.32 Allowed Glycine 0 CA--C 1.517 0.195 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.781 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.7 m -150.82 141.01 22.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.107 0.479 . . . . 0.0 111.635 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.69 -145.78 0.15 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.6 t -166.45 133.06 2.49 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.867 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 p -103.48 -53.01 2.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 107.562 -1.274 . . . . 0.0 107.562 177.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.618 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.8 t90 -177.87 -69.46 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.731 0 CA-C-N 114.329 -1.305 . . . . 0.0 111.013 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.618 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.6 Cg_endo -97.39 9.5 1.22 Allowed 'Trans proline' 0 N--CA 1.439 -1.702 0 CA-C-N 121.104 1.43 . . . . 0.0 111.727 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 21' ' ' PRO . 3.9 m -151.35 132.91 5.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-O 121.531 0.682 . . . . 0.0 111.063 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 66.6 m -76.87 59.29 1.59 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.75 -1.113 . . . . 0.0 110.739 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.326 -0.435 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.977 -179.774 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.2 m . . . . . 0 CA--C 1.52 -0.191 0 CA-C-O 121.189 0.518 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.99 24.02 75.9 Favored Glycine 0 N--CA 1.448 -0.552 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.531 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -118.02 152.06 36.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.158 -0.521 . . . . 0.0 110.194 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 59.5 p -110.72 142.13 43.07 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.551 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.78 42.77 2.55 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-O 121.37 0.605 . . . . 0.0 110.452 178.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.3 t -54.96 -22.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.388 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.27 25.09 27.16 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.815 -0.707 . . . . 0.0 111.442 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.23 37.04 85.54 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.489 -0.355 . . . . 0.0 112.522 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.54 140.46 21.92 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.6 m -126.96 134.56 50.37 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.233 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -86.68 -37.22 18.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.685 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.551 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 2.6 m -61.77 116.89 23.57 Favored Pre-proline 0 C--O 1.236 0.344 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.504 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 15.9 Cg_exo -68.52 114.78 3.6 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.597 2.198 . . . . 0.0 112.887 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.61 -8.71 28.15 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.469 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.551 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 86.0 m -89.0 134.69 33.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.71 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.635 HG22 ' HA ' ' A' ' 24' ' ' THR . 11.5 t -88.94 -159.71 0.59 Allowed 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 26.2 t -156.38 131.62 9.29 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 119.922 -0.711 . . . . 0.0 112.907 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.9 t -93.74 -53.01 4.2 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 176.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.625 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 179.23 -69.61 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.728 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.21 175.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.625 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.8 Cg_endo -98.06 12.04 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.627 0 CA-C-N 120.634 1.262 . . . . 0.0 111.497 -178.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.434 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.4 131.37 3.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.844 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 90.9 m -82.17 119.87 24.61 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.307 -0.861 . . . . 0.0 108.758 178.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.635 ' HA ' HG22 ' A' ' 17' ' ' THR . 48.3 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.696 -178.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.61 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 5.9 m . . . . . 0 N--CA 1.456 -0.169 0 CA-C-O 121.237 0.542 . . . . 0.0 109.951 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.43 23.16 75.13 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.41 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 31.9 tt0 -122.13 148.58 44.73 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.281 -0.46 . . . . 0.0 110.144 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 63.2 p -107.8 142.8 37.28 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.205 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.593 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -116.66 41.76 2.61 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.337 0.589 . . . . 0.0 110.385 178.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.6 t -54.85 -22.31 9.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.394 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.47 25.78 23.55 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.808 -0.71 . . . . 0.0 111.403 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.15 37.07 91.2 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.584 -0.308 . . . . 0.0 112.43 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.64 140.24 21.6 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.593 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 76.0 m -128.95 133.69 47.92 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.296 178.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.41 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.4 m-80 -81.21 -33.17 33.09 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 179.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.463 HG21 ' SG ' ' A' ' 16' ' ' CYS . 1.2 m -69.39 114.26 22.72 Favored Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.316 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -61.85 -46.05 14.85 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.982 2.455 . . . . 0.0 113.991 -177.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.36 2.7 Favored Glycine 0 CA--C 1.508 -0.355 0 C-N-CA 120.306 -0.949 . . . . 0.0 111.938 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.463 ' SG ' HG21 ' A' ' 13' ' ' THR . 77.3 m -142.62 132.38 24.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.176 0.513 . . . . 0.0 112.147 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.541 HG23 ' O ' ' A' ' 24' ' ' THR . 15.4 t -89.71 -162.19 0.86 Allowed 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 177.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 18.1 t -148.86 129.29 13.87 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 119.887 -0.725 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 m -89.8 -52.69 4.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.638 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.85 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.695 0 CA-C-N 113.877 -1.511 . . . . 0.0 110.363 175.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.638 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.2 Cg_endo -98.41 9.8 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.664 0 CA-C-N 120.524 1.223 . . . . 0.0 111.792 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.9 m -152.67 132.23 3.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.8 m -93.38 136.24 33.84 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 176.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.61 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.8 t . . . . . 0 C--N 1.323 -0.554 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.384 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.968 0.414 . . . . 0.0 109.95 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.5 24.97 71.24 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -111.57 154.44 24.82 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.017 -0.591 . . . . 0.0 110.163 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.423 HG23 ' O ' ' A' ' 21' ' ' PRO . 81.4 p -113.25 143.77 43.85 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -122.95 43.41 2.94 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.384 0.611 . . . . 0.0 110.315 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.4 t -53.72 -22.39 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 114.702 -1.135 . . . . 0.0 110.823 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.08 23.19 25.93 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.692 -0.766 . . . . 0.0 111.606 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.72 36.28 93.08 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 112.345 -0.302 . . . . 0.0 112.345 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.4 p -141.98 134.06 27.54 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 99.2 m -127.34 132.8 50.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.964 177.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -83.1 -37.72 23.42 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.732 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.581 HG22 ' SG ' ' A' ' 16' ' ' CYS . 3.3 m -67.3 115.25 24.28 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -60.4 -47.92 12.93 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.936 2.424 . . . . 0.0 113.77 -178.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.27 39.84 2.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.971 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.581 ' SG ' HG22 ' A' ' 13' ' ' THR . 97.7 m -141.88 133.2 26.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.313 0.578 . . . . 0.0 112.134 -179.022 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.708 HG21 ' HA ' ' A' ' 24' ' ' THR . 9.8 t -89.89 -154.58 0.33 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.3 t -155.86 129.44 8.39 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 121.702 -0.624 . . . . 0.0 112.41 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.9 m -91.76 -53.32 4.34 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.8 t90 179.01 -69.85 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.754 0 CA-C-N 113.826 -1.534 . . . . 0.0 110.241 175.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -97.62 11.4 1.02 Allowed 'Trans proline' 0 N--CA 1.44 -1.652 0 CA-C-N 120.671 1.275 . . . . 0.0 111.392 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.442 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.7 m -152.82 131.58 2.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.825 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 95.3 m -76.38 122.1 23.99 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.708 ' HA ' HG21 ' A' ' 17' ' ' THR . 97.1 m . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.324 -177.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.606 ' SG ' HG21 ' A' ' 13' ' ' THR . 57.1 m . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.973 0.415 . . . . 0.0 110.338 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.05 21.6 71.82 Favored Glycine 0 C--N 1.333 0.398 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.949 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.405 ' HB3' ' HB2' ' A' ' 23' ' ' CYS . 87.4 tt0 -97.6 160.0 14.58 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.831 -0.685 . . . . 0.0 109.481 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.8 p -113.67 141.69 46.92 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.526 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.7 p -117.92 42.85 2.55 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.304 0.573 . . . . 0.0 110.458 178.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -54.95 -22.41 10.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.367 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.38 25.88 23.38 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.441 178.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.5 37.0 87.35 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.432 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.6 140.76 22.17 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 73.8 m -127.18 131.49 50.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.258 178.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -78.99 -38.35 36.99 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.606 HG21 ' SG ' ' A' ' 2' ' ' CYS . 1.4 m -75.27 116.06 50.97 Favored Pre-proline 0 N--CA 1.45 -0.461 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.988 179.281 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -61.46 -38.15 65.68 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 123.182 2.588 . . . . 0.0 113.852 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.89 35.19 1.44 Allowed Glycine 0 C--O 1.228 -0.253 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.651 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.462 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 4.3 m -151.0 135.74 17.24 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.056 0.455 . . . . 0.0 111.957 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 24' ' ' THR . 13.7 t -89.29 -157.54 0.46 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.3 t -146.55 128.02 15.01 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 119.575 -0.85 . . . . 0.0 113.124 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.6 m -89.83 -52.83 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.647 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.9 t90 178.62 -69.9 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.717 0 CA-C-N 113.742 -1.572 . . . . 0.0 110.082 175.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.647 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.87 12.07 0.72 Allowed 'Trans proline' 0 N--CA 1.44 -1.668 0 CA-C-N 120.55 1.232 . . . . 0.0 111.573 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG23 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.29 132.82 4.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.668 0.747 . . . . 0.0 112.928 -178.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 83.9 m -96.57 124.99 40.73 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.809 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.485 ' O ' HG23 ' A' ' 17' ' ' THR . 9.1 t . . . . . 0 C--N 1.324 -0.533 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.288 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.637 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 9.3 m . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 121.235 0.54 . . . . 0.0 109.939 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 69.31 22.3 76.2 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.875 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.413 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 33.1 tt0 -123.07 149.82 43.94 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.265 -0.467 . . . . 0.0 110.222 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.408 HG21 ' O ' ' A' ' 21' ' ' PRO . 59.9 p -110.38 144.3 39.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.294 -0.412 . . . . 0.0 109.892 178.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.65 41.97 2.72 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.384 0.611 . . . . 0.0 110.33 178.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 t -55.17 -22.59 11.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.304 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.64 25.46 25.6 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.464 178.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.95 36.7 89.22 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.529 -0.336 . . . . 0.0 112.577 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 140.72 22.0 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.5 m -128.88 133.66 48.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.355 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . 0.413 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.3 m-80 -81.49 -33.08 32.13 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.13 114.35 22.88 Favored Pre-proline 0 CA--C 1.535 0.377 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.227 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -62.08 -45.98 14.38 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.952 2.435 . . . . 0.0 114.002 -177.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.08 2.67 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.951 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.7 m -142.93 132.17 23.29 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.198 0.523 . . . . 0.0 112.088 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.539 HG22 ' O ' ' A' ' 24' ' ' THR . 15.2 t -89.73 -161.51 0.79 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 17.1 t -149.14 129.47 13.77 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 119.873 -0.731 . . . . 0.0 112.798 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.4 m -89.85 -52.57 4.91 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.75 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.66 0 CA-C-N 113.821 -1.536 . . . . 0.0 110.274 175.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.9 Cg_endo -98.69 10.81 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.676 0 CA-C-N 120.502 1.215 . . . . 0.0 111.805 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.8 m -153.14 133.46 4.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.444 0.64 . . . . 0.0 112.669 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.4 m -95.07 136.3 35.56 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 176.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.637 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.1 t . . . . . 0 C--N 1.323 -0.549 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.394 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 m . . . . . 0 N--CA 1.456 -0.156 0 CA-C-O 121.078 0.466 . . . . 0.0 109.824 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.83 28.17 73.05 Favored Glycine 0 C--N 1.334 0.431 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.813 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -122.44 150.08 42.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.13 -0.535 . . . . 0.0 109.976 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 21' ' ' PRO . 72.0 p -109.37 143.46 38.89 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.381 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.615 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.4 p -117.78 41.13 2.94 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.359 0.6 . . . . 0.0 110.562 178.219 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.3 t -54.76 -21.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.587 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.2 25.33 23.86 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.476 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 61.2 36.83 93.0 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.572 -0.314 . . . . 0.0 112.348 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.62 142.48 23.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.235 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.615 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.6 m -133.1 130.6 39.51 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -78.33 -30.39 48.18 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.743 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.6 OUTLIER -77.68 113.99 37.16 Favored Pre-proline 0 N--CA 1.45 -0.452 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 177.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -63.91 -45.06 11.32 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 123.074 2.516 . . . . 0.0 114.593 -177.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.17 45.72 2.6 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.468 -0.873 . . . . 0.0 112.498 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.743 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 56.7 m -136.89 127.64 27.22 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.324 0.583 . . . . 0.0 112.545 -178.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.6 p -89.71 114.64 26.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.264 178.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.6 t -77.24 127.3 32.37 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 m -93.19 -52.46 4.54 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.627 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 179.14 -69.21 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.734 0 CA-C-N 113.965 -1.47 . . . . 0.0 110.451 175.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.627 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.9 Cg_endo -97.94 8.48 1.15 Allowed 'Trans proline' 0 N--CA 1.439 -1.692 0 CA-C-N 120.443 1.194 . . . . 0.0 111.653 -178.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 21' ' ' PRO . 5.1 m -152.36 134.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.583 0.706 . . . . 0.0 112.309 -178.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 67.5 m -89.85 100.4 13.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.528 ' HG1' ' HA ' ' A' ' 16' ' ' CYS . 90.9 m . . . . . 0 N--CA 1.464 0.25 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.868 -177.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 121.298 0.571 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 66.44 23.53 71.93 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.307 -0.86 . . . . 0.0 112.352 179.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -113.56 153.85 28.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 58.2 p -113.6 142.83 45.5 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 6.3 p -119.25 43.99 2.46 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.186 0.517 . . . . 0.0 110.475 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.1 t -52.89 -21.73 3.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.96 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -111.52 25.06 14.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.697 -0.764 . . . . 0.0 111.671 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.46 36.01 92.53 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.619 -0.291 . . . . 0.0 112.444 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.7 p -140.53 134.75 31.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.6 m -129.97 130.38 44.98 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.556 177.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.7 m-80 -80.4 -40.05 27.17 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.251 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.792 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.9 OUTLIER -72.61 116.81 53.5 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.59 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -63.68 -45.67 10.65 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.209 2.606 . . . . 0.0 114.901 -176.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.72 44.95 2.61 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.388 -0.91 . . . . 0.0 112.368 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.792 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 20.0 m -139.48 129.63 25.19 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.855 0.359 . . . . 0.0 111.947 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -93.07 141.38 28.47 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 39.7 t -95.02 125.18 39.51 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 m -93.51 -52.88 4.29 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 176.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.645 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.02 -70.92 0.0 OUTLIER Pre-proline 0 C--O 1.213 -0.831 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.963 175.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.645 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.9 Cg_endo -98.49 12.92 0.74 Allowed 'Trans proline' 0 N--CA 1.44 -1.625 0 CA-C-N 120.738 1.299 . . . . 0.0 111.348 -178.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.443 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.5 133.09 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-O 121.453 0.644 . . . . 0.0 112.417 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.548 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 78.2 m -90.72 57.79 3.68 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.044 177.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 21.4 m . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 121.242 0.544 . . . . 0.0 111.474 -178.865 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 32.6 m . . . . . 0 N--CA 1.456 -0.171 0 CA-C-O 120.742 0.306 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.11 33.38 87.1 Favored Glycine 0 C--N 1.333 0.38 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 3.2 tp10 -127.28 151.96 48.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.804 -0.698 . . . . 0.0 110.0 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.431 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -113.79 144.59 42.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.385 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.486 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.4 p -119.39 40.66 3.29 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.289 0.566 . . . . 0.0 110.319 178.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.403 HG21 ' HB ' ' A' ' 5' ' ' THR . 23.6 t -55.61 -21.93 11.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.227 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.81 26.25 21.58 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.519 178.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.01 36.59 89.05 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.661 -0.27 . . . . 0.0 112.482 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.55 140.86 22.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.486 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.0 m -124.99 123.87 40.78 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.178 178.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -73.59 -35.02 65.35 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.109 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.609 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -71.45 116.69 49.98 Favored Pre-proline 0 C--O 1.234 0.261 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.438 179.61 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.86 119.83 6.08 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.443 2.095 . . . . 0.0 112.948 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.06 -8.29 31.27 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.916 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.609 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.3 m -88.92 130.89 35.35 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.977 0.418 . . . . 0.0 111.518 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -88.11 144.93 26.21 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 36.5 t -103.17 132.01 49.76 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 113.731 1.011 . . . . 0.0 113.731 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 m -95.97 -52.66 3.96 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 176.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.635 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.5 t90 178.99 -69.63 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.667 0 CA-C-N 113.708 -1.587 . . . . 0.0 110.467 175.423 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.635 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.1 9.94 1.02 Allowed 'Trans proline' 0 N--CA 1.442 -1.544 0 CA-C-N 120.567 1.238 . . . . 0.0 111.615 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.429 HG11 ' O ' ' A' ' 21' ' ' PRO . 4.8 m -152.39 135.18 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.62 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.504 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 84.7 m -90.04 37.74 0.9 Allowed 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.277 178.592 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 25.8 m . . . . . 0 C--O 1.238 0.468 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.525 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.583 ' SG ' HG21 ' A' ' 13' ' ' THR . 82.7 m . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.906 0.384 . . . . 0.0 110.409 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.23 28.87 74.06 Favored Glycine 0 C--N 1.334 0.418 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.112 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -112.12 147.78 35.37 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.653 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 78.8 p -101.73 142.62 32.79 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 120.688 0.28 . . . . 0.0 110.44 179.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.493 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.1 p -119.72 42.7 2.84 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 121.313 0.578 . . . . 0.0 110.198 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.7 t -52.51 -21.96 3.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.93 -1.032 . . . . 0.0 111.136 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -109.74 24.62 19.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.549 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.67 36.31 93.09 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 112.235 -0.346 . . . . 0.0 112.235 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.2 p -142.04 133.85 27.13 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -179.036 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.493 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.5 m -126.58 129.09 47.88 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 177.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 -81.21 -34.53 32.19 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.583 HG21 ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -77.59 117.31 64.79 Favored Pre-proline 0 N--CA 1.447 -0.589 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.862 179.245 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -63.38 -39.53 36.64 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 123.169 2.579 . . . . 0.0 113.878 -178.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.69 33.6 1.2 Allowed Glycine 0 C--N 1.321 -0.28 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.815 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 11.0 m -150.9 135.04 16.8 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.957 0.408 . . . . 0.0 111.816 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.9 t -89.12 -161.22 0.74 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 35.1 t -144.29 130.78 19.92 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.951 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.7 t -93.35 -52.81 4.35 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 176.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.7 t90 179.3 -70.16 0.0 OUTLIER Pre-proline 0 C--O 1.214 -0.781 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.407 175.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.76 9.42 1.13 Allowed 'Trans proline' 0 N--CA 1.441 -1.598 0 CA-C-N 120.742 1.301 . . . . 0.0 111.711 -178.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.8 m -151.81 129.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.595 0.712 . . . . 0.0 112.396 -178.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 82.4 m -83.34 72.32 10.21 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.215 177.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.315 -178.876 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.449 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 29.0 m . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.97 0.414 . . . . 0.0 110.132 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.46 31.08 73.45 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.831 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -133.27 154.03 51.04 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.403 ' HB ' HG22 ' A' ' 7' ' ' VAL . 62.8 p -106.91 148.06 29.05 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.947 0.403 . . . . 0.0 110.736 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.435 ' HB3' ' SG ' ' A' ' 23' ' ' CYS . 4.1 p -121.97 39.02 3.98 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.514 0.673 . . . . 0.0 110.02 178.18 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.403 HG22 ' HB ' ' A' ' 5' ' ' THR . 23.0 t -56.32 -21.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.226 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.63 25.91 22.94 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.55 178.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.44 38.71 93.89 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.399 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.18 140.16 21.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 18' ' ' CYS . 91.9 m -123.4 127.34 48.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.556 178.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -77.45 -38.52 49.27 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.759 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.751 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -70.65 118.31 63.63 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.388 179.671 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -70.74 119.18 6.13 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.342 2.028 . . . . 0.0 112.711 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.19 -4.43 33.53 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.831 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.751 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 89.9 m -88.5 131.52 34.87 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.219 0.533 . . . . 0.0 111.596 -179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.44 142.76 27.45 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 31.0 t -103.04 130.11 50.04 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 113.072 0.768 . . . . 0.0 113.072 -178.048 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.14 -52.5 4.8 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.58 -68.52 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.656 0 CA-C-N 113.648 -1.615 . . . . 0.0 110.396 175.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.4 Cg_endo -98.05 6.66 1.22 Allowed 'Trans proline' 0 N--CA 1.44 -1.673 0 CA-C-N 120.24 1.121 . . . . 0.0 112.126 -178.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.472 HG11 ' O ' ' A' ' 21' ' ' PRO . 5.5 m -152.33 133.74 5.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.435 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.8 m -93.36 130.83 39.0 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.102 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.449 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 11.6 t . . . . . 0 C--N 1.326 -0.454 0 C-N-CA 121.08 -0.248 . . . . 0.0 111.222 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 58.27 28.97 62.39 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.051 -0.977 . . . . 0.0 113.309 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -124.77 153.28 42.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.7 0.286 . . . . 0.0 110.524 -179.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.4 p -105.79 147.47 28.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.249 179.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.7 p -118.62 41.69 2.93 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.487 0.66 . . . . 0.0 110.085 178.162 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.8 t -56.25 -22.7 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.139 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -102.57 24.47 30.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.411 178.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.81 33.59 73.89 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.5 -0.35 . . . . 0.0 112.354 -179.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.48 140.22 21.73 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.4 m -122.27 138.33 54.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.295 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -74.2 -46.51 41.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.867 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.5 OUTLIER -76.17 118.79 73.83 Favored Pre-proline 0 N--CA 1.449 -0.49 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.304 178.742 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -64.67 -44.19 11.33 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 123.075 2.517 . . . . 0.0 114.061 -177.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.32 46.6 2.79 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.314 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.867 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.4 m -135.57 131.89 36.5 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.121 0.486 . . . . 0.0 111.907 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -88.39 127.36 35.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.829 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.8 t -93.96 127.59 39.82 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -93.57 -52.74 4.35 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 177.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.626 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 179.01 -68.9 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.706 0 CA-C-N 113.657 -1.61 . . . . 0.0 109.866 175.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.626 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -98.52 12.95 0.73 Allowed 'Trans proline' 0 N--CA 1.438 -1.735 0 CA-C-N 120.471 1.204 . . . . 0.0 111.386 -178.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.437 HG21 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -153.14 134.08 4.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.178 0.513 . . . . 0.0 111.978 -178.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.558 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 70.9 m -91.62 34.61 0.97 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.366 -0.833 . . . . 0.0 110.125 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 87.9 m . . . . . 0 C--O 1.237 0.435 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.087 -179.27 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.6 m . . . . . 0 N--CA 1.456 -0.165 0 CA-C-O 120.744 0.307 . . . . 0.0 110.594 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.25 26.51 70.57 Favored Glycine 0 C--N 1.334 0.464 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.846 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -103.58 155.34 18.61 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.676 -0.762 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.401 HG21 ' O ' ' A' ' 21' ' ' PRO . 82.3 p -107.15 144.1 34.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.848 0.356 . . . . 0.0 110.196 178.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.2 p -121.1 39.09 3.9 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.398 0.618 . . . . 0.0 110.279 178.528 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.35 -22.14 10.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.157 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.55 25.31 27.21 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.502 178.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.29 36.18 87.83 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.407 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 139.97 21.25 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.011 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.9 m -124.23 120.96 33.74 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.579 177.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -67.49 -38.65 84.68 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.393 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 m -82.18 120.79 77.97 Favored Pre-proline 0 N--CA 1.451 -0.408 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.41 ' C ' ' H ' ' A' ' 16' ' ' CYS . 33.2 Cg_endo -65.91 -37.58 26.36 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 123.099 2.532 . . . . 0.0 113.965 -178.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.42 34.42 0.97 Allowed Glycine 0 CA--C 1.518 0.265 0 C-N-CA 121.22 -0.514 . . . . 0.0 114.033 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.41 ' H ' ' C ' ' A' ' 14' ' ' PRO . 16.5 m -151.15 142.0 22.89 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.95 0.405 . . . . 0.0 111.247 179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.5 t -89.39 -156.29 0.39 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.1 t -153.38 129.27 10.22 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.247 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.3 p -93.13 -53.12 4.25 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 176.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.607 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 5.8 t90 179.21 -66.85 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.37 175.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.607 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.8 Cg_endo -97.34 2.78 1.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.791 0 CA-C-N 120.285 1.137 . . . . 0.0 112.383 -178.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.488 HG13 ' O ' ' A' ' 21' ' ' PRO . 5.4 m -151.15 129.88 2.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.765 0.793 . . . . 0.0 112.658 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 81.5 m -82.24 81.41 8.14 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 114.504 -1.225 . . . . 0.0 109.391 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.8 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-O 121.041 0.448 . . . . 0.0 111.852 -179.036 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.387 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.06 28.62 73.84 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.581 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.447 ' HG3' ' N ' ' A' ' 5' ' ' THR . 3.3 tp10 -128.06 150.79 49.8 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.005 -0.597 . . . . 0.0 110.144 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.447 ' N ' ' HG3' ' A' ' 4' ' ' GLU . 75.8 p -112.96 143.04 44.92 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 178.214 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.505 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.0 p -118.18 40.45 3.17 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.345 0.593 . . . . 0.0 110.571 178.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 t -55.04 -22.19 10.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.319 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.9 26.73 18.43 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.477 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 37.48 91.75 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.632 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.66 140.03 21.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.505 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.6 m -126.14 125.17 42.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.064 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 70.5 m-80 -77.07 -32.58 56.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.3 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.463 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -66.72 116.94 40.01 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.722 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 10.1 Cg_exo -71.66 118.84 5.85 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.51 2.14 . . . . 0.0 112.598 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.25 -12.56 33.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.748 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.463 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 94.9 m -88.71 136.47 32.98 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.958 0.408 . . . . 0.0 111.418 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.524 HG23 ' HB ' ' A' ' 24' ' ' THR . 12.9 t -89.09 -161.48 0.77 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 19.3 t -152.99 132.67 13.09 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 36.6 t -94.77 -52.64 4.18 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.9 t90 179.22 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.638 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.875 175.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.5 Cg_endo -97.57 7.34 1.31 Allowed 'Trans proline' 0 N--CA 1.441 -1.58 0 CA-C-N 120.635 1.263 . . . . 0.0 111.996 -178.127 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 21' ' ' PRO . 5.0 m -152.37 133.12 4.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.222 0.534 . . . . 0.0 111.789 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 84.1 m -86.73 115.92 24.49 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.447 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' THR . . . . . 0.524 ' HB ' HG23 ' A' ' 17' ' ' THR . 6.5 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.045 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 121.03 0.443 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.13 25.76 71.15 Favored Glycine 0 C--O 1.227 -0.328 0 CA-C-N 115.466 -0.788 . . . . 0.0 113.193 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -122.53 152.54 40.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.417 ' HB ' HG23 ' A' ' 7' ' ' VAL . 68.3 p -106.84 146.89 30.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.581 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.484 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.3 p -119.7 39.52 3.61 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.56 0.695 . . . . 0.0 110.056 178.193 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.417 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -56.49 -21.85 13.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.253 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.96 25.6 24.86 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.828 -0.701 . . . . 0.0 111.551 178.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.61 37.93 92.98 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.591 -0.338 . . . . 0.0 112.321 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.21 139.02 20.84 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.484 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 66.1 m -123.48 133.85 53.98 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.027 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -80.98 -42.78 20.66 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.615 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.642 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.7 OUTLIER -72.22 119.03 72.43 Favored Pre-proline 0 C--N 1.327 -0.373 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.175 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.404 ' C ' ' H ' ' A' ' 16' ' ' CYS . 19.0 Cg_endo -61.04 -47.3 12.93 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.986 2.457 . . . . 0.0 113.834 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.34 41.04 2.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.188 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.642 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 74.3 m -140.78 133.57 28.94 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.963 0.411 . . . . 0.0 111.403 -178.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.5 t -89.4 -159.0 0.54 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.5 t -153.63 129.54 10.22 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.161 -0.616 . . . . 0.0 112.442 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.7 m -91.97 -52.84 4.53 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.632 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.89 -68.44 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.691 0 CA-C-N 113.899 -1.501 . . . . 0.0 110.451 175.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.632 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.89 9.76 1.08 Allowed 'Trans proline' 0 N--CA 1.441 -1.583 0 CA-C-N 120.402 1.179 . . . . 0.0 111.717 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.459 HG12 ' O ' ' A' ' 21' ' ' PRO . 4.2 m -152.84 133.17 4.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 0.0 111.896 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 80.3 m -85.78 35.8 0.64 Allowed 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.5 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.8 p . . . . . 0 C--O 1.238 0.469 0 C-N-CA 123.035 0.534 . . . . 0.0 112.056 -179.639 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.52 -0.195 0 CA-C-O 120.868 0.366 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.82 31.62 80.97 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.458 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 4.4 tp10 -128.04 150.2 50.04 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.858 -0.671 . . . . 0.0 110.407 -178.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 21' ' ' PRO . 70.4 p -113.61 145.09 41.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.336 178.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.3 p -120.18 40.0 3.56 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.354 0.597 . . . . 0.0 110.17 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.408 HG22 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -54.35 -21.94 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.633 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.04 23.48 25.34 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.672 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 63.58 34.97 91.37 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.571 -0.315 . . . . 0.0 112.45 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.8 p -143.34 132.95 23.66 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 61.2 m -122.4 119.86 32.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.244 177.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -71.5 -34.78 70.43 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.854 -1.067 . . . . 0.0 109.977 179.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.5 115.11 40.41 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.93 -45.76 9.85 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.879 2.386 . . . . 0.0 113.826 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.01 40.87 2.55 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.235 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -142.06 140.11 32.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.106 0.479 . . . . 0.0 111.729 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.3 t -89.04 -156.87 0.41 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.439 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.7 t -160.04 130.21 5.45 Favored 'General case' 0 C--N 1.322 -0.592 0 O-C-N 121.963 -0.46 . . . . 0.0 111.876 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -98.46 -52.12 3.74 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.609 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.98 -68.28 0.0 OUTLIER Pre-proline 0 C--O 1.218 -0.602 0 CA-C-N 114.24 -1.345 . . . . 0.0 111.028 175.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.609 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.0 Cg_endo -97.11 6.98 1.46 Allowed 'Trans proline' 0 N--CA 1.439 -1.69 0 CA-C-N 120.786 1.317 . . . . 0.0 112.06 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.465 HG12 ' O ' ' A' ' 21' ' ' PRO . 5.0 m -152.15 135.0 6.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.093 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.458 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 90.3 m -77.76 53.31 1.11 Allowed 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.187 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.911 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 120.856 0.36 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.91 31.93 81.11 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.635 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 2.4 tp10 -132.97 152.42 51.94 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.545 -0.828 . . . . 0.0 109.778 -178.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 21' ' ' PRO . 72.2 p -116.3 142.8 46.37 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.036 0.446 . . . . 0.0 110.769 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.9 p -117.5 41.54 2.8 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.265 0.555 . . . . 0.0 110.378 178.32 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.511 HG23 ' HA ' ' A' ' 21' ' ' PRO . 24.0 t -54.7 -21.96 8.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.617 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.15 22.77 26.66 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.598 178.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 64.41 30.54 78.13 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.624 -0.288 . . . . 0.0 112.596 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -146.87 134.7 21.25 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 122.678 -0.307 . . . . 0.0 111.524 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.9 m -115.34 128.68 56.25 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.818 178.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -73.65 -34.42 64.96 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.89 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.532 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -68.83 117.45 51.31 Favored Pre-proline 0 C--O 1.232 0.182 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.676 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 7.5 Cg_exo -73.27 119.52 6.05 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 122.441 2.094 . . . . 0.0 112.855 -179.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.35 -7.19 36.91 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.987 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.532 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 90.4 m -89.02 142.3 27.75 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.934 0.397 . . . . 0.0 111.627 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.7 t -88.53 -162.83 0.89 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.7 t -155.97 132.1 10.0 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -179.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.1 m -96.83 -51.88 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.626 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.1 t90 179.17 -70.27 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 114.156 -1.384 . . . . 0.0 110.721 175.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.626 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.2 Cg_endo -98.12 10.39 0.98 Allowed 'Trans proline' 0 N--CA 1.441 -1.603 0 CA-C-N 120.603 1.251 . . . . 0.0 111.606 -178.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.434 HG12 ' O ' ' A' ' 21' ' ' PRO . 4.7 m -152.6 135.68 7.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.37 -178.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . 0.635 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 75.5 m -90.11 115.06 27.08 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.495 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 16.4 m . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.909 -178.404 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.518 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 35.2 m . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.804 0.335 . . . . 0.0 110.27 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.39 20.6 71.69 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.993 178.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 7.3 tp10 -97.05 157.23 16.01 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.425 ' HB ' HG21 ' A' ' 7' ' ' VAL . 64.7 p -100.61 144.86 29.09 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.054 0.454 . . . . 0.0 110.504 178.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' CYS . . . . . 0.546 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.4 p -120.77 41.57 3.25 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.602 0.715 . . . . 0.0 109.906 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.425 HG21 ' HB ' ' A' ' 5' ' ' THR . 24.9 t -56.06 -22.75 14.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.272 179.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.32 23.43 35.3 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.351 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.31 32.48 72.38 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.504 -0.348 . . . . 0.0 112.321 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.85 139.54 20.7 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' CYS . . . . . 0.546 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.6 m -118.63 137.39 53.31 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.295 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -76.53 -43.89 37.33 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.919 0.39 . . . . 0.0 110.07 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.518 ' HB ' ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -78.58 122.05 84.41 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.121 179.209 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 16' ' ' CYS . 31.5 Cg_endo -65.6 -37.15 30.23 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 123.047 2.498 . . . . 0.0 113.692 -178.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.74 35.9 1.02 Allowed Glycine 0 C--N 1.321 -0.28 0 CA-C-N 115.991 -0.549 . . . . 0.0 113.899 -178.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.408 ' H ' ' C ' ' A' ' 14' ' ' PRO . 15.2 m -150.73 140.74 22.02 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.967 0.413 . . . . 0.0 111.258 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.8 t -89.57 -151.61 0.23 Allowed 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.3 t -158.06 128.91 6.4 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 119.996 -0.682 . . . . 0.0 112.569 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.2 m -90.69 -51.87 5.16 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 176.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TRP . . . . . 0.631 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 178.62 -69.36 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.632 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.108 175.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.631 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.3 Cg_endo -97.76 10.5 1.06 Allowed 'Trans proline' 0 N--CA 1.44 -1.632 0 CA-C-N 120.421 1.186 . . . . 0.0 111.45 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 21' ' ' PRO . 3.6 m -152.33 129.42 2.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.509 0.671 . . . . 0.0 112.457 -178.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 73.7 m -82.09 78.25 8.8 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.038 177.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.214 -178.684 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 44.4 t . . . . . 0 CA--C 1.521 -0.171 0 CA-C-O 121.394 0.616 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m -78.99 -20.56 48.79 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.463 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.58 24.25 67.69 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.725 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -116.9 152.02 35.38 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 115.266 -0.467 . . . . 0.0 110.608 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.405 HG21 ' O ' ' A' ' 21' ' ' PRO . 78.4 p -111.89 142.61 44.07 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.595 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.1 p -118.58 42.32 2.78 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.463 0.649 . . . . 0.0 110.403 178.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.423 HG23 ' HA ' ' A' ' 21' ' ' PRO . 25.1 t -55.58 -22.57 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.261 179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.86 24.85 28.32 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.412 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.51 37.28 88.14 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.582 -0.309 . . . . 0.0 112.378 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.57 140.44 21.87 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.595 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 90.1 m -128.83 135.06 48.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.237 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -82.42 -38.13 24.49 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.602 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.495 HG22 ' SG ' ' A' ' 16' ' ' CYS . 3.1 m -66.9 114.9 20.09 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.571 179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.36 -45.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.968 2.446 . . . . 0.0 113.789 -177.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.09 39.32 2.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.38 -0.914 . . . . 0.0 112.087 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.495 ' SG ' HG22 ' A' ' 13' ' ' THR . 89.6 m -143.37 131.39 21.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.128 0.489 . . . . 0.0 111.779 -178.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.708 HG23 ' HB ' ' A' ' 24' ' ' THR . 9.2 t -89.79 -153.34 0.28 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.0 t -154.61 131.67 10.96 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.7 m -91.59 -53.24 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.625 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 178.96 -69.74 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.671 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.393 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.625 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.3 Cg_endo -97.99 11.36 0.94 Allowed 'Trans proline' 0 N--CA 1.44 -1.619 0 CA-C-N 120.546 1.231 . . . . 0.0 111.482 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.6 m -152.49 130.63 2.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.188 0.518 . . . . 0.0 111.881 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.5 m -81.47 113.39 19.5 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.708 ' HB ' HG23 ' A' ' 17' ' ' THR . 1.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.337 -178.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.9 m . . . . . 0 CA--C 1.526 0.042 0 CA-C-O 121.4 0.619 . . . . 0.0 110.522 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.492 ' SG ' HG23 ' A' ' 13' ' ' THR . 71.1 m -83.86 -12.84 54.95 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.36 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.01 13.07 72.32 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.245 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -98.09 151.7 20.09 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.104 -0.548 . . . . 0.0 109.748 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -105.97 143.83 33.56 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.849 0.357 . . . . 0.0 110.133 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.559 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.0 p -119.38 42.29 2.89 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.367 0.603 . . . . 0.0 110.203 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.6 t -54.94 -22.53 10.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.324 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.78 25.2 26.27 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.463 178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.94 36.74 89.35 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.524 -0.338 . . . . 0.0 112.417 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.69 140.45 21.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.559 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.2 m -127.13 132.61 50.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.162 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -81.65 -34.7 30.65 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.492 HG23 ' SG ' ' A' ' 2' ' ' CYS . 0.3 OUTLIER -76.48 115.33 46.61 Favored Pre-proline 0 N--CA 1.449 -0.476 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.914 179.318 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -62.11 -37.9 60.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 123.11 2.54 . . . . 0.0 113.858 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.99 33.93 1.47 Allowed Glycine 0 C--N 1.322 -0.202 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.801 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.0 m -150.71 140.29 21.59 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.123 0.487 . . . . 0.0 112.002 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -90.08 -149.38 0.2 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.2 t -156.82 128.37 7.07 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.051 -0.659 . . . . 0.0 112.519 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.5 m -92.13 -52.13 4.85 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 178.77 -70.04 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.703 0 CA-C-N 113.825 -1.534 . . . . 0.0 110.121 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.8 Cg_endo -97.99 11.17 0.96 Allowed 'Trans proline' 0 N--CA 1.439 -1.733 0 CA-C-N 120.632 1.261 . . . . 0.0 111.51 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.446 HG12 ' O ' ' A' ' 21' ' ' PRO . 3.6 m -152.54 130.73 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 CA-C-O 121.45 0.643 . . . . 0.0 112.335 -178.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.7 m -84.67 80.57 9.2 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.651 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.113 -178.402 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 14.4 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.776 0.322 . . . . 0.0 110.256 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.536 ' SG ' HG21 ' A' ' 13' ' ' THR . 19.5 m -78.77 -28.32 44.72 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 -179.114 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.74 23.85 65.75 Favored Glycine 0 C--N 1.334 0.44 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -94.71 155.35 16.88 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.717 -0.742 . . . . 0.0 110.28 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.413 HG21 ' O ' ' A' ' 21' ' ' PRO . 82.2 p -108.85 142.55 39.27 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.556 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.7 p -119.95 42.28 2.97 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.324 0.583 . . . . 0.0 110.352 178.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.514 HG21 ' HA ' ' A' ' 21' ' ' PRO . 25.5 t -54.24 -22.55 8.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.402 179.767 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.55 24.95 27.28 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.446 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.96 36.41 87.95 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.478 -0.361 . . . . 0.0 112.475 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.76 140.45 21.71 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.556 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 98.2 m -126.56 132.41 51.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.598 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -80.18 -40.06 28.0 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.776 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.536 HG21 ' SG ' ' A' ' 2' ' ' CYS . 1.5 m -76.08 116.71 58.27 Favored Pre-proline 0 N--CA 1.45 -0.451 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.171 179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.1 -37.3 64.73 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 123.23 2.62 . . . . 0.0 113.734 -178.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.31 35.46 1.32 Allowed Glycine 0 CA--C 1.517 0.195 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.781 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.7 m -150.82 141.01 22.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.107 0.479 . . . . 0.0 111.635 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.69 -145.78 0.15 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.6 t -166.45 133.06 2.49 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.867 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 p -103.48 -53.01 2.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 107.562 -1.274 . . . . 0.0 107.562 177.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.618 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.8 t90 -177.87 -69.46 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.731 0 CA-C-N 114.329 -1.305 . . . . 0.0 111.013 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.618 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.6 Cg_endo -97.39 9.5 1.22 Allowed 'Trans proline' 0 N--CA 1.439 -1.702 0 CA-C-N 121.104 1.43 . . . . 0.0 111.727 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 21' ' ' PRO . 3.9 m -151.35 132.91 5.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-O 121.531 0.682 . . . . 0.0 111.063 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 66.6 m -76.87 59.29 1.59 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.75 -1.113 . . . . 0.0 110.739 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.326 -0.435 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.977 -179.774 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.228 -0.072 0 CA-C-O 121.106 0.479 . . . . 0.0 110.631 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.2 m -79.28 -21.75 45.61 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.693 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.99 24.02 75.9 Favored Glycine 0 N--CA 1.448 -0.552 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.531 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -118.02 152.06 36.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.158 -0.521 . . . . 0.0 110.194 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 59.5 p -110.72 142.13 43.07 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 178.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.551 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.78 42.77 2.55 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-O 121.37 0.605 . . . . 0.0 110.452 178.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.3 t -54.96 -22.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.388 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.27 25.09 27.16 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.815 -0.707 . . . . 0.0 111.442 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.23 37.04 85.54 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.489 -0.355 . . . . 0.0 112.522 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.54 140.46 21.92 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.551 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.6 m -126.96 134.56 50.37 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.233 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -86.68 -37.22 18.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.685 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.551 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 2.6 m -61.77 116.89 23.57 Favored Pre-proline 0 C--O 1.236 0.344 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.504 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 15.9 Cg_exo -68.52 114.78 3.6 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.597 2.198 . . . . 0.0 112.887 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.61 -8.71 28.15 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.469 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.551 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 86.0 m -89.0 134.69 33.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.71 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.635 HG22 ' HA ' ' A' ' 24' ' ' THR . 11.5 t -88.94 -159.71 0.59 Allowed 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 26.2 t -156.38 131.62 9.29 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 119.922 -0.711 . . . . 0.0 112.907 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.9 t -93.74 -53.01 4.2 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 176.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.625 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 179.23 -69.61 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.728 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.21 175.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.625 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.8 Cg_endo -98.06 12.04 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.627 0 CA-C-N 120.634 1.262 . . . . 0.0 111.497 -178.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.434 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.4 131.37 3.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.844 -178.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 90.9 m -82.17 119.87 24.61 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.307 -0.861 . . . . 0.0 108.758 178.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.635 ' HA ' HG22 ' A' ' 17' ' ' THR . 48.3 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.696 -178.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.46 0.073 0 CA-C-O 121.234 0.54 . . . . 0.0 110.602 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.61 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 5.9 m -79.84 -20.37 46.18 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.951 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.43 23.16 75.13 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.41 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 31.9 tt0 -122.13 148.58 44.73 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.281 -0.46 . . . . 0.0 110.144 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 63.2 p -107.8 142.8 37.28 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.205 178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.593 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -116.66 41.76 2.61 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.337 0.589 . . . . 0.0 110.385 178.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.6 t -54.85 -22.31 9.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.394 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.47 25.78 23.55 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.808 -0.71 . . . . 0.0 111.403 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.15 37.07 91.2 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.584 -0.308 . . . . 0.0 112.43 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.64 140.24 21.6 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.593 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 76.0 m -128.95 133.69 47.92 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.296 178.358 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.41 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.4 m-80 -81.21 -33.17 33.09 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 179.125 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.463 HG21 ' SG ' ' A' ' 16' ' ' CYS . 1.2 m -69.39 114.26 22.72 Favored Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.316 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -61.85 -46.05 14.85 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.982 2.455 . . . . 0.0 113.991 -177.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.36 2.7 Favored Glycine 0 CA--C 1.508 -0.355 0 C-N-CA 120.306 -0.949 . . . . 0.0 111.938 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.463 ' SG ' HG21 ' A' ' 13' ' ' THR . 77.3 m -142.62 132.38 24.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.176 0.513 . . . . 0.0 112.147 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.541 HG23 ' O ' ' A' ' 24' ' ' THR . 15.4 t -89.71 -162.19 0.86 Allowed 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 177.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 18.1 t -148.86 129.29 13.87 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 119.887 -0.725 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 m -89.8 -52.69 4.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.638 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.85 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.695 0 CA-C-N 113.877 -1.511 . . . . 0.0 110.363 175.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.638 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.2 Cg_endo -98.41 9.8 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.664 0 CA-C-N 120.524 1.223 . . . . 0.0 111.792 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.9 m -152.67 132.23 3.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -178.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.8 m -93.38 136.24 33.84 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 176.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.61 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.8 t . . . . . 0 C--N 1.323 -0.554 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.384 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 CA--C 1.524 -0.024 0 CA-C-O 121.38 0.609 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.2 -31.39 43.76 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.95 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.5 24.97 71.24 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -111.57 154.44 24.82 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.017 -0.591 . . . . 0.0 110.163 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.423 HG23 ' O ' ' A' ' 21' ' ' PRO . 81.4 p -113.25 143.77 43.85 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -122.95 43.41 2.94 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.384 0.611 . . . . 0.0 110.315 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.4 t -53.72 -22.39 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 114.702 -1.135 . . . . 0.0 110.823 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.08 23.19 25.93 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.692 -0.766 . . . . 0.0 111.606 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.72 36.28 93.08 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 112.345 -0.302 . . . . 0.0 112.345 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.4 p -141.98 134.06 27.54 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 99.2 m -127.34 132.8 50.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.964 177.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -83.1 -37.72 23.42 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.732 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.581 HG22 ' SG ' ' A' ' 16' ' ' CYS . 3.3 m -67.3 115.25 24.28 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.076 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -60.4 -47.92 12.93 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.936 2.424 . . . . 0.0 113.77 -178.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.27 39.84 2.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.971 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.581 ' SG ' HG22 ' A' ' 13' ' ' THR . 97.7 m -141.88 133.2 26.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.313 0.578 . . . . 0.0 112.134 -179.022 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.708 HG21 ' HA ' ' A' ' 24' ' ' THR . 9.8 t -89.89 -154.58 0.33 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.584 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.3 t -155.86 129.44 8.39 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 121.702 -0.624 . . . . 0.0 112.41 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.9 m -91.76 -53.32 4.34 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.8 t90 179.01 -69.85 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.754 0 CA-C-N 113.826 -1.534 . . . . 0.0 110.241 175.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -97.62 11.4 1.02 Allowed 'Trans proline' 0 N--CA 1.44 -1.652 0 CA-C-N 120.671 1.275 . . . . 0.0 111.392 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.442 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.7 m -152.82 131.58 2.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.825 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 95.3 m -76.38 122.1 23.99 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.708 ' HA ' HG21 ' A' ' 17' ' ' THR . 97.1 m . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.324 -177.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.449 HG11 ' H ' ' A' ' 3' ' ' GLY . 37.8 t . . . . . 0 N--CA 1.454 -0.242 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.606 ' SG ' HG21 ' A' ' 13' ' ' THR . 57.1 m -79.27 -26.16 42.39 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.973 0.415 . . . . 0.0 110.338 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.449 ' H ' HG11 ' A' ' 1' ' ' VAL . . . 67.05 21.6 71.82 Favored Glycine 0 C--N 1.333 0.398 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.949 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.405 ' HB3' ' HB2' ' A' ' 23' ' ' CYS . 87.4 tt0 -97.6 160.0 14.58 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.831 -0.685 . . . . 0.0 109.481 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 73.8 p -113.67 141.69 46.92 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.526 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.7 p -117.92 42.85 2.55 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.304 0.573 . . . . 0.0 110.458 178.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -54.95 -22.41 10.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.367 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.38 25.88 23.38 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.441 178.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.5 37.0 87.35 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.432 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.6 140.76 22.17 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.052 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.526 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 73.8 m -127.18 131.49 50.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.258 178.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -78.99 -38.35 36.99 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.606 HG21 ' SG ' ' A' ' 2' ' ' CYS . 1.4 m -75.27 116.06 50.97 Favored Pre-proline 0 N--CA 1.45 -0.461 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.988 179.281 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -61.46 -38.15 65.68 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 123.182 2.588 . . . . 0.0 113.852 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.89 35.19 1.44 Allowed Glycine 0 C--O 1.228 -0.253 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.651 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.462 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 4.3 m -151.0 135.74 17.24 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.056 0.455 . . . . 0.0 111.957 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 24' ' ' THR . 13.7 t -89.29 -157.54 0.46 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.3 t -146.55 128.02 15.01 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 119.575 -0.85 . . . . 0.0 113.124 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.6 m -89.83 -52.83 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.647 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.9 t90 178.62 -69.9 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.717 0 CA-C-N 113.742 -1.572 . . . . 0.0 110.082 175.536 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.647 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.87 12.07 0.72 Allowed 'Trans proline' 0 N--CA 1.44 -1.668 0 CA-C-N 120.55 1.232 . . . . 0.0 111.573 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG23 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.29 132.82 4.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.668 0.747 . . . . 0.0 112.928 -178.328 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 83.9 m -96.57 124.99 40.73 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.809 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.485 ' O ' HG23 ' A' ' 17' ' ' THR . 9.1 t . . . . . 0 C--N 1.324 -0.533 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.288 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 N--CA 1.46 0.075 0 CA-C-O 121.229 0.538 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.637 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 9.3 m -80.76 -18.57 47.27 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.939 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 69.31 22.3 76.2 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.875 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.413 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 33.1 tt0 -123.07 149.82 43.94 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.265 -0.467 . . . . 0.0 110.222 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.408 HG21 ' O ' ' A' ' 21' ' ' PRO . 59.9 p -110.38 144.3 39.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.294 -0.412 . . . . 0.0 109.892 178.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.581 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.65 41.97 2.72 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.384 0.611 . . . . 0.0 110.33 178.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 t -55.17 -22.59 11.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.304 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.64 25.46 25.6 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.464 178.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.95 36.7 89.22 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.529 -0.336 . . . . 0.0 112.577 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 140.72 22.0 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.581 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.5 m -128.88 133.66 48.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.355 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . 0.413 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.3 m-80 -81.49 -33.08 32.13 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.13 114.35 22.88 Favored Pre-proline 0 CA--C 1.535 0.377 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.227 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -62.08 -45.98 14.38 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.952 2.435 . . . . 0.0 114.002 -177.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.08 2.67 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.951 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.7 m -142.93 132.17 23.29 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.198 0.523 . . . . 0.0 112.088 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.539 HG22 ' O ' ' A' ' 24' ' ' THR . 15.2 t -89.73 -161.51 0.79 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 17.1 t -149.14 129.47 13.77 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 119.873 -0.731 . . . . 0.0 112.798 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.4 m -89.85 -52.57 4.91 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.75 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.66 0 CA-C-N 113.821 -1.536 . . . . 0.0 110.274 175.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.9 Cg_endo -98.69 10.81 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.676 0 CA-C-N 120.502 1.215 . . . . 0.0 111.805 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.46 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.8 m -153.14 133.46 4.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.444 0.64 . . . . 0.0 112.669 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.4 m -95.07 136.3 35.56 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 176.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.637 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.1 t . . . . . 0 C--N 1.323 -0.549 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.394 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.729 HG22 HG22 ' A' ' 24' ' ' THR . 34.3 m . . . . . 0 N--CA 1.461 0.077 0 CA-C-O 121.029 0.442 . . . . 0.0 110.709 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 m -78.87 -24.43 44.29 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.824 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.83 28.17 73.05 Favored Glycine 0 C--N 1.334 0.431 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.813 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -122.44 150.08 42.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.13 -0.535 . . . . 0.0 109.976 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 21' ' ' PRO . 72.0 p -109.37 143.46 38.89 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.381 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.615 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.4 p -117.78 41.13 2.94 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.359 0.6 . . . . 0.0 110.562 178.219 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.3 t -54.76 -21.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.587 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.2 25.33 23.86 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.476 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 61.2 36.83 93.0 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.572 -0.314 . . . . 0.0 112.348 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.62 142.48 23.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.235 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.615 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.6 m -133.1 130.6 39.51 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.567 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -78.33 -30.39 48.18 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.743 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.6 OUTLIER -77.68 113.99 37.16 Favored Pre-proline 0 N--CA 1.45 -0.452 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 177.977 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -63.91 -45.06 11.32 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 123.074 2.516 . . . . 0.0 114.593 -177.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.17 45.72 2.6 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.468 -0.873 . . . . 0.0 112.498 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.743 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 56.7 m -136.89 127.64 27.22 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.324 0.583 . . . . 0.0 112.545 -178.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.6 p -89.71 114.64 26.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.264 178.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.6 t -77.24 127.3 32.37 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 m -93.19 -52.46 4.54 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.627 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 179.14 -69.21 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.734 0 CA-C-N 113.965 -1.47 . . . . 0.0 110.451 175.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.627 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.9 Cg_endo -97.94 8.48 1.15 Allowed 'Trans proline' 0 N--CA 1.439 -1.692 0 CA-C-N 120.443 1.194 . . . . 0.0 111.653 -178.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.44 HG13 ' O ' ' A' ' 21' ' ' PRO . 5.1 m -152.36 134.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.583 0.706 . . . . 0.0 112.309 -178.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 67.5 m -89.85 100.4 13.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.729 HG22 HG22 ' A' ' 1' ' ' VAL . 90.9 m . . . . . 0 N--CA 1.464 0.25 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.868 -177.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 CA--C 1.527 0.084 0 CA-C-O 121.183 0.516 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 21.3 m -79.66 -18.62 51.0 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.723 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 66.44 23.53 71.93 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.307 -0.86 . . . . 0.0 112.352 179.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -113.56 153.85 28.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 58.2 p -113.6 142.83 45.5 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 6.3 p -119.25 43.99 2.46 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.186 0.517 . . . . 0.0 110.475 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.1 t -52.89 -21.73 3.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.96 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -111.52 25.06 14.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.697 -0.764 . . . . 0.0 111.671 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.46 36.01 92.53 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.619 -0.291 . . . . 0.0 112.444 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.7 p -140.53 134.75 31.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.6 m -129.97 130.38 44.98 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.556 177.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.7 m-80 -80.4 -40.05 27.17 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.251 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.792 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.9 OUTLIER -72.61 116.81 53.5 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.59 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -63.68 -45.67 10.65 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.209 2.606 . . . . 0.0 114.901 -176.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.72 44.95 2.61 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.388 -0.91 . . . . 0.0 112.368 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.792 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 20.0 m -139.48 129.63 25.19 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.855 0.359 . . . . 0.0 111.947 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -93.07 141.38 28.47 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 39.7 t -95.02 125.18 39.51 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 m -93.51 -52.88 4.29 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 176.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.645 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.02 -70.92 0.0 OUTLIER Pre-proline 0 C--O 1.213 -0.831 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.963 175.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.645 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.9 Cg_endo -98.49 12.92 0.74 Allowed 'Trans proline' 0 N--CA 1.44 -1.625 0 CA-C-N 120.738 1.299 . . . . 0.0 111.348 -178.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.443 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.5 133.09 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-O 121.453 0.644 . . . . 0.0 112.417 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.548 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 78.2 m -90.72 57.79 3.68 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.044 177.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 21.4 m . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 121.242 0.544 . . . . 0.0 111.474 -178.865 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 N--CA 1.458 -0.062 0 CA-C-O 121.321 0.581 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 32.6 m -79.63 -24.67 41.76 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.338 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.11 33.38 87.1 Favored Glycine 0 C--N 1.333 0.38 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 3.2 tp10 -127.28 151.96 48.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.804 -0.698 . . . . 0.0 110.0 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.431 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -113.79 144.59 42.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.385 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.486 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.4 p -119.39 40.66 3.29 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.289 0.566 . . . . 0.0 110.319 178.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.403 HG21 ' HB ' ' A' ' 5' ' ' THR . 23.6 t -55.61 -21.93 11.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.227 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.81 26.25 21.58 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.519 178.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.01 36.59 89.05 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.661 -0.27 . . . . 0.0 112.482 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.55 140.86 22.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.486 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.0 m -124.99 123.87 40.78 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.178 178.489 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -73.59 -35.02 65.35 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.109 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.609 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -71.45 116.69 49.98 Favored Pre-proline 0 C--O 1.234 0.261 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.438 179.61 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.86 119.83 6.08 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.443 2.095 . . . . 0.0 112.948 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.06 -8.29 31.27 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.916 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.609 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.3 m -88.92 130.89 35.35 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.977 0.418 . . . . 0.0 111.518 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -88.11 144.93 26.21 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 36.5 t -103.17 132.01 49.76 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 113.731 1.011 . . . . 0.0 113.731 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 m -95.97 -52.66 3.96 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 176.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.635 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.5 t90 178.99 -69.63 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.667 0 CA-C-N 113.708 -1.587 . . . . 0.0 110.467 175.423 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.635 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.1 9.94 1.02 Allowed 'Trans proline' 0 N--CA 1.442 -1.544 0 CA-C-N 120.567 1.238 . . . . 0.0 111.615 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.429 HG11 ' O ' ' A' ' 21' ' ' PRO . 4.8 m -152.39 135.18 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.62 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.504 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 84.7 m -90.04 37.74 0.9 Allowed 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.277 178.592 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 25.8 m . . . . . 0 C--O 1.238 0.468 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.525 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.454 -0.262 0 CA-C-O 120.655 0.264 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.583 ' SG ' HG21 ' A' ' 13' ' ' THR . 82.7 m -79.42 -21.49 45.49 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.409 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.23 28.87 74.06 Favored Glycine 0 C--N 1.334 0.418 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.112 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -112.12 147.78 35.37 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.653 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 78.8 p -101.73 142.62 32.79 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 120.688 0.28 . . . . 0.0 110.44 179.221 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.493 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.1 p -119.72 42.7 2.84 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 121.313 0.578 . . . . 0.0 110.198 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.7 t -52.51 -21.96 3.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.93 -1.032 . . . . 0.0 111.136 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -109.74 24.62 19.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.549 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.67 36.31 93.09 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 112.235 -0.346 . . . . 0.0 112.235 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.2 p -142.04 133.85 27.13 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -179.036 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.493 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.5 m -126.58 129.09 47.88 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 177.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 -81.21 -34.53 32.19 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.583 HG21 ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -77.59 117.31 64.79 Favored Pre-proline 0 N--CA 1.447 -0.589 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.862 179.245 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_endo -63.38 -39.53 36.64 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 123.169 2.579 . . . . 0.0 113.878 -178.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.69 33.6 1.2 Allowed Glycine 0 C--N 1.321 -0.28 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.815 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 11.0 m -150.9 135.04 16.8 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.957 0.408 . . . . 0.0 111.816 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.9 t -89.12 -161.22 0.74 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 35.1 t -144.29 130.78 19.92 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.951 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.7 t -93.35 -52.81 4.35 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 176.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.7 t90 179.3 -70.16 0.0 OUTLIER Pre-proline 0 C--O 1.214 -0.781 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.407 175.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.76 9.42 1.13 Allowed 'Trans proline' 0 N--CA 1.441 -1.598 0 CA-C-N 120.742 1.301 . . . . 0.0 111.711 -178.526 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.435 HG11 ' O ' ' A' ' 21' ' ' PRO . 3.8 m -151.81 129.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.595 0.712 . . . . 0.0 112.396 -178.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 82.4 m -83.34 72.32 10.21 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.215 177.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.315 -178.876 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.455 -0.175 0 CA-C-O 120.803 0.335 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.449 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 29.0 m -79.36 -27.34 41.96 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.132 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.46 31.08 73.45 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.831 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -133.27 154.03 51.04 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.403 ' HB ' HG22 ' A' ' 7' ' ' VAL . 62.8 p -106.91 148.06 29.05 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.947 0.403 . . . . 0.0 110.736 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.435 ' HB3' ' SG ' ' A' ' 23' ' ' CYS . 4.1 p -121.97 39.02 3.98 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.514 0.673 . . . . 0.0 110.02 178.18 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.403 HG22 ' HB ' ' A' ' 5' ' ' THR . 23.0 t -56.32 -21.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.226 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.63 25.91 22.94 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.55 178.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.44 38.71 93.89 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.399 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.18 140.16 21.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 18' ' ' CYS . 91.9 m -123.4 127.34 48.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.556 178.028 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -77.45 -38.52 49.27 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.759 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.751 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -70.65 118.31 63.63 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.388 179.671 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -70.74 119.18 6.13 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.342 2.028 . . . . 0.0 112.711 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.19 -4.43 33.53 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.831 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.751 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 89.9 m -88.5 131.52 34.87 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.219 0.533 . . . . 0.0 111.596 -179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.44 142.76 27.45 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 31.0 t -103.04 130.11 50.04 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 113.072 0.768 . . . . 0.0 113.072 -178.048 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.14 -52.5 4.8 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.58 -68.52 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.656 0 CA-C-N 113.648 -1.615 . . . . 0.0 110.396 175.399 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.4 Cg_endo -98.05 6.66 1.22 Allowed 'Trans proline' 0 N--CA 1.44 -1.673 0 CA-C-N 120.24 1.121 . . . . 0.0 112.126 -178.194 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.472 HG11 ' O ' ' A' ' 21' ' ' PRO . 5.5 m -152.33 133.74 5.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.563 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.435 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.8 m -93.36 130.83 39.0 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.102 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.449 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 11.6 t . . . . . 0 C--N 1.326 -0.454 0 C-N-CA 121.08 -0.248 . . . . 0.0 111.222 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 43.2 t . . . . . 0 CA--C 1.52 -0.183 0 CA-C-O 121.268 0.556 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.5 m -78.87 -22.3 46.22 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.433 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 58.27 28.97 62.39 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.051 -0.977 . . . . 0.0 113.309 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -124.77 153.28 42.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.7 0.286 . . . . 0.0 110.524 -179.669 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 67.4 p -105.79 147.47 28.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.249 179.006 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.563 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.7 p -118.62 41.69 2.93 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.487 0.66 . . . . 0.0 110.085 178.162 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.8 t -56.25 -22.7 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.139 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -102.57 24.47 30.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.411 178.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.81 33.59 73.89 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.5 -0.35 . . . . 0.0 112.354 -179.582 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.48 140.22 21.73 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.563 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.4 m -122.27 138.33 54.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.295 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -74.2 -46.51 41.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.867 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.5 OUTLIER -76.17 118.79 73.83 Favored Pre-proline 0 N--CA 1.449 -0.49 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.304 178.742 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -64.67 -44.19 11.33 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 123.075 2.517 . . . . 0.0 114.061 -177.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.32 46.6 2.79 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.314 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.867 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.4 m -135.57 131.89 36.5 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.121 0.486 . . . . 0.0 111.907 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -88.39 127.36 35.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.829 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.8 t -93.96 127.59 39.82 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -93.57 -52.74 4.35 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 177.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.626 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 179.01 -68.9 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.706 0 CA-C-N 113.657 -1.61 . . . . 0.0 109.866 175.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.626 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -98.52 12.95 0.73 Allowed 'Trans proline' 0 N--CA 1.438 -1.735 0 CA-C-N 120.471 1.204 . . . . 0.0 111.386 -178.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.437 HG21 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -153.14 134.08 4.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.178 0.513 . . . . 0.0 111.978 -178.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.558 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 70.9 m -91.62 34.61 0.97 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.366 -0.833 . . . . 0.0 110.125 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 87.9 m . . . . . 0 C--O 1.237 0.435 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.087 -179.27 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.431 HG23 ' H ' ' A' ' 3' ' ' GLY . 12.0 p . . . . . 0 N--CA 1.455 -0.205 0 CA-C-O 120.756 0.312 . . . . 0.0 110.321 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.6 m -79.23 -26.55 42.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.594 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.431 ' H ' HG23 ' A' ' 1' ' ' VAL . . . 64.25 26.51 70.57 Favored Glycine 0 C--N 1.334 0.464 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.846 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -103.58 155.34 18.61 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.676 -0.762 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.401 HG21 ' O ' ' A' ' 21' ' ' PRO . 82.3 p -107.15 144.1 34.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.848 0.356 . . . . 0.0 110.196 178.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.497 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.2 p -121.1 39.09 3.9 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.398 0.618 . . . . 0.0 110.279 178.528 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.8 t -55.35 -22.14 10.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.157 179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.55 25.31 27.21 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.502 178.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.29 36.18 87.83 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.407 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 139.97 21.25 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.011 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.497 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.9 m -124.23 120.96 33.74 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.579 177.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -67.49 -38.65 84.68 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.393 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 m -82.18 120.79 77.97 Favored Pre-proline 0 N--CA 1.451 -0.408 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.41 ' C ' ' H ' ' A' ' 16' ' ' CYS . 33.2 Cg_endo -65.91 -37.58 26.36 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 123.099 2.532 . . . . 0.0 113.965 -178.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.42 34.42 0.97 Allowed Glycine 0 CA--C 1.518 0.265 0 C-N-CA 121.22 -0.514 . . . . 0.0 114.033 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.41 ' H ' ' C ' ' A' ' 14' ' ' PRO . 16.5 m -151.15 142.0 22.89 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.95 0.405 . . . . 0.0 111.247 179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.5 t -89.39 -156.29 0.39 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.1 t -153.38 129.27 10.22 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.247 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.3 p -93.13 -53.12 4.25 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 176.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.607 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 5.8 t90 179.21 -66.85 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.37 175.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.607 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.8 Cg_endo -97.34 2.78 1.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.791 0 CA-C-N 120.285 1.137 . . . . 0.0 112.383 -178.072 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.488 HG13 ' O ' ' A' ' 21' ' ' PRO . 5.4 m -151.15 129.88 2.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.765 0.793 . . . . 0.0 112.658 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 81.5 m -82.24 81.41 8.14 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 114.504 -1.225 . . . . 0.0 109.391 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.8 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-O 121.041 0.448 . . . . 0.0 111.852 -179.036 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.306 0.575 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.0 m -80.16 -17.59 52.03 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.387 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.06 28.62 73.84 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.581 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.447 ' HG3' ' N ' ' A' ' 5' ' ' THR . 3.3 tp10 -128.06 150.79 49.8 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.005 -0.597 . . . . 0.0 110.144 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.447 ' N ' ' HG3' ' A' ' 4' ' ' GLU . 75.8 p -112.96 143.04 44.92 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 178.214 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.505 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.0 p -118.18 40.45 3.17 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.345 0.593 . . . . 0.0 110.571 178.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 t -55.04 -22.19 10.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.319 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.9 26.73 18.43 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.477 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 37.48 91.75 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.632 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.66 140.03 21.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.505 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.6 m -126.14 125.17 42.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.064 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 70.5 m-80 -77.07 -32.58 56.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.3 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.463 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -66.72 116.94 40.01 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.722 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 10.1 Cg_exo -71.66 118.84 5.85 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.51 2.14 . . . . 0.0 112.598 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.25 -12.56 33.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.748 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.463 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 94.9 m -88.71 136.47 32.98 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.958 0.408 . . . . 0.0 111.418 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.524 HG23 ' HB ' ' A' ' 24' ' ' THR . 12.9 t -89.09 -161.48 0.77 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 19.3 t -152.99 132.67 13.09 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 36.6 t -94.77 -52.64 4.18 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.9 t90 179.22 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.638 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.875 175.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.5 Cg_endo -97.57 7.34 1.31 Allowed 'Trans proline' 0 N--CA 1.441 -1.58 0 CA-C-N 120.635 1.263 . . . . 0.0 111.996 -178.127 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 21' ' ' PRO . 5.0 m -152.37 133.12 4.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.222 0.534 . . . . 0.0 111.789 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 84.1 m -86.73 115.92 24.49 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.447 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' THR . . . . . 0.524 ' HB ' HG23 ' A' ' 17' ' ' THR . 6.5 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.045 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.8 t . . . . . 0 CA--C 1.528 0.132 0 CA-C-O 121.669 0.747 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.2 m -79.65 -26.87 40.96 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.035 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.13 25.76 71.15 Favored Glycine 0 C--O 1.227 -0.328 0 CA-C-N 115.466 -0.788 . . . . 0.0 113.193 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -122.53 152.54 40.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.417 ' HB ' HG23 ' A' ' 7' ' ' VAL . 68.3 p -106.84 146.89 30.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.581 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.484 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.3 p -119.7 39.52 3.61 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.56 0.695 . . . . 0.0 110.056 178.193 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.417 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -56.49 -21.85 13.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.253 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.96 25.6 24.86 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.828 -0.701 . . . . 0.0 111.551 178.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.61 37.93 92.98 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.591 -0.338 . . . . 0.0 112.321 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.21 139.02 20.84 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.484 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 66.1 m -123.48 133.85 53.98 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.027 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -80.98 -42.78 20.66 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.615 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.642 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.7 OUTLIER -72.22 119.03 72.43 Favored Pre-proline 0 C--N 1.327 -0.373 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.175 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.404 ' C ' ' H ' ' A' ' 16' ' ' CYS . 19.0 Cg_endo -61.04 -47.3 12.93 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.986 2.457 . . . . 0.0 113.834 -178.112 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.34 41.04 2.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.188 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.642 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 74.3 m -140.78 133.57 28.94 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.963 0.411 . . . . 0.0 111.403 -178.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.5 t -89.4 -159.0 0.54 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.5 t -153.63 129.54 10.22 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.161 -0.616 . . . . 0.0 112.442 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.7 m -91.97 -52.84 4.53 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.021 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.632 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.89 -68.44 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.691 0 CA-C-N 113.899 -1.501 . . . . 0.0 110.451 175.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.632 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.89 9.76 1.08 Allowed 'Trans proline' 0 N--CA 1.441 -1.583 0 CA-C-N 120.402 1.179 . . . . 0.0 111.717 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.459 HG12 ' O ' ' A' ' 21' ' ' PRO . 4.2 m -152.84 133.17 4.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 0.0 111.896 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 80.3 m -85.78 35.8 0.64 Allowed 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.5 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.8 p . . . . . 0 C--O 1.238 0.469 0 C-N-CA 123.035 0.534 . . . . 0.0 112.056 -179.639 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 37.5 t . . . . . 0 N--CA 1.455 -0.197 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 8.0 m -79.39 -25.28 42.18 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.333 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.82 31.62 80.97 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.458 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 4.4 tp10 -128.04 150.2 50.04 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.858 -0.671 . . . . 0.0 110.407 -178.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.435 HG22 ' O ' ' A' ' 21' ' ' PRO . 70.4 p -113.61 145.09 41.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.336 178.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.3 p -120.18 40.0 3.56 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.354 0.597 . . . . 0.0 110.17 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.408 HG22 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -54.35 -21.94 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.633 179.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.04 23.48 25.34 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.672 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 63.58 34.97 91.37 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.571 -0.315 . . . . 0.0 112.45 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.8 p -143.34 132.95 23.66 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 61.2 m -122.4 119.86 32.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.244 177.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -71.5 -34.78 70.43 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.854 -1.067 . . . . 0.0 109.977 179.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.5 115.11 40.41 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.93 -45.76 9.85 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.879 2.386 . . . . 0.0 113.826 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.01 40.87 2.55 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.235 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -142.06 140.11 32.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.106 0.479 . . . . 0.0 111.729 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.3 t -89.04 -156.87 0.41 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.439 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.7 t -160.04 130.21 5.45 Favored 'General case' 0 C--N 1.322 -0.592 0 O-C-N 121.963 -0.46 . . . . 0.0 111.876 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -98.46 -52.12 3.74 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.609 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.98 -68.28 0.0 OUTLIER Pre-proline 0 C--O 1.218 -0.602 0 CA-C-N 114.24 -1.345 . . . . 0.0 111.028 175.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.609 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.0 Cg_endo -97.11 6.98 1.46 Allowed 'Trans proline' 0 N--CA 1.439 -1.69 0 CA-C-N 120.786 1.317 . . . . 0.0 112.06 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.465 HG12 ' O ' ' A' ' 21' ' ' PRO . 5.0 m -152.15 135.0 6.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.093 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.458 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 90.3 m -77.76 53.31 1.11 Allowed 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.187 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.911 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.228 -0.072 0 CA-C-O 121.184 0.516 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m -79.87 -14.74 58.43 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.179 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.91 31.93 81.11 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.635 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 2.4 tp10 -132.97 152.42 51.94 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.545 -0.828 . . . . 0.0 109.778 -178.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.434 HG23 ' O ' ' A' ' 21' ' ' PRO . 72.2 p -116.3 142.8 46.37 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.036 0.446 . . . . 0.0 110.769 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.516 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.9 p -117.5 41.54 2.8 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.265 0.555 . . . . 0.0 110.378 178.32 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.511 HG23 ' HA ' ' A' ' 21' ' ' PRO . 24.0 t -54.7 -21.96 8.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.617 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.15 22.77 26.66 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.598 178.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 64.41 30.54 78.13 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.624 -0.288 . . . . 0.0 112.596 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -146.87 134.7 21.25 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 122.678 -0.307 . . . . 0.0 111.524 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.516 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.9 m -115.34 128.68 56.25 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.818 178.813 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -73.65 -34.42 64.96 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.89 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.532 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -68.83 117.45 51.31 Favored Pre-proline 0 C--O 1.232 0.182 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.676 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.427 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 7.5 Cg_exo -73.27 119.52 6.05 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 122.441 2.094 . . . . 0.0 112.855 -179.469 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.35 -7.19 36.91 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.987 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.532 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 90.4 m -89.02 142.3 27.75 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.934 0.397 . . . . 0.0 111.627 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.7 t -88.53 -162.83 0.89 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.7 t -155.97 132.1 10.0 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -179.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.1 m -96.83 -51.88 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.626 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.1 t90 179.17 -70.27 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 114.156 -1.384 . . . . 0.0 110.721 175.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.626 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.2 Cg_endo -98.12 10.39 0.98 Allowed 'Trans proline' 0 N--CA 1.441 -1.603 0 CA-C-N 120.603 1.251 . . . . 0.0 111.606 -178.395 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.434 HG12 ' O ' ' A' ' 21' ' ' PRO . 4.7 m -152.6 135.68 7.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.37 -178.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . 0.635 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 75.5 m -90.11 115.06 27.08 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.495 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 16.4 m . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.909 -178.404 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.413 HG13 ' H ' ' A' ' 3' ' ' GLY . 35.6 t . . . . . 0 N--CA 1.454 -0.273 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.518 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 35.2 m -78.65 -31.69 46.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.27 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.413 ' H ' HG13 ' A' ' 1' ' ' VAL . . . 67.39 20.6 71.69 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.993 178.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 7.3 tp10 -97.05 157.23 16.01 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.425 ' HB ' HG21 ' A' ' 7' ' ' VAL . 64.7 p -100.61 144.86 29.09 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.054 0.454 . . . . 0.0 110.504 178.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.546 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.4 p -120.77 41.57 3.25 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.602 0.715 . . . . 0.0 109.906 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.425 HG21 ' HB ' ' A' ' 5' ' ' THR . 24.9 t -56.06 -22.75 14.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.272 179.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.32 23.43 35.3 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.351 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.31 32.48 72.38 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.504 -0.348 . . . . 0.0 112.321 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.85 139.54 20.7 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.136 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' CYS . . . . . 0.546 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.6 m -118.63 137.39 53.31 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.295 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -76.53 -43.89 37.33 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.919 0.39 . . . . 0.0 110.07 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.518 ' HB ' ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -78.58 122.05 84.41 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.121 179.209 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 16' ' ' CYS . 31.5 Cg_endo -65.6 -37.15 30.23 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 123.047 2.498 . . . . 0.0 113.692 -178.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.74 35.9 1.02 Allowed Glycine 0 C--N 1.321 -0.28 0 CA-C-N 115.991 -0.549 . . . . 0.0 113.899 -178.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.408 ' H ' ' C ' ' A' ' 14' ' ' PRO . 15.2 m -150.73 140.74 22.02 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.967 0.413 . . . . 0.0 111.258 179.387 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.8 t -89.57 -151.61 0.23 Allowed 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.3 t -158.06 128.91 6.4 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 119.996 -0.682 . . . . 0.0 112.569 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.2 m -90.69 -51.87 5.16 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 176.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TRP . . . . . 0.631 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 178.62 -69.36 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.632 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.108 175.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.631 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.3 Cg_endo -97.76 10.5 1.06 Allowed 'Trans proline' 0 N--CA 1.44 -1.632 0 CA-C-N 120.421 1.186 . . . . 0.0 111.45 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 21' ' ' PRO . 3.6 m -152.33 129.42 2.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.509 0.671 . . . . 0.0 112.457 -178.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 73.7 m -82.09 78.25 8.8 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.038 177.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.214 -178.684 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 121.381 0.61 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.58 24.25 67.69 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.725 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -116.9 152.02 35.38 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 115.266 -0.467 . . . . 0.0 110.608 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.568 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.4 p -111.89 142.61 44.07 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.1 p -118.58 42.32 2.78 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.463 0.649 . . . . 0.0 110.403 178.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -55.58 -22.57 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.261 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.86 24.85 28.32 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.412 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.51 37.28 88.14 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.582 -0.309 . . . . 0.0 112.378 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.57 140.44 21.87 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 90.1 m -128.83 135.06 48.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.237 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -82.42 -38.13 24.49 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.602 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.1 m -66.9 114.9 20.09 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.571 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.36 -45.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.968 2.446 . . . . 0.0 113.789 -177.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.09 39.32 2.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.38 -0.914 . . . . 0.0 112.087 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 89.6 m -143.37 131.39 21.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.128 0.489 . . . . 0.0 111.779 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.527 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 9.2 t -89.79 -153.34 0.28 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.0 t -154.61 131.67 10.96 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.7 m -91.59 -53.24 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.619 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 178.96 -69.74 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.671 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.393 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.619 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.3 Cg_endo -97.99 11.36 0.94 Allowed 'Trans proline' 0 N--CA 1.44 -1.619 0 CA-C-N 120.546 1.231 . . . . 0.0 111.482 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.49 130.63 2.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.188 0.518 . . . . 0.0 111.881 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.5 m -81.47 113.39 19.5 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.527 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 1.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.337 -178.315 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.1 m . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 121.075 0.464 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.01 13.07 72.32 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.245 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -98.09 151.7 20.09 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.104 -0.548 . . . . 0.0 109.748 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -105.97 143.83 33.56 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.849 0.357 . . . . 0.0 110.133 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.0 p -119.38 42.29 2.89 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.367 0.603 . . . . 0.0 110.203 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.6 t -54.94 -22.53 10.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.324 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.78 25.2 26.27 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.463 178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.94 36.74 89.35 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.524 -0.338 . . . . 0.0 112.417 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.69 140.45 21.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.2 m -127.13 132.61 50.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.162 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -81.65 -34.7 30.65 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.48 115.33 46.61 Favored Pre-proline 0 N--CA 1.449 -0.476 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.914 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -62.11 -37.9 60.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 123.11 2.54 . . . . 0.0 113.858 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.99 33.93 1.47 Allowed Glycine 0 C--N 1.322 -0.202 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.801 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.0 m -150.71 140.29 21.59 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.123 0.487 . . . . 0.0 112.002 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -90.08 -149.38 0.2 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.2 t -156.82 128.37 7.07 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.051 -0.659 . . . . 0.0 112.519 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.5 m -92.13 -52.13 4.85 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.631 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 178.77 -70.04 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.703 0 CA-C-N 113.825 -1.534 . . . . 0.0 110.121 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.631 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.8 Cg_endo -97.99 11.17 0.96 Allowed 'Trans proline' 0 N--CA 1.439 -1.733 0 CA-C-N 120.632 1.261 . . . . 0.0 111.51 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.54 130.73 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 CA-C-O 121.45 0.643 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.7 m -84.67 80.57 9.2 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.651 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.113 -178.402 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 19.5 m . . . . . 0 CA--C 1.522 -0.119 0 CA-C-O 120.807 0.337 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.74 23.85 65.75 Favored Glycine 0 C--N 1.334 0.44 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -94.71 155.35 16.88 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.717 -0.742 . . . . 0.0 110.28 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.2 p -108.85 142.55 39.27 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.7 p -119.95 42.28 2.97 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.324 0.583 . . . . 0.0 110.352 178.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.5 t -54.24 -22.55 8.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.402 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.55 24.95 27.28 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.446 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.96 36.41 87.95 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.478 -0.361 . . . . 0.0 112.475 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.76 140.45 21.71 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 98.2 m -126.56 132.41 51.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.598 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -80.18 -40.06 28.0 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.776 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -76.08 116.71 58.27 Favored Pre-proline 0 N--CA 1.45 -0.451 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.171 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.1 -37.3 64.73 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 123.23 2.62 . . . . 0.0 113.734 -178.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.31 35.46 1.32 Allowed Glycine 0 CA--C 1.517 0.195 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.781 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.7 m -150.82 141.01 22.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.107 0.479 . . . . 0.0 111.635 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.69 -145.78 0.15 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.6 t -166.45 133.06 2.49 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.867 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 p -103.48 -53.01 2.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 107.562 -1.274 . . . . 0.0 107.562 177.187 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.611 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.8 t90 -177.87 -69.46 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.731 0 CA-C-N 114.329 -1.305 . . . . 0.0 111.013 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.611 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.6 Cg_endo -97.39 9.5 1.22 Allowed 'Trans proline' 0 N--CA 1.439 -1.702 0 CA-C-N 121.104 1.43 . . . . 0.0 111.727 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.9 m -151.35 132.91 5.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-O 121.531 0.682 . . . . 0.0 111.063 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 66.6 m -76.87 59.29 1.59 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.75 -1.113 . . . . 0.0 110.739 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.326 -0.435 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.977 -179.774 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.2 m . . . . . 0 CA--C 1.52 -0.191 0 CA-C-O 121.189 0.518 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.99 24.02 75.9 Favored Glycine 0 N--CA 1.448 -0.552 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.531 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -118.02 152.06 36.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.158 -0.521 . . . . 0.0 110.194 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.55 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.5 p -110.72 142.13 43.07 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 178.293 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.564 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.78 42.77 2.55 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-O 121.37 0.605 . . . . 0.0 110.452 178.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.3 t -54.96 -22.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.388 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.27 25.09 27.16 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.815 -0.707 . . . . 0.0 111.442 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.23 37.04 85.54 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.489 -0.355 . . . . 0.0 112.522 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.54 140.46 21.92 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.564 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.6 m -126.96 134.56 50.37 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.233 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -86.68 -37.22 18.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.685 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.545 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 2.6 m -61.77 116.89 23.57 Favored Pre-proline 0 C--O 1.236 0.344 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.504 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 15.9 Cg_exo -68.52 114.78 3.6 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.597 2.198 . . . . 0.0 112.887 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.61 -8.71 28.15 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.469 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 86.0 m -89.0 134.69 33.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.71 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.5 t -88.94 -159.71 0.59 Allowed 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 178.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 26.2 t -156.38 131.62 9.29 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 119.922 -0.711 . . . . 0.0 112.907 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.9 t -93.74 -53.01 4.2 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 176.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 179.23 -69.61 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.728 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.21 175.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.8 Cg_endo -98.06 12.04 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.627 0 CA-C-N 120.634 1.262 . . . . 0.0 111.497 -178.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.4 131.37 3.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.844 -178.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 90.9 m -82.17 119.87 24.61 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.307 -0.861 . . . . 0.0 108.758 178.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 48.3 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.696 -178.049 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.629 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 5.9 m . . . . . 0 N--CA 1.456 -0.169 0 CA-C-O 121.237 0.542 . . . . 0.0 109.951 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.43 23.16 75.13 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 31.9 tt0 -122.13 148.58 44.73 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.281 -0.46 . . . . 0.0 110.144 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.541 HG22 ' O ' ' A' ' 21' ' ' PRO . 63.2 p -107.8 142.8 37.28 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.205 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -116.66 41.76 2.61 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.337 0.589 . . . . 0.0 110.385 178.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.6 t -54.85 -22.31 9.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.394 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.47 25.78 23.55 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.808 -0.71 . . . . 0.0 111.403 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.15 37.07 91.2 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.584 -0.308 . . . . 0.0 112.43 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.64 140.24 21.6 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 76.0 m -128.95 133.69 47.92 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.296 178.358 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.436 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.4 m-80 -81.21 -33.17 33.09 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 179.125 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.39 114.26 22.72 Favored Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.316 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -61.85 -46.05 14.85 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.982 2.455 . . . . 0.0 113.991 -177.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.36 2.7 Favored Glycine 0 CA--C 1.508 -0.355 0 C-N-CA 120.306 -0.949 . . . . 0.0 111.938 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 77.3 m -142.62 132.38 24.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.176 0.513 . . . . 0.0 112.147 -178.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.47 HG22 ' O ' ' A' ' 24' ' ' THR . 15.4 t -89.71 -162.19 0.86 Allowed 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 177.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 18.1 t -148.86 129.29 13.87 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 119.887 -0.725 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 m -89.8 -52.69 4.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.85 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.695 0 CA-C-N 113.877 -1.511 . . . . 0.0 110.363 175.627 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.2 Cg_endo -98.41 9.8 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.664 0 CA-C-N 120.524 1.223 . . . . 0.0 111.792 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.9 m -152.67 132.23 3.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -178.411 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.8 m -93.38 136.24 33.84 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 176.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.629 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.8 t . . . . . 0 C--N 1.323 -0.554 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.384 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.968 0.414 . . . . 0.0 109.95 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.5 24.97 71.24 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -111.57 154.44 24.82 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.017 -0.591 . . . . 0.0 110.163 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.594 HG22 ' O ' ' A' ' 21' ' ' PRO . 81.4 p -113.25 143.77 43.85 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -122.95 43.41 2.94 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.384 0.611 . . . . 0.0 110.315 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.4 t -53.72 -22.39 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 114.702 -1.135 . . . . 0.0 110.823 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.08 23.19 25.93 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.692 -0.766 . . . . 0.0 111.606 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.72 36.28 93.08 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 112.345 -0.302 . . . . 0.0 112.345 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.4 p -141.98 134.06 27.54 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 99.2 m -127.34 132.8 50.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.964 177.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -83.1 -37.72 23.42 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.732 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.3 m -67.3 115.25 24.28 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -60.4 -47.92 12.93 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.936 2.424 . . . . 0.0 113.77 -178.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.27 39.84 2.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.971 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 97.7 m -141.88 133.2 26.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.313 0.578 . . . . 0.0 112.134 -179.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.8 t -89.89 -154.58 0.33 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.3 t -155.86 129.44 8.39 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 121.702 -0.624 . . . . 0.0 112.41 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.9 m -91.76 -53.32 4.34 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.614 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.8 t90 179.01 -69.85 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.754 0 CA-C-N 113.826 -1.534 . . . . 0.0 110.241 175.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -97.62 11.4 1.02 Allowed 'Trans proline' 0 N--CA 1.44 -1.652 0 CA-C-N 120.671 1.275 . . . . 0.0 111.392 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.7 m -152.82 131.58 2.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.825 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 95.3 m -76.38 122.1 23.99 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.1 m . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.324 -177.359 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.1 m . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.973 0.415 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.05 21.6 71.82 Favored Glycine 0 C--N 1.333 0.398 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.949 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.407 ' HB3' ' HB2' ' A' ' 23' ' ' CYS . 87.4 tt0 -97.6 160.0 14.58 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.831 -0.685 . . . . 0.0 109.481 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 21' ' ' PRO . 73.8 p -113.67 141.69 46.92 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.539 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.7 p -117.92 42.85 2.55 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.304 0.573 . . . . 0.0 110.458 178.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -54.95 -22.41 10.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.367 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.38 25.88 23.38 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.441 178.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.5 37.0 87.35 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.432 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.6 140.76 22.17 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.052 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.539 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 73.8 m -127.18 131.49 50.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.258 178.438 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -78.99 -38.35 36.99 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 m -75.27 116.06 50.97 Favored Pre-proline 0 N--CA 1.45 -0.461 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.988 179.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -61.46 -38.15 65.68 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 123.182 2.588 . . . . 0.0 113.852 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.89 35.19 1.44 Allowed Glycine 0 C--O 1.228 -0.253 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.651 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 4.3 m -151.0 135.74 17.24 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.056 0.455 . . . . 0.0 111.957 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.489 HG22 ' O ' ' A' ' 24' ' ' THR . 13.7 t -89.29 -157.54 0.46 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.3 t -146.55 128.02 15.01 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 119.575 -0.85 . . . . 0.0 113.124 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.6 m -89.83 -52.83 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.641 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.9 t90 178.62 -69.9 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.717 0 CA-C-N 113.742 -1.572 . . . . 0.0 110.082 175.536 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.641 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.87 12.07 0.72 Allowed 'Trans proline' 0 N--CA 1.44 -1.668 0 CA-C-N 120.55 1.232 . . . . 0.0 111.573 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.405 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.29 132.82 4.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.668 0.747 . . . . 0.0 112.928 -178.328 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 83.9 m -96.57 124.99 40.73 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.809 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.489 ' O ' HG22 ' A' ' 17' ' ' THR . 9.1 t . . . . . 0 C--N 1.324 -0.533 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.288 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.654 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 9.3 m . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 121.235 0.54 . . . . 0.0 109.939 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 69.31 22.3 76.2 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.875 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.437 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 33.1 tt0 -123.07 149.82 43.94 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.265 -0.467 . . . . 0.0 110.222 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.9 p -110.38 144.3 39.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.294 -0.412 . . . . 0.0 109.892 178.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.65 41.97 2.72 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.384 0.611 . . . . 0.0 110.33 178.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 t -55.17 -22.59 11.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.304 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.64 25.46 25.6 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.464 178.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.95 36.7 89.22 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.529 -0.336 . . . . 0.0 112.577 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 140.72 22.0 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.5 m -128.88 133.66 48.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.355 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASN . . . . . 0.437 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.3 m-80 -81.49 -33.08 32.13 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.13 114.35 22.88 Favored Pre-proline 0 CA--C 1.535 0.377 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.227 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -62.08 -45.98 14.38 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.952 2.435 . . . . 0.0 114.002 -177.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.08 2.67 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.951 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.7 m -142.93 132.17 23.29 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.198 0.523 . . . . 0.0 112.088 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.467 HG22 ' O ' ' A' ' 24' ' ' THR . 15.2 t -89.73 -161.51 0.79 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 17.1 t -149.14 129.47 13.77 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 119.873 -0.731 . . . . 0.0 112.798 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.4 m -89.85 -52.57 4.91 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.628 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.75 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.66 0 CA-C-N 113.821 -1.536 . . . . 0.0 110.274 175.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.628 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.9 Cg_endo -98.69 10.81 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.676 0 CA-C-N 120.502 1.215 . . . . 0.0 111.805 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.8 m -153.14 133.46 4.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.444 0.64 . . . . 0.0 112.669 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.4 m -95.07 136.3 35.56 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 176.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.654 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.1 t . . . . . 0 C--N 1.323 -0.549 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.394 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 m . . . . . 0 N--CA 1.456 -0.156 0 CA-C-O 121.078 0.466 . . . . 0.0 109.824 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.83 28.17 73.05 Favored Glycine 0 C--N 1.334 0.431 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.813 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -122.44 150.08 42.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.13 -0.535 . . . . 0.0 109.976 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.558 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.0 p -109.37 143.46 38.89 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.381 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.632 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.4 p -117.78 41.13 2.94 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.359 0.6 . . . . 0.0 110.562 178.219 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.3 t -54.76 -21.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.587 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.2 25.33 23.86 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.476 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 61.2 36.83 93.0 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.572 -0.314 . . . . 0.0 112.348 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.62 142.48 23.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.235 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.632 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.6 m -133.1 130.6 39.51 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -78.33 -30.39 48.18 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.748 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.6 OUTLIER -77.68 113.99 37.16 Favored Pre-proline 0 N--CA 1.45 -0.452 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 177.977 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -63.91 -45.06 11.32 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 123.074 2.516 . . . . 0.0 114.593 -177.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.17 45.72 2.6 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.468 -0.873 . . . . 0.0 112.498 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.748 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 56.7 m -136.89 127.64 27.22 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.324 0.583 . . . . 0.0 112.545 -178.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.6 p -89.71 114.64 26.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.264 178.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.6 t -77.24 127.3 32.37 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.292 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 m -93.19 -52.46 4.54 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 179.14 -69.21 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.734 0 CA-C-N 113.965 -1.47 . . . . 0.0 110.451 175.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.9 Cg_endo -97.94 8.48 1.15 Allowed 'Trans proline' 0 N--CA 1.439 -1.692 0 CA-C-N 120.443 1.194 . . . . 0.0 111.653 -178.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.1 m -152.36 134.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.583 0.706 . . . . 0.0 112.309 -178.568 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 67.5 m -89.85 100.4 13.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.431 ' OG1' ' HA ' ' A' ' 16' ' ' CYS . 90.9 m . . . . . 0 N--CA 1.464 0.25 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.868 -177.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 121.298 0.571 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 66.44 23.53 71.93 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.307 -0.86 . . . . 0.0 112.352 179.163 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -113.56 153.85 28.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 ' O ' ' A' ' 21' ' ' PRO . 58.2 p -113.6 142.83 45.5 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.579 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 6.3 p -119.25 43.99 2.46 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.186 0.517 . . . . 0.0 110.475 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.1 t -52.89 -21.73 3.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.96 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -111.52 25.06 14.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.697 -0.764 . . . . 0.0 111.671 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.46 36.01 92.53 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.619 -0.291 . . . . 0.0 112.444 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.7 p -140.53 134.75 31.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.579 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.6 m -129.97 130.38 44.98 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.556 177.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.7 m-80 -80.4 -40.05 27.17 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.251 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.797 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.9 OUTLIER -72.61 116.81 53.5 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.59 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -63.68 -45.67 10.65 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.209 2.606 . . . . 0.0 114.901 -176.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.72 44.95 2.61 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.388 -0.91 . . . . 0.0 112.368 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.797 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 20.0 m -139.48 129.63 25.19 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.855 0.359 . . . . 0.0 111.947 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -93.07 141.38 28.47 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 39.7 t -95.02 125.18 39.51 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 m -93.51 -52.88 4.29 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 176.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.02 -70.92 0.0 OUTLIER Pre-proline 0 C--O 1.213 -0.831 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.963 175.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.9 Cg_endo -98.49 12.92 0.74 Allowed 'Trans proline' 0 N--CA 1.44 -1.625 0 CA-C-N 120.738 1.299 . . . . 0.0 111.348 -178.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.412 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.5 133.09 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-O 121.453 0.644 . . . . 0.0 112.417 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.553 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 78.2 m -90.72 57.79 3.68 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.044 177.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 21.4 m . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 121.242 0.544 . . . . 0.0 111.474 -178.865 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 32.6 m . . . . . 0 N--CA 1.456 -0.171 0 CA-C-O 120.742 0.306 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.11 33.38 87.1 Favored Glycine 0 C--N 1.333 0.38 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.456 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 3.2 tp10 -127.28 151.96 48.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.804 -0.698 . . . . 0.0 110.0 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.57 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -113.79 144.59 42.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.385 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.4 p -119.39 40.66 3.29 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.289 0.566 . . . . 0.0 110.319 178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.6 t -55.61 -21.93 11.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.227 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.81 26.25 21.58 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.519 178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.01 36.59 89.05 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.661 -0.27 . . . . 0.0 112.482 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.55 140.86 22.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.0 m -124.99 123.87 40.78 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.178 178.489 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -73.59 -35.02 65.35 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.109 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.619 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -71.45 116.69 49.98 Favored Pre-proline 0 C--O 1.234 0.261 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.438 179.61 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.86 119.83 6.08 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.443 2.095 . . . . 0.0 112.948 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.06 -8.29 31.27 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.916 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.619 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.3 m -88.92 130.89 35.35 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.977 0.418 . . . . 0.0 111.518 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -88.11 144.93 26.21 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 36.5 t -103.17 132.01 49.76 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 113.731 1.011 . . . . 0.0 113.731 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 m -95.97 -52.66 3.96 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 176.068 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.5 t90 178.99 -69.63 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.667 0 CA-C-N 113.708 -1.587 . . . . 0.0 110.467 175.423 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.1 9.94 1.02 Allowed 'Trans proline' 0 N--CA 1.442 -1.544 0 CA-C-N 120.567 1.238 . . . . 0.0 111.615 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.8 m -152.39 135.18 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.62 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.506 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 84.7 m -90.04 37.74 0.9 Allowed 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.277 178.592 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 25.8 m . . . . . 0 C--O 1.238 0.468 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.525 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 82.7 m . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.906 0.384 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.23 28.87 74.06 Favored Glycine 0 C--N 1.334 0.418 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.112 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -112.12 147.78 35.37 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.653 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.561 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.8 p -101.73 142.62 32.79 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 120.688 0.28 . . . . 0.0 110.44 179.221 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.507 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.1 p -119.72 42.7 2.84 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 121.313 0.578 . . . . 0.0 110.198 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.7 t -52.51 -21.96 3.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.93 -1.032 . . . . 0.0 111.136 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -109.74 24.62 19.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.549 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.67 36.31 93.09 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 112.235 -0.346 . . . . 0.0 112.235 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.2 p -142.04 133.85 27.13 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -179.036 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.507 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.5 m -126.58 129.09 47.88 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 177.449 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 -81.21 -34.53 32.19 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.41 ' HA ' ' HD2' ' A' ' 14' ' ' PRO . 0.2 OUTLIER -77.59 117.31 64.79 Favored Pre-proline 0 N--CA 1.447 -0.589 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.862 179.245 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 13' ' ' THR . 24.5 Cg_endo -63.38 -39.53 36.64 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 123.169 2.579 . . . . 0.0 113.878 -178.46 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.69 33.6 1.2 Allowed Glycine 0 C--N 1.321 -0.28 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.815 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 11.0 m -150.9 135.04 16.8 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.957 0.408 . . . . 0.0 111.816 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.9 t -89.12 -161.22 0.74 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.541 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 35.1 t -144.29 130.78 19.92 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.951 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.7 t -93.35 -52.81 4.35 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 176.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.634 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.7 t90 179.3 -70.16 0.0 OUTLIER Pre-proline 0 C--O 1.214 -0.781 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.407 175.829 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.634 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.76 9.42 1.13 Allowed 'Trans proline' 0 N--CA 1.441 -1.598 0 CA-C-N 120.742 1.301 . . . . 0.0 111.711 -178.526 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.8 m -151.81 129.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.595 0.712 . . . . 0.0 112.396 -178.657 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.413 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 82.4 m -83.34 72.32 10.21 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.215 177.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.315 -178.876 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.466 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 29.0 m . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.97 0.414 . . . . 0.0 110.132 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.46 31.08 73.45 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.831 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -133.27 154.03 51.04 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 21' ' ' PRO . 62.8 p -106.91 148.06 29.05 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.947 0.403 . . . . 0.0 110.736 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' SG ' ' A' ' 23' ' ' CYS . 4.1 p -121.97 39.02 3.98 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.514 0.673 . . . . 0.0 110.02 178.18 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.451 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.0 t -56.32 -21.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.226 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.63 25.91 22.94 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.55 178.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.44 38.71 93.89 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.399 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.18 140.16 21.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 18' ' ' CYS . 91.9 m -123.4 127.34 48.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.556 178.028 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -77.45 -38.52 49.27 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.759 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.761 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -70.65 118.31 63.63 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.388 179.671 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -70.74 119.18 6.13 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.342 2.028 . . . . 0.0 112.711 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.19 -4.43 33.53 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.831 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.761 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 89.9 m -88.5 131.52 34.87 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.219 0.533 . . . . 0.0 111.596 -179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.44 142.76 27.45 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.443 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 31.0 t -103.04 130.11 50.04 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 113.072 0.768 . . . . 0.0 113.072 -178.048 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.14 -52.5 4.8 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.63 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.58 -68.52 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.656 0 CA-C-N 113.648 -1.615 . . . . 0.0 110.396 175.399 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.63 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.4 Cg_endo -98.05 6.66 1.22 Allowed 'Trans proline' 0 N--CA 1.44 -1.673 0 CA-C-N 120.24 1.121 . . . . 0.0 112.126 -178.194 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.5 m -152.33 133.74 5.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.563 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.8 m -93.36 130.83 39.0 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.102 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.466 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 11.6 t . . . . . 0 C--N 1.326 -0.454 0 C-N-CA 121.08 -0.248 . . . . 0.0 111.222 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 58.27 28.97 62.39 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.051 -0.977 . . . . 0.0 113.309 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -124.77 153.28 42.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.7 0.286 . . . . 0.0 110.524 -179.669 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' O ' ' A' ' 21' ' ' PRO . 67.4 p -105.79 147.47 28.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.249 179.006 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.7 p -118.62 41.69 2.93 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.487 0.66 . . . . 0.0 110.085 178.162 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.8 t -56.25 -22.7 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.139 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -102.57 24.47 30.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.411 178.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.81 33.59 73.89 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.5 -0.35 . . . . 0.0 112.354 -179.582 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.48 140.22 21.73 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.4 m -122.27 138.33 54.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.295 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.8 m-20 -74.2 -46.51 41.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.879 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.5 OUTLIER -76.17 118.79 73.83 Favored Pre-proline 0 N--CA 1.449 -0.49 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.304 178.742 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -64.67 -44.19 11.33 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 123.075 2.517 . . . . 0.0 114.061 -177.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.32 46.6 2.79 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.314 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.879 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.4 m -135.57 131.89 36.5 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.121 0.486 . . . . 0.0 111.907 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -88.39 127.36 35.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.829 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.8 t -93.96 127.59 39.82 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -93.57 -52.74 4.35 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 177.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 179.01 -68.9 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.706 0 CA-C-N 113.657 -1.61 . . . . 0.0 109.866 175.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -98.52 12.95 0.73 Allowed 'Trans proline' 0 N--CA 1.438 -1.735 0 CA-C-N 120.471 1.204 . . . . 0.0 111.386 -178.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -153.14 134.08 4.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.178 0.513 . . . . 0.0 111.978 -178.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.563 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 70.9 m -91.62 34.61 0.97 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.366 -0.833 . . . . 0.0 110.125 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 87.9 m . . . . . 0 C--O 1.237 0.435 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.087 -179.27 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.6 m . . . . . 0 N--CA 1.456 -0.165 0 CA-C-O 120.744 0.307 . . . . 0.0 110.594 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.25 26.51 70.57 Favored Glycine 0 C--N 1.334 0.464 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.846 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -103.58 155.34 18.61 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.676 -0.762 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.551 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.3 p -107.15 144.1 34.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.848 0.356 . . . . 0.0 110.196 178.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.2 p -121.1 39.09 3.9 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.398 0.618 . . . . 0.0 110.279 178.528 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.427 HG23 ' HB ' ' A' ' 5' ' ' THR . 21.8 t -55.35 -22.14 10.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.157 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.55 25.31 27.21 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.502 178.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.29 36.18 87.83 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.407 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 139.97 21.25 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.011 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.9 m -124.23 120.96 33.74 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.579 177.868 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -67.49 -38.65 84.68 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.393 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 m -82.18 120.79 77.97 Favored Pre-proline 0 N--CA 1.451 -0.408 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.91 -37.58 26.36 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 123.099 2.532 . . . . 0.0 113.965 -178.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.42 34.42 0.97 Allowed Glycine 0 CA--C 1.518 0.265 0 C-N-CA 121.22 -0.514 . . . . 0.0 114.033 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.5 m -151.15 142.0 22.89 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.95 0.405 . . . . 0.0 111.247 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.5 t -89.39 -156.29 0.39 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.237 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.1 t -153.38 129.27 10.22 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.247 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.3 p -93.13 -53.12 4.25 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 176.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 5.8 t90 179.21 -66.85 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.37 175.826 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.6 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.8 Cg_endo -97.34 2.78 1.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.791 0 CA-C-N 120.285 1.137 . . . . 0.0 112.383 -178.072 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 m -151.15 129.88 2.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.765 0.793 . . . . 0.0 112.658 -178.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 81.5 m -82.24 81.41 8.14 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 114.504 -1.225 . . . . 0.0 109.391 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.8 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-O 121.041 0.448 . . . . 0.0 111.852 -179.036 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.387 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.06 28.62 73.84 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.581 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 5' ' ' THR . 3.3 tp10 -128.06 150.79 49.8 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.005 -0.597 . . . . 0.0 110.144 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.555 HG22 ' O ' ' A' ' 21' ' ' PRO . 75.8 p -112.96 143.04 44.92 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 178.214 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.518 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.0 p -118.18 40.45 3.17 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.345 0.593 . . . . 0.0 110.571 178.78 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 t -55.04 -22.19 10.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.319 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.9 26.73 18.43 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.477 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 37.48 91.75 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.632 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.66 140.03 21.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.174 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.518 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.6 m -126.14 125.17 42.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.064 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 70.5 m-80 -77.07 -32.58 56.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.3 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.471 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -66.72 116.94 40.01 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.722 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 10.1 Cg_exo -71.66 118.84 5.85 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.51 2.14 . . . . 0.0 112.598 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.25 -12.56 33.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.748 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.471 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 94.9 m -88.71 136.47 32.98 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.958 0.408 . . . . 0.0 111.418 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.5 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 12.9 t -89.09 -161.48 0.77 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 19.3 t -152.99 132.67 13.09 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 36.6 t -94.77 -52.64 4.18 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.623 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.9 t90 179.22 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.638 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.875 175.676 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.623 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.5 Cg_endo -97.57 7.34 1.31 Allowed 'Trans proline' 0 N--CA 1.441 -1.58 0 CA-C-N 120.635 1.263 . . . . 0.0 111.996 -178.127 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.0 m -152.37 133.12 4.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.222 0.534 . . . . 0.0 111.789 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 84.1 m -86.73 115.92 24.49 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.447 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' THR . . . . . 0.5 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 6.5 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.045 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 121.03 0.443 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.13 25.76 71.15 Favored Glycine 0 C--O 1.227 -0.328 0 CA-C-N 115.466 -0.788 . . . . 0.0 113.193 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -122.53 152.54 40.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.525 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -106.84 146.89 30.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.581 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.498 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.3 p -119.7 39.52 3.61 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.56 0.695 . . . . 0.0 110.056 178.193 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -56.49 -21.85 13.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.253 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.96 25.6 24.86 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.828 -0.701 . . . . 0.0 111.551 178.854 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.61 37.93 92.98 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.591 -0.338 . . . . 0.0 112.321 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.21 139.02 20.84 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 66.1 m -123.48 133.85 53.98 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.027 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -80.98 -42.78 20.66 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.615 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.647 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.7 OUTLIER -72.22 119.03 72.43 Favored Pre-proline 0 C--N 1.327 -0.373 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.175 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.04 -47.3 12.93 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.986 2.457 . . . . 0.0 113.834 -178.112 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.34 41.04 2.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.188 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.647 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 74.3 m -140.78 133.57 28.94 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.963 0.411 . . . . 0.0 111.403 -178.934 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.5 t -89.4 -159.0 0.54 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.5 t -153.63 129.54 10.22 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.161 -0.616 . . . . 0.0 112.442 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.7 m -91.97 -52.84 4.53 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.021 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.89 -68.44 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.691 0 CA-C-N 113.899 -1.501 . . . . 0.0 110.451 175.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.89 9.76 1.08 Allowed 'Trans proline' 0 N--CA 1.441 -1.583 0 CA-C-N 120.402 1.179 . . . . 0.0 111.717 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.2 m -152.84 133.17 4.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 0.0 111.896 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 80.3 m -85.78 35.8 0.64 Allowed 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.5 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.8 p . . . . . 0 C--O 1.238 0.469 0 C-N-CA 123.035 0.534 . . . . 0.0 112.056 -179.639 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.52 -0.195 0 CA-C-O 120.868 0.366 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.82 31.62 80.97 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.475 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 4.4 tp10 -128.04 150.2 50.04 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.858 -0.671 . . . . 0.0 110.407 -178.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.554 HG22 ' O ' ' A' ' 21' ' ' PRO . 70.4 p -113.61 145.09 41.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.336 178.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.3 p -120.18 40.0 3.56 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.354 0.597 . . . . 0.0 110.17 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.7 t -54.35 -21.94 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.633 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.04 23.48 25.34 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.672 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 63.58 34.97 91.37 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.571 -0.315 . . . . 0.0 112.45 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.8 p -143.34 132.95 23.66 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 61.2 m -122.4 119.86 32.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.244 177.688 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -71.5 -34.78 70.43 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.854 -1.067 . . . . 0.0 109.977 179.35 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.5 115.11 40.41 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.93 -45.76 9.85 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.879 2.386 . . . . 0.0 113.826 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.01 40.87 2.55 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.235 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -142.06 140.11 32.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.106 0.479 . . . . 0.0 111.729 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.3 t -89.04 -156.87 0.41 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.811 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.7 t -160.04 130.21 5.45 Favored 'General case' 0 C--N 1.322 -0.592 0 O-C-N 121.963 -0.46 . . . . 0.0 111.876 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -98.46 -52.12 3.74 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.601 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.98 -68.28 0.0 OUTLIER Pre-proline 0 C--O 1.218 -0.602 0 CA-C-N 114.24 -1.345 . . . . 0.0 111.028 175.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.601 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.0 Cg_endo -97.11 6.98 1.46 Allowed 'Trans proline' 0 N--CA 1.439 -1.69 0 CA-C-N 120.786 1.317 . . . . 0.0 112.06 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.0 m -152.15 135.0 6.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.093 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.475 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 90.3 m -77.76 53.31 1.11 Allowed 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.187 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.911 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 120.856 0.36 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.91 31.93 81.11 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.659 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 2.4 tp10 -132.97 152.42 51.94 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.545 -0.828 . . . . 0.0 109.778 -178.642 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.2 p -116.3 142.8 46.37 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.036 0.446 . . . . 0.0 110.769 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.9 p -117.5 41.54 2.8 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.265 0.555 . . . . 0.0 110.378 178.32 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.0 t -54.7 -21.96 8.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.15 22.77 26.66 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.598 178.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 64.41 30.54 78.13 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.624 -0.288 . . . . 0.0 112.596 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -146.87 134.7 21.25 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 122.678 -0.307 . . . . 0.0 111.524 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.9 m -115.34 128.68 56.25 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.818 178.813 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.9 m-20 -73.65 -34.42 64.96 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.89 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.539 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -68.83 117.45 51.31 Favored Pre-proline 0 C--O 1.232 0.182 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.676 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 7.5 Cg_exo -73.27 119.52 6.05 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 122.441 2.094 . . . . 0.0 112.855 -179.469 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.35 -7.19 36.91 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.987 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.539 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 90.4 m -89.02 142.3 27.75 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.934 0.397 . . . . 0.0 111.627 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.7 t -88.53 -162.83 0.89 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.7 t -155.97 132.1 10.0 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -179.283 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.1 m -96.83 -51.88 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.1 t90 179.17 -70.27 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 114.156 -1.384 . . . . 0.0 110.721 175.502 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.2 Cg_endo -98.12 10.39 0.98 Allowed 'Trans proline' 0 N--CA 1.441 -1.603 0 CA-C-N 120.603 1.251 . . . . 0.0 111.606 -178.395 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.7 m -152.6 135.68 7.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.37 -178.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' CYS . . . . . 0.659 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 75.5 m -90.11 115.06 27.08 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.495 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 16.4 m . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.909 -178.404 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.522 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 35.2 m . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.804 0.335 . . . . 0.0 110.27 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.39 20.6 71.69 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.993 178.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 7.3 tp10 -97.05 157.23 16.01 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.483 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.545 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -100.61 144.86 29.09 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.054 0.454 . . . . 0.0 110.504 178.809 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.4 p -120.77 41.57 3.25 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.602 0.715 . . . . 0.0 109.906 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.9 t -56.06 -22.75 14.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.272 179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.32 23.43 35.3 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.351 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.31 32.48 72.38 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.504 -0.348 . . . . 0.0 112.321 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.85 139.54 20.7 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.136 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.6 m -118.63 137.39 53.31 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.295 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.5 m-20 -76.53 -43.89 37.33 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.919 0.39 . . . . 0.0 110.07 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -78.58 122.05 84.41 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.121 179.209 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -65.6 -37.15 30.23 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 123.047 2.498 . . . . 0.0 113.692 -178.653 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.74 35.9 1.02 Allowed Glycine 0 C--N 1.321 -0.28 0 CA-C-N 115.991 -0.549 . . . . 0.0 113.899 -178.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -150.73 140.74 22.02 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.967 0.413 . . . . 0.0 111.258 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.8 t -89.57 -151.61 0.23 Allowed 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.3 t -158.06 128.91 6.4 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 119.996 -0.682 . . . . 0.0 112.569 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.2 m -90.69 -51.87 5.16 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 176.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TRP . . . . . 0.627 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 178.62 -69.36 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.632 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.108 175.675 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.627 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.3 Cg_endo -97.76 10.5 1.06 Allowed 'Trans proline' 0 N--CA 1.44 -1.632 0 CA-C-N 120.421 1.186 . . . . 0.0 111.45 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.33 129.42 2.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.509 0.671 . . . . 0.0 112.457 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 73.7 m -82.09 78.25 8.8 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.038 177.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.214 -178.684 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 44.4 t . . . . . 0 CA--C 1.521 -0.171 0 CA-C-O 121.394 0.616 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m -78.99 -20.56 48.79 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.463 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.58 24.25 67.69 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.725 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -116.9 152.02 35.38 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 115.266 -0.467 . . . . 0.0 110.608 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.568 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.4 p -111.89 142.61 44.07 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.1 p -118.58 42.32 2.78 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.463 0.649 . . . . 0.0 110.403 178.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -55.58 -22.57 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.261 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.86 24.85 28.32 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.412 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.51 37.28 88.14 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.582 -0.309 . . . . 0.0 112.378 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.57 140.44 21.87 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 90.1 m -128.83 135.06 48.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.237 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -82.42 -38.13 24.49 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.602 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.1 m -66.9 114.9 20.09 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.571 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.36 -45.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.968 2.446 . . . . 0.0 113.789 -177.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.09 39.32 2.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.38 -0.914 . . . . 0.0 112.087 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 89.6 m -143.37 131.39 21.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.128 0.489 . . . . 0.0 111.779 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.527 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 9.2 t -89.79 -153.34 0.28 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.0 t -154.61 131.67 10.96 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.7 m -91.59 -53.24 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.619 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 178.96 -69.74 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.671 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.393 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.619 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.3 Cg_endo -97.99 11.36 0.94 Allowed 'Trans proline' 0 N--CA 1.44 -1.619 0 CA-C-N 120.546 1.231 . . . . 0.0 111.482 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.49 130.63 2.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.188 0.518 . . . . 0.0 111.881 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.5 m -81.47 113.39 19.5 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.527 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 1.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.337 -178.315 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.9 m . . . . . 0 CA--C 1.526 0.042 0 CA-C-O 121.4 0.619 . . . . 0.0 110.522 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.1 m -83.86 -12.84 54.95 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.01 13.07 72.32 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.245 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -98.09 151.7 20.09 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.104 -0.548 . . . . 0.0 109.748 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -105.97 143.83 33.56 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.849 0.357 . . . . 0.0 110.133 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.0 p -119.38 42.29 2.89 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.367 0.603 . . . . 0.0 110.203 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.6 t -54.94 -22.53 10.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.324 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.78 25.2 26.27 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.463 178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.94 36.74 89.35 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.524 -0.338 . . . . 0.0 112.417 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.69 140.45 21.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.2 m -127.13 132.61 50.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.162 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -81.65 -34.7 30.65 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.48 115.33 46.61 Favored Pre-proline 0 N--CA 1.449 -0.476 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.914 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -62.11 -37.9 60.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 123.11 2.54 . . . . 0.0 113.858 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.99 33.93 1.47 Allowed Glycine 0 C--N 1.322 -0.202 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.801 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.0 m -150.71 140.29 21.59 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.123 0.487 . . . . 0.0 112.002 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -90.08 -149.38 0.2 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.2 t -156.82 128.37 7.07 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.051 -0.659 . . . . 0.0 112.519 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.5 m -92.13 -52.13 4.85 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.631 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 178.77 -70.04 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.703 0 CA-C-N 113.825 -1.534 . . . . 0.0 110.121 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.631 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.8 Cg_endo -97.99 11.17 0.96 Allowed 'Trans proline' 0 N--CA 1.439 -1.733 0 CA-C-N 120.632 1.261 . . . . 0.0 111.51 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.54 130.73 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 CA-C-O 121.45 0.643 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.7 m -84.67 80.57 9.2 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.651 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.113 -178.402 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.579 HG22 ' H ' ' A' ' 3' ' ' GLY . 14.4 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.776 0.322 . . . . 0.0 110.256 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 19.5 m -78.77 -28.32 44.72 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 -179.114 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.579 ' H ' HG22 ' A' ' 1' ' ' VAL . . . 62.74 23.85 65.75 Favored Glycine 0 C--N 1.334 0.44 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -94.71 155.35 16.88 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.717 -0.742 . . . . 0.0 110.28 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.2 p -108.85 142.55 39.27 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.7 p -119.95 42.28 2.97 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.324 0.583 . . . . 0.0 110.352 178.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.5 t -54.24 -22.55 8.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.402 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.55 24.95 27.28 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.446 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.96 36.41 87.95 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.478 -0.361 . . . . 0.0 112.475 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.76 140.45 21.71 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 98.2 m -126.56 132.41 51.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.598 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -80.18 -40.06 28.0 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.776 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -76.08 116.71 58.27 Favored Pre-proline 0 N--CA 1.45 -0.451 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.171 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.1 -37.3 64.73 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 123.23 2.62 . . . . 0.0 113.734 -178.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.31 35.46 1.32 Allowed Glycine 0 CA--C 1.517 0.195 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.781 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.7 m -150.82 141.01 22.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.107 0.479 . . . . 0.0 111.635 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.69 -145.78 0.15 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.6 t -166.45 133.06 2.49 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.867 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 p -103.48 -53.01 2.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 107.562 -1.274 . . . . 0.0 107.562 177.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.611 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.8 t90 -177.87 -69.46 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.731 0 CA-C-N 114.329 -1.305 . . . . 0.0 111.013 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.611 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.6 Cg_endo -97.39 9.5 1.22 Allowed 'Trans proline' 0 N--CA 1.439 -1.702 0 CA-C-N 121.104 1.43 . . . . 0.0 111.727 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.9 m -151.35 132.91 5.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-O 121.531 0.682 . . . . 0.0 111.063 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 66.6 m -76.87 59.29 1.59 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.75 -1.113 . . . . 0.0 110.739 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.326 -0.435 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.977 -179.774 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.228 -0.072 0 CA-C-O 121.106 0.479 . . . . 0.0 110.631 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.2 m -79.28 -21.75 45.61 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.693 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.99 24.02 75.9 Favored Glycine 0 N--CA 1.448 -0.552 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.531 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -118.02 152.06 36.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.158 -0.521 . . . . 0.0 110.194 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.55 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.5 p -110.72 142.13 43.07 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 178.293 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.564 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.78 42.77 2.55 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-O 121.37 0.605 . . . . 0.0 110.452 178.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.3 t -54.96 -22.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.388 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.27 25.09 27.16 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.815 -0.707 . . . . 0.0 111.442 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.23 37.04 85.54 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.489 -0.355 . . . . 0.0 112.522 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.54 140.46 21.92 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.564 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.6 m -126.96 134.56 50.37 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.233 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -86.68 -37.22 18.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.685 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.545 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 2.6 m -61.77 116.89 23.57 Favored Pre-proline 0 C--O 1.236 0.344 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.504 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 15.9 Cg_exo -68.52 114.78 3.6 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.597 2.198 . . . . 0.0 112.887 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.61 -8.71 28.15 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.469 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 86.0 m -89.0 134.69 33.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.71 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.5 t -88.94 -159.71 0.59 Allowed 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 178.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 26.2 t -156.38 131.62 9.29 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 119.922 -0.711 . . . . 0.0 112.907 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.9 t -93.74 -53.01 4.2 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 176.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 179.23 -69.61 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.728 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.21 175.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.8 Cg_endo -98.06 12.04 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.627 0 CA-C-N 120.634 1.262 . . . . 0.0 111.497 -178.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.4 131.37 3.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.844 -178.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 90.9 m -82.17 119.87 24.61 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.307 -0.861 . . . . 0.0 108.758 178.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 48.3 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.696 -178.049 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.46 0.073 0 CA-C-O 121.234 0.54 . . . . 0.0 110.602 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.629 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 5.9 m -79.84 -20.37 46.18 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.951 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.43 23.16 75.13 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 31.9 tt0 -122.13 148.58 44.73 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.281 -0.46 . . . . 0.0 110.144 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.541 HG22 ' O ' ' A' ' 21' ' ' PRO . 63.2 p -107.8 142.8 37.28 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.205 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -116.66 41.76 2.61 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.337 0.589 . . . . 0.0 110.385 178.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.6 t -54.85 -22.31 9.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.394 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.47 25.78 23.55 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.808 -0.71 . . . . 0.0 111.403 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.15 37.07 91.2 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.584 -0.308 . . . . 0.0 112.43 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.64 140.24 21.6 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 76.0 m -128.95 133.69 47.92 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.296 178.358 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.436 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.4 m-80 -81.21 -33.17 33.09 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 179.125 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.39 114.26 22.72 Favored Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.316 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -61.85 -46.05 14.85 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.982 2.455 . . . . 0.0 113.991 -177.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.36 2.7 Favored Glycine 0 CA--C 1.508 -0.355 0 C-N-CA 120.306 -0.949 . . . . 0.0 111.938 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 77.3 m -142.62 132.38 24.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.176 0.513 . . . . 0.0 112.147 -178.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.47 HG22 ' O ' ' A' ' 24' ' ' THR . 15.4 t -89.71 -162.19 0.86 Allowed 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 177.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 18.1 t -148.86 129.29 13.87 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 119.887 -0.725 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 m -89.8 -52.69 4.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.85 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.695 0 CA-C-N 113.877 -1.511 . . . . 0.0 110.363 175.627 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.2 Cg_endo -98.41 9.8 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.664 0 CA-C-N 120.524 1.223 . . . . 0.0 111.792 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.9 m -152.67 132.23 3.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -178.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.8 m -93.38 136.24 33.84 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 176.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.629 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.8 t . . . . . 0 C--N 1.323 -0.554 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.384 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 CA--C 1.524 -0.024 0 CA-C-O 121.38 0.609 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.2 -31.39 43.76 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.95 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.5 24.97 71.24 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -111.57 154.44 24.82 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.017 -0.591 . . . . 0.0 110.163 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.594 HG22 ' O ' ' A' ' 21' ' ' PRO . 81.4 p -113.25 143.77 43.85 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -122.95 43.41 2.94 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.384 0.611 . . . . 0.0 110.315 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.4 t -53.72 -22.39 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 114.702 -1.135 . . . . 0.0 110.823 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.08 23.19 25.93 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.692 -0.766 . . . . 0.0 111.606 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.72 36.28 93.08 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 112.345 -0.302 . . . . 0.0 112.345 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.4 p -141.98 134.06 27.54 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 99.2 m -127.34 132.8 50.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.964 177.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -83.1 -37.72 23.42 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.732 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.3 m -67.3 115.25 24.28 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -60.4 -47.92 12.93 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.936 2.424 . . . . 0.0 113.77 -178.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.27 39.84 2.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.971 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 97.7 m -141.88 133.2 26.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.313 0.578 . . . . 0.0 112.134 -179.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.8 t -89.89 -154.58 0.33 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.3 t -155.86 129.44 8.39 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 121.702 -0.624 . . . . 0.0 112.41 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.9 m -91.76 -53.32 4.34 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.614 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.8 t90 179.01 -69.85 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.754 0 CA-C-N 113.826 -1.534 . . . . 0.0 110.241 175.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -97.62 11.4 1.02 Allowed 'Trans proline' 0 N--CA 1.44 -1.652 0 CA-C-N 120.671 1.275 . . . . 0.0 111.392 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.7 m -152.82 131.58 2.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.825 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 95.3 m -76.38 122.1 23.99 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.1 m . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.324 -177.359 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 3' ' ' GLY . 37.8 t . . . . . 0 N--CA 1.454 -0.242 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.1 m -79.27 -26.16 42.39 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.973 0.415 . . . . 0.0 110.338 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.508 ' H ' HG12 ' A' ' 1' ' ' VAL . . . 67.05 21.6 71.82 Favored Glycine 0 C--N 1.333 0.398 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.949 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.407 ' HB3' ' HB2' ' A' ' 23' ' ' CYS . 87.4 tt0 -97.6 160.0 14.58 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.831 -0.685 . . . . 0.0 109.481 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 21' ' ' PRO . 73.8 p -113.67 141.69 46.92 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.539 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.7 p -117.92 42.85 2.55 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.304 0.573 . . . . 0.0 110.458 178.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -54.95 -22.41 10.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.367 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.38 25.88 23.38 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.441 178.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.5 37.0 87.35 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.432 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.6 140.76 22.17 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.052 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.539 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 73.8 m -127.18 131.49 50.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.258 178.438 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -78.99 -38.35 36.99 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 m -75.27 116.06 50.97 Favored Pre-proline 0 N--CA 1.45 -0.461 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.988 179.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -61.46 -38.15 65.68 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 123.182 2.588 . . . . 0.0 113.852 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.89 35.19 1.44 Allowed Glycine 0 C--O 1.228 -0.253 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.651 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 4.3 m -151.0 135.74 17.24 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.056 0.455 . . . . 0.0 111.957 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.489 HG22 ' O ' ' A' ' 24' ' ' THR . 13.7 t -89.29 -157.54 0.46 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.3 t -146.55 128.02 15.01 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 119.575 -0.85 . . . . 0.0 113.124 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.6 m -89.83 -52.83 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.641 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.9 t90 178.62 -69.9 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.717 0 CA-C-N 113.742 -1.572 . . . . 0.0 110.082 175.536 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.641 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.87 12.07 0.72 Allowed 'Trans proline' 0 N--CA 1.44 -1.668 0 CA-C-N 120.55 1.232 . . . . 0.0 111.573 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.405 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.29 132.82 4.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.668 0.747 . . . . 0.0 112.928 -178.328 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 83.9 m -96.57 124.99 40.73 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.809 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.489 ' O ' HG22 ' A' ' 17' ' ' THR . 9.1 t . . . . . 0 C--N 1.324 -0.533 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.288 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 N--CA 1.46 0.075 0 CA-C-O 121.229 0.538 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.654 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 9.3 m -80.76 -18.57 47.27 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.939 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 69.31 22.3 76.2 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.875 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.437 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 33.1 tt0 -123.07 149.82 43.94 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.265 -0.467 . . . . 0.0 110.222 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.9 p -110.38 144.3 39.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.294 -0.412 . . . . 0.0 109.892 178.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.65 41.97 2.72 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.384 0.611 . . . . 0.0 110.33 178.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 t -55.17 -22.59 11.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.304 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.64 25.46 25.6 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.464 178.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.95 36.7 89.22 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.529 -0.336 . . . . 0.0 112.577 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 140.72 22.0 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.5 m -128.88 133.66 48.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.355 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASN . . . . . 0.437 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.3 m-80 -81.49 -33.08 32.13 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.13 114.35 22.88 Favored Pre-proline 0 CA--C 1.535 0.377 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.227 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -62.08 -45.98 14.38 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.952 2.435 . . . . 0.0 114.002 -177.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.08 2.67 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.951 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.7 m -142.93 132.17 23.29 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.198 0.523 . . . . 0.0 112.088 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.467 HG22 ' O ' ' A' ' 24' ' ' THR . 15.2 t -89.73 -161.51 0.79 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 17.1 t -149.14 129.47 13.77 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 119.873 -0.731 . . . . 0.0 112.798 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.4 m -89.85 -52.57 4.91 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.628 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.75 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.66 0 CA-C-N 113.821 -1.536 . . . . 0.0 110.274 175.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.628 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.9 Cg_endo -98.69 10.81 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.676 0 CA-C-N 120.502 1.215 . . . . 0.0 111.805 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.8 m -153.14 133.46 4.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.444 0.64 . . . . 0.0 112.669 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.4 m -95.07 136.3 35.56 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 176.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.654 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.1 t . . . . . 0 C--N 1.323 -0.549 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.394 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 N--CA 1.461 0.077 0 CA-C-O 121.029 0.442 . . . . 0.0 110.709 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 m -78.87 -24.43 44.29 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.824 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.83 28.17 73.05 Favored Glycine 0 C--N 1.334 0.431 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.813 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -122.44 150.08 42.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.13 -0.535 . . . . 0.0 109.976 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.558 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.0 p -109.37 143.46 38.89 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.381 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.632 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.4 p -117.78 41.13 2.94 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.359 0.6 . . . . 0.0 110.562 178.219 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.3 t -54.76 -21.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.587 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.2 25.33 23.86 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.476 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 61.2 36.83 93.0 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.572 -0.314 . . . . 0.0 112.348 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.62 142.48 23.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.235 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.632 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.6 m -133.1 130.6 39.51 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -78.33 -30.39 48.18 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.748 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.6 OUTLIER -77.68 113.99 37.16 Favored Pre-proline 0 N--CA 1.45 -0.452 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 177.977 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -63.91 -45.06 11.32 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 123.074 2.516 . . . . 0.0 114.593 -177.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.17 45.72 2.6 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.468 -0.873 . . . . 0.0 112.498 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.748 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 56.7 m -136.89 127.64 27.22 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.324 0.583 . . . . 0.0 112.545 -178.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.6 p -89.71 114.64 26.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.264 178.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.6 t -77.24 127.3 32.37 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.292 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 m -93.19 -52.46 4.54 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 179.14 -69.21 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.734 0 CA-C-N 113.965 -1.47 . . . . 0.0 110.451 175.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.9 Cg_endo -97.94 8.48 1.15 Allowed 'Trans proline' 0 N--CA 1.439 -1.692 0 CA-C-N 120.443 1.194 . . . . 0.0 111.653 -178.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.1 m -152.36 134.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.583 0.706 . . . . 0.0 112.309 -178.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 67.5 m -89.85 100.4 13.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.431 ' OG1' ' HA ' ' A' ' 16' ' ' CYS . 90.9 m . . . . . 0 N--CA 1.464 0.25 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.868 -177.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 CA--C 1.527 0.084 0 CA-C-O 121.183 0.516 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 21.3 m -79.66 -18.62 51.0 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.723 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 66.44 23.53 71.93 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.307 -0.86 . . . . 0.0 112.352 179.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -113.56 153.85 28.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 ' O ' ' A' ' 21' ' ' PRO . 58.2 p -113.6 142.83 45.5 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.579 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 6.3 p -119.25 43.99 2.46 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.186 0.517 . . . . 0.0 110.475 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.1 t -52.89 -21.73 3.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.96 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -111.52 25.06 14.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.697 -0.764 . . . . 0.0 111.671 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.46 36.01 92.53 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.619 -0.291 . . . . 0.0 112.444 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.7 p -140.53 134.75 31.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.579 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.6 m -129.97 130.38 44.98 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.556 177.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.7 m-80 -80.4 -40.05 27.17 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.251 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.797 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.9 OUTLIER -72.61 116.81 53.5 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.59 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -63.68 -45.67 10.65 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.209 2.606 . . . . 0.0 114.901 -176.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.72 44.95 2.61 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.388 -0.91 . . . . 0.0 112.368 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.797 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 20.0 m -139.48 129.63 25.19 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.855 0.359 . . . . 0.0 111.947 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -93.07 141.38 28.47 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 39.7 t -95.02 125.18 39.51 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 m -93.51 -52.88 4.29 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 176.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.02 -70.92 0.0 OUTLIER Pre-proline 0 C--O 1.213 -0.831 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.963 175.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.9 Cg_endo -98.49 12.92 0.74 Allowed 'Trans proline' 0 N--CA 1.44 -1.625 0 CA-C-N 120.738 1.299 . . . . 0.0 111.348 -178.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.412 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.5 133.09 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-O 121.453 0.644 . . . . 0.0 112.417 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.553 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 78.2 m -90.72 57.79 3.68 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.044 177.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 21.4 m . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 121.242 0.544 . . . . 0.0 111.474 -178.865 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 N--CA 1.458 -0.062 0 CA-C-O 121.321 0.581 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 32.6 m -79.63 -24.67 41.76 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.338 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.11 33.38 87.1 Favored Glycine 0 C--N 1.333 0.38 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.456 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 3.2 tp10 -127.28 151.96 48.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.804 -0.698 . . . . 0.0 110.0 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.57 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -113.79 144.59 42.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.385 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.4 p -119.39 40.66 3.29 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.289 0.566 . . . . 0.0 110.319 178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.6 t -55.61 -21.93 11.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.227 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.81 26.25 21.58 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.519 178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.01 36.59 89.05 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.661 -0.27 . . . . 0.0 112.482 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.55 140.86 22.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.0 m -124.99 123.87 40.78 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.178 178.489 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -73.59 -35.02 65.35 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.109 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.619 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -71.45 116.69 49.98 Favored Pre-proline 0 C--O 1.234 0.261 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.438 179.61 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.86 119.83 6.08 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.443 2.095 . . . . 0.0 112.948 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.06 -8.29 31.27 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.916 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.619 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.3 m -88.92 130.89 35.35 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.977 0.418 . . . . 0.0 111.518 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -88.11 144.93 26.21 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 36.5 t -103.17 132.01 49.76 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 113.731 1.011 . . . . 0.0 113.731 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 m -95.97 -52.66 3.96 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 176.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.5 t90 178.99 -69.63 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.667 0 CA-C-N 113.708 -1.587 . . . . 0.0 110.467 175.423 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.1 9.94 1.02 Allowed 'Trans proline' 0 N--CA 1.442 -1.544 0 CA-C-N 120.567 1.238 . . . . 0.0 111.615 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.8 m -152.39 135.18 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.62 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.506 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 84.7 m -90.04 37.74 0.9 Allowed 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.277 178.592 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 25.8 m . . . . . 0 C--O 1.238 0.468 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.525 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.454 -0.262 0 CA-C-O 120.655 0.264 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 82.7 m -79.42 -21.49 45.49 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.409 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.23 28.87 74.06 Favored Glycine 0 C--N 1.334 0.418 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.112 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -112.12 147.78 35.37 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.653 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.561 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.8 p -101.73 142.62 32.79 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 120.688 0.28 . . . . 0.0 110.44 179.221 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.507 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.1 p -119.72 42.7 2.84 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 121.313 0.578 . . . . 0.0 110.198 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.7 t -52.51 -21.96 3.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.93 -1.032 . . . . 0.0 111.136 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -109.74 24.62 19.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.549 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.67 36.31 93.09 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 112.235 -0.346 . . . . 0.0 112.235 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.2 p -142.04 133.85 27.13 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -179.036 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.507 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.5 m -126.58 129.09 47.88 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 177.449 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 -81.21 -34.53 32.19 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.41 ' HA ' ' HD2' ' A' ' 14' ' ' PRO . 0.2 OUTLIER -77.59 117.31 64.79 Favored Pre-proline 0 N--CA 1.447 -0.589 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.862 179.245 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 13' ' ' THR . 24.5 Cg_endo -63.38 -39.53 36.64 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 123.169 2.579 . . . . 0.0 113.878 -178.46 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.69 33.6 1.2 Allowed Glycine 0 C--N 1.321 -0.28 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.815 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 11.0 m -150.9 135.04 16.8 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.957 0.408 . . . . 0.0 111.816 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.9 t -89.12 -161.22 0.74 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 35.1 t -144.29 130.78 19.92 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.951 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.7 t -93.35 -52.81 4.35 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 176.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.634 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.7 t90 179.3 -70.16 0.0 OUTLIER Pre-proline 0 C--O 1.214 -0.781 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.407 175.829 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.634 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.76 9.42 1.13 Allowed 'Trans proline' 0 N--CA 1.441 -1.598 0 CA-C-N 120.742 1.301 . . . . 0.0 111.711 -178.526 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.8 m -151.81 129.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.595 0.712 . . . . 0.0 112.396 -178.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.413 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 82.4 m -83.34 72.32 10.21 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.215 177.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.315 -178.876 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.455 -0.175 0 CA-C-O 120.803 0.335 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.466 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 29.0 m -79.36 -27.34 41.96 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.132 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.46 31.08 73.45 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.831 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -133.27 154.03 51.04 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 21' ' ' PRO . 62.8 p -106.91 148.06 29.05 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.947 0.403 . . . . 0.0 110.736 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' SG ' ' A' ' 23' ' ' CYS . 4.1 p -121.97 39.02 3.98 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.514 0.673 . . . . 0.0 110.02 178.18 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.451 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.0 t -56.32 -21.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.226 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.63 25.91 22.94 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.55 178.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.44 38.71 93.89 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.399 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.18 140.16 21.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 18' ' ' CYS . 91.9 m -123.4 127.34 48.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.556 178.028 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -77.45 -38.52 49.27 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.759 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.761 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -70.65 118.31 63.63 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.388 179.671 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -70.74 119.18 6.13 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.342 2.028 . . . . 0.0 112.711 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.19 -4.43 33.53 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.831 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.761 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 89.9 m -88.5 131.52 34.87 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.219 0.533 . . . . 0.0 111.596 -179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.44 142.76 27.45 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.443 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 31.0 t -103.04 130.11 50.04 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 113.072 0.768 . . . . 0.0 113.072 -178.048 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.14 -52.5 4.8 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.63 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.58 -68.52 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.656 0 CA-C-N 113.648 -1.615 . . . . 0.0 110.396 175.399 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.63 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.4 Cg_endo -98.05 6.66 1.22 Allowed 'Trans proline' 0 N--CA 1.44 -1.673 0 CA-C-N 120.24 1.121 . . . . 0.0 112.126 -178.194 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.5 m -152.33 133.74 5.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.563 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.8 m -93.36 130.83 39.0 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.102 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.466 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 11.6 t . . . . . 0 C--N 1.326 -0.454 0 C-N-CA 121.08 -0.248 . . . . 0.0 111.222 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 43.2 t . . . . . 0 CA--C 1.52 -0.183 0 CA-C-O 121.268 0.556 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.5 m -78.87 -22.3 46.22 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.433 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 58.27 28.97 62.39 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.051 -0.977 . . . . 0.0 113.309 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -124.77 153.28 42.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.7 0.286 . . . . 0.0 110.524 -179.669 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' O ' ' A' ' 21' ' ' PRO . 67.4 p -105.79 147.47 28.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.249 179.006 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.7 p -118.62 41.69 2.93 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.487 0.66 . . . . 0.0 110.085 178.162 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.8 t -56.25 -22.7 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.139 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -102.57 24.47 30.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.411 178.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.81 33.59 73.89 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.5 -0.35 . . . . 0.0 112.354 -179.582 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.48 140.22 21.73 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.4 m -122.27 138.33 54.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.295 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 31.8 m-20 -74.2 -46.51 41.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.879 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.5 OUTLIER -76.17 118.79 73.83 Favored Pre-proline 0 N--CA 1.449 -0.49 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.304 178.742 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -64.67 -44.19 11.33 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 123.075 2.517 . . . . 0.0 114.061 -177.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.32 46.6 2.79 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.314 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.879 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.4 m -135.57 131.89 36.5 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.121 0.486 . . . . 0.0 111.907 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -88.39 127.36 35.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.829 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.8 t -93.96 127.59 39.82 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -93.57 -52.74 4.35 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 177.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 179.01 -68.9 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.706 0 CA-C-N 113.657 -1.61 . . . . 0.0 109.866 175.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -98.52 12.95 0.73 Allowed 'Trans proline' 0 N--CA 1.438 -1.735 0 CA-C-N 120.471 1.204 . . . . 0.0 111.386 -178.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -153.14 134.08 4.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.178 0.513 . . . . 0.0 111.978 -178.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.563 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 70.9 m -91.62 34.61 0.97 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.366 -0.833 . . . . 0.0 110.125 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 87.9 m . . . . . 0 C--O 1.237 0.435 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.087 -179.27 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.617 HG22 ' H ' ' A' ' 3' ' ' GLY . 12.0 p . . . . . 0 N--CA 1.455 -0.205 0 CA-C-O 120.756 0.312 . . . . 0.0 110.321 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.6 m -79.23 -26.55 42.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.594 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.617 ' H ' HG22 ' A' ' 1' ' ' VAL . . . 64.25 26.51 70.57 Favored Glycine 0 C--N 1.334 0.464 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.846 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -103.58 155.34 18.61 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.676 -0.762 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.551 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.3 p -107.15 144.1 34.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.848 0.356 . . . . 0.0 110.196 178.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.2 p -121.1 39.09 3.9 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.398 0.618 . . . . 0.0 110.279 178.528 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.427 HG23 ' HB ' ' A' ' 5' ' ' THR . 21.8 t -55.35 -22.14 10.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.157 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.55 25.31 27.21 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.502 178.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.29 36.18 87.83 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.407 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 139.97 21.25 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.011 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.9 m -124.23 120.96 33.74 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.579 177.868 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -67.49 -38.65 84.68 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.393 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 m -82.18 120.79 77.97 Favored Pre-proline 0 N--CA 1.451 -0.408 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.91 -37.58 26.36 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 123.099 2.532 . . . . 0.0 113.965 -178.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.42 34.42 0.97 Allowed Glycine 0 CA--C 1.518 0.265 0 C-N-CA 121.22 -0.514 . . . . 0.0 114.033 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.5 m -151.15 142.0 22.89 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.95 0.405 . . . . 0.0 111.247 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.5 t -89.39 -156.29 0.39 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.1 t -153.38 129.27 10.22 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.247 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.3 p -93.13 -53.12 4.25 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 176.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 5.8 t90 179.21 -66.85 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.37 175.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.6 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.8 Cg_endo -97.34 2.78 1.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.791 0 CA-C-N 120.285 1.137 . . . . 0.0 112.383 -178.072 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 m -151.15 129.88 2.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.765 0.793 . . . . 0.0 112.658 -178.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 81.5 m -82.24 81.41 8.14 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 114.504 -1.225 . . . . 0.0 109.391 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.8 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-O 121.041 0.448 . . . . 0.0 111.852 -179.036 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.306 0.575 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.0 m -80.16 -17.59 52.03 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.387 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.06 28.62 73.84 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.581 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 5' ' ' THR . 3.3 tp10 -128.06 150.79 49.8 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.005 -0.597 . . . . 0.0 110.144 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.555 HG22 ' O ' ' A' ' 21' ' ' PRO . 75.8 p -112.96 143.04 44.92 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 178.214 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.518 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.0 p -118.18 40.45 3.17 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.345 0.593 . . . . 0.0 110.571 178.78 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 t -55.04 -22.19 10.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.319 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.9 26.73 18.43 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.477 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 37.48 91.75 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.632 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.66 140.03 21.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.174 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.518 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.6 m -126.14 125.17 42.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.064 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 70.5 m-80 -77.07 -32.58 56.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.3 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.471 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -66.72 116.94 40.01 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.722 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 10.1 Cg_exo -71.66 118.84 5.85 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.51 2.14 . . . . 0.0 112.598 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.25 -12.56 33.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.748 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.471 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 94.9 m -88.71 136.47 32.98 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.958 0.408 . . . . 0.0 111.418 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.5 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 12.9 t -89.09 -161.48 0.77 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 19.3 t -152.99 132.67 13.09 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 36.6 t -94.77 -52.64 4.18 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.623 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.9 t90 179.22 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.638 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.875 175.676 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.623 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.5 Cg_endo -97.57 7.34 1.31 Allowed 'Trans proline' 0 N--CA 1.441 -1.58 0 CA-C-N 120.635 1.263 . . . . 0.0 111.996 -178.127 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.0 m -152.37 133.12 4.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.222 0.534 . . . . 0.0 111.789 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 84.1 m -86.73 115.92 24.49 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.447 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' THR . . . . . 0.5 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 6.5 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.045 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.8 t . . . . . 0 CA--C 1.528 0.132 0 CA-C-O 121.669 0.747 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.2 m -79.65 -26.87 40.96 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.035 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.13 25.76 71.15 Favored Glycine 0 C--O 1.227 -0.328 0 CA-C-N 115.466 -0.788 . . . . 0.0 113.193 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -122.53 152.54 40.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.525 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -106.84 146.89 30.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.581 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.498 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.3 p -119.7 39.52 3.61 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.56 0.695 . . . . 0.0 110.056 178.193 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -56.49 -21.85 13.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.253 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.96 25.6 24.86 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.828 -0.701 . . . . 0.0 111.551 178.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.61 37.93 92.98 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.591 -0.338 . . . . 0.0 112.321 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.21 139.02 20.84 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 66.1 m -123.48 133.85 53.98 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.027 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -80.98 -42.78 20.66 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.615 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.647 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.7 OUTLIER -72.22 119.03 72.43 Favored Pre-proline 0 C--N 1.327 -0.373 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.175 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.04 -47.3 12.93 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.986 2.457 . . . . 0.0 113.834 -178.112 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.34 41.04 2.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.188 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.647 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 74.3 m -140.78 133.57 28.94 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.963 0.411 . . . . 0.0 111.403 -178.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.5 t -89.4 -159.0 0.54 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.5 t -153.63 129.54 10.22 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.161 -0.616 . . . . 0.0 112.442 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.7 m -91.97 -52.84 4.53 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.021 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.89 -68.44 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.691 0 CA-C-N 113.899 -1.501 . . . . 0.0 110.451 175.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.89 9.76 1.08 Allowed 'Trans proline' 0 N--CA 1.441 -1.583 0 CA-C-N 120.402 1.179 . . . . 0.0 111.717 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.2 m -152.84 133.17 4.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 0.0 111.896 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 80.3 m -85.78 35.8 0.64 Allowed 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.5 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.8 p . . . . . 0 C--O 1.238 0.469 0 C-N-CA 123.035 0.534 . . . . 0.0 112.056 -179.639 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.498 HG12 ' H ' ' A' ' 3' ' ' GLY . 37.5 t . . . . . 0 N--CA 1.455 -0.197 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 8.0 m -79.39 -25.28 42.18 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.333 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.498 ' H ' HG12 ' A' ' 1' ' ' VAL . . . 62.82 31.62 80.97 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.475 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 4.4 tp10 -128.04 150.2 50.04 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.858 -0.671 . . . . 0.0 110.407 -178.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.554 HG22 ' O ' ' A' ' 21' ' ' PRO . 70.4 p -113.61 145.09 41.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.336 178.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.3 p -120.18 40.0 3.56 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.354 0.597 . . . . 0.0 110.17 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.7 t -54.35 -21.94 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.633 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.04 23.48 25.34 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.672 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 63.58 34.97 91.37 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.571 -0.315 . . . . 0.0 112.45 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.8 p -143.34 132.95 23.66 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 61.2 m -122.4 119.86 32.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.244 177.688 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -71.5 -34.78 70.43 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.854 -1.067 . . . . 0.0 109.977 179.35 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.5 115.11 40.41 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.93 -45.76 9.85 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.879 2.386 . . . . 0.0 113.826 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.01 40.87 2.55 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.235 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -142.06 140.11 32.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.106 0.479 . . . . 0.0 111.729 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.3 t -89.04 -156.87 0.41 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.7 t -160.04 130.21 5.45 Favored 'General case' 0 C--N 1.322 -0.592 0 O-C-N 121.963 -0.46 . . . . 0.0 111.876 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -98.46 -52.12 3.74 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.601 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.98 -68.28 0.0 OUTLIER Pre-proline 0 C--O 1.218 -0.602 0 CA-C-N 114.24 -1.345 . . . . 0.0 111.028 175.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.601 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.0 Cg_endo -97.11 6.98 1.46 Allowed 'Trans proline' 0 N--CA 1.439 -1.69 0 CA-C-N 120.786 1.317 . . . . 0.0 112.06 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.0 m -152.15 135.0 6.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.093 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.475 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 90.3 m -77.76 53.31 1.11 Allowed 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.187 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.911 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.228 -0.072 0 CA-C-O 121.184 0.516 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m -79.87 -14.74 58.43 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.179 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.91 31.93 81.11 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.659 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 2.4 tp10 -132.97 152.42 51.94 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.545 -0.828 . . . . 0.0 109.778 -178.642 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.2 p -116.3 142.8 46.37 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.036 0.446 . . . . 0.0 110.769 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.9 p -117.5 41.54 2.8 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.265 0.555 . . . . 0.0 110.378 178.32 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.0 t -54.7 -21.96 8.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.15 22.77 26.66 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.598 178.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 64.41 30.54 78.13 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.624 -0.288 . . . . 0.0 112.596 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -146.87 134.7 21.25 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 122.678 -0.307 . . . . 0.0 111.524 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.9 m -115.34 128.68 56.25 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.818 178.813 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 23.9 m-20 -73.65 -34.42 64.96 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.89 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.539 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -68.83 117.45 51.31 Favored Pre-proline 0 C--O 1.232 0.182 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.676 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 7.5 Cg_exo -73.27 119.52 6.05 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 122.441 2.094 . . . . 0.0 112.855 -179.469 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.35 -7.19 36.91 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.987 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.539 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 90.4 m -89.02 142.3 27.75 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.934 0.397 . . . . 0.0 111.627 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.7 t -88.53 -162.83 0.89 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.7 t -155.97 132.1 10.0 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -179.283 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.1 m -96.83 -51.88 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.1 t90 179.17 -70.27 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 114.156 -1.384 . . . . 0.0 110.721 175.502 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.2 Cg_endo -98.12 10.39 0.98 Allowed 'Trans proline' 0 N--CA 1.441 -1.603 0 CA-C-N 120.603 1.251 . . . . 0.0 111.606 -178.395 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.7 m -152.6 135.68 7.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.37 -178.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' CYS . . . . . 0.659 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 75.5 m -90.11 115.06 27.08 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.495 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 16.4 m . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.909 -178.404 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.4 HG12 ' H ' ' A' ' 3' ' ' GLY . 35.6 t . . . . . 0 N--CA 1.454 -0.273 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.522 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 35.2 m -78.65 -31.69 46.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.27 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.4 ' H ' HG12 ' A' ' 1' ' ' VAL . . . 67.39 20.6 71.69 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.993 178.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 7.3 tp10 -97.05 157.23 16.01 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.483 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.545 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -100.61 144.86 29.09 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.054 0.454 . . . . 0.0 110.504 178.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.4 p -120.77 41.57 3.25 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.602 0.715 . . . . 0.0 109.906 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.9 t -56.06 -22.75 14.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.272 179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.32 23.43 35.3 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.351 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.31 32.48 72.38 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.504 -0.348 . . . . 0.0 112.321 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.85 139.54 20.7 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.136 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.6 m -118.63 137.39 53.31 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.295 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 37.5 m-20 -76.53 -43.89 37.33 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.919 0.39 . . . . 0.0 110.07 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -78.58 122.05 84.41 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.121 179.209 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -65.6 -37.15 30.23 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 123.047 2.498 . . . . 0.0 113.692 -178.653 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.74 35.9 1.02 Allowed Glycine 0 C--N 1.321 -0.28 0 CA-C-N 115.991 -0.549 . . . . 0.0 113.899 -178.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -150.73 140.74 22.02 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.967 0.413 . . . . 0.0 111.258 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.8 t -89.57 -151.61 0.23 Allowed 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.3 t -158.06 128.91 6.4 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 119.996 -0.682 . . . . 0.0 112.569 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.2 m -90.69 -51.87 5.16 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 176.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TRP . . . . . 0.627 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 178.62 -69.36 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.632 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.108 175.675 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.627 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.3 Cg_endo -97.76 10.5 1.06 Allowed 'Trans proline' 0 N--CA 1.44 -1.632 0 CA-C-N 120.421 1.186 . . . . 0.0 111.45 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.33 129.42 2.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.509 0.671 . . . . 0.0 112.457 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 73.7 m -82.09 78.25 8.8 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.038 177.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.214 -178.684 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.519 -0.241 0 CA-C-O 121.381 0.61 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.58 24.25 67.69 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.725 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -116.9 152.02 35.38 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 115.266 -0.467 . . . . 0.0 110.608 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.568 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.4 p -111.89 142.61 44.07 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.1 p -118.58 42.32 2.78 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.463 0.649 . . . . 0.0 110.403 178.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -55.58 -22.57 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.261 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.86 24.85 28.32 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.412 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.51 37.28 88.14 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.582 -0.309 . . . . 0.0 112.378 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.57 140.44 21.87 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 90.1 m -128.83 135.06 48.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.237 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -82.42 -38.13 24.49 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.602 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.1 m -66.9 114.9 20.09 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.571 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.36 -45.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.968 2.446 . . . . 0.0 113.789 -177.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.09 39.32 2.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.38 -0.914 . . . . 0.0 112.087 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 89.6 m -143.37 131.39 21.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.128 0.489 . . . . 0.0 111.779 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.527 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 9.2 t -89.79 -153.34 0.28 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.0 t -154.61 131.67 10.96 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.7 m -91.59 -53.24 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.619 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 178.96 -69.74 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.671 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.393 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.619 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.3 Cg_endo -97.99 11.36 0.94 Allowed 'Trans proline' 0 N--CA 1.44 -1.619 0 CA-C-N 120.546 1.231 . . . . 0.0 111.482 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.49 130.63 2.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.188 0.518 . . . . 0.0 111.881 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.5 m -81.47 113.39 19.5 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.527 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 1.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.337 -178.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.1 m . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 121.075 0.464 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.01 13.07 72.32 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.245 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -98.09 151.7 20.09 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.104 -0.548 . . . . 0.0 109.748 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -105.97 143.83 33.56 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.849 0.357 . . . . 0.0 110.133 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.0 p -119.38 42.29 2.89 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.367 0.603 . . . . 0.0 110.203 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.6 t -54.94 -22.53 10.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.324 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.78 25.2 26.27 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.463 178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.94 36.74 89.35 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.524 -0.338 . . . . 0.0 112.417 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.69 140.45 21.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.2 m -127.13 132.61 50.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.162 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -81.65 -34.7 30.65 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.48 115.33 46.61 Favored Pre-proline 0 N--CA 1.449 -0.476 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.914 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -62.11 -37.9 60.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 123.11 2.54 . . . . 0.0 113.858 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.99 33.93 1.47 Allowed Glycine 0 C--N 1.322 -0.202 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.801 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.0 m -150.71 140.29 21.59 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.123 0.487 . . . . 0.0 112.002 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -90.08 -149.38 0.2 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.2 t -156.82 128.37 7.07 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.051 -0.659 . . . . 0.0 112.519 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.5 m -92.13 -52.13 4.85 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.631 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 178.77 -70.04 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.703 0 CA-C-N 113.825 -1.534 . . . . 0.0 110.121 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.631 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.8 Cg_endo -97.99 11.17 0.96 Allowed 'Trans proline' 0 N--CA 1.439 -1.733 0 CA-C-N 120.632 1.261 . . . . 0.0 111.51 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.54 130.73 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 CA-C-O 121.45 0.643 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.7 m -84.67 80.57 9.2 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.651 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.113 -178.402 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 19.5 m . . . . . 0 CA--C 1.522 -0.119 0 CA-C-O 120.807 0.337 . . . . 0.0 110.343 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.74 23.85 65.75 Favored Glycine 0 C--N 1.334 0.44 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -94.71 155.35 16.88 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.717 -0.742 . . . . 0.0 110.28 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.2 p -108.85 142.55 39.27 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.7 p -119.95 42.28 2.97 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.324 0.583 . . . . 0.0 110.352 178.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.5 t -54.24 -22.55 8.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.402 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.55 24.95 27.28 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.446 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.96 36.41 87.95 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.478 -0.361 . . . . 0.0 112.475 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.76 140.45 21.71 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 98.2 m -126.56 132.41 51.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.598 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -80.18 -40.06 28.0 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.776 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -76.08 116.71 58.27 Favored Pre-proline 0 N--CA 1.45 -0.451 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.171 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.1 -37.3 64.73 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 123.23 2.62 . . . . 0.0 113.734 -178.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.31 35.46 1.32 Allowed Glycine 0 CA--C 1.517 0.195 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.781 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.7 m -150.82 141.01 22.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.107 0.479 . . . . 0.0 111.635 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.69 -145.78 0.15 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.6 t -166.45 133.06 2.49 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.867 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 p -103.48 -53.01 2.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 107.562 -1.274 . . . . 0.0 107.562 177.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.611 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.8 t90 -177.87 -69.46 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.731 0 CA-C-N 114.329 -1.305 . . . . 0.0 111.013 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.611 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.6 Cg_endo -97.39 9.5 1.22 Allowed 'Trans proline' 0 N--CA 1.439 -1.702 0 CA-C-N 121.104 1.43 . . . . 0.0 111.727 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.9 m -151.35 132.91 5.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-O 121.531 0.682 . . . . 0.0 111.063 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 66.6 m -76.87 59.29 1.59 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.75 -1.113 . . . . 0.0 110.739 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.326 -0.435 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.977 -179.774 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.2 m . . . . . 0 CA--C 1.52 -0.191 0 CA-C-O 121.189 0.518 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.99 24.02 75.9 Favored Glycine 0 N--CA 1.448 -0.552 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.531 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -118.02 152.06 36.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.158 -0.521 . . . . 0.0 110.194 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.55 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.5 p -110.72 142.13 43.07 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 178.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.564 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.78 42.77 2.55 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-O 121.37 0.605 . . . . 0.0 110.452 178.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.3 t -54.96 -22.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.388 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.27 25.09 27.16 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.815 -0.707 . . . . 0.0 111.442 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.23 37.04 85.54 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.489 -0.355 . . . . 0.0 112.522 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.54 140.46 21.92 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.564 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.6 m -126.96 134.56 50.37 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.233 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -86.68 -37.22 18.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.685 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.545 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 2.6 m -61.77 116.89 23.57 Favored Pre-proline 0 C--O 1.236 0.344 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.504 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 15.9 Cg_exo -68.52 114.78 3.6 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.597 2.198 . . . . 0.0 112.887 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.61 -8.71 28.15 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.469 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 86.0 m -89.0 134.69 33.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.71 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.5 t -88.94 -159.71 0.59 Allowed 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 178.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 26.2 t -156.38 131.62 9.29 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 119.922 -0.711 . . . . 0.0 112.907 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.9 t -93.74 -53.01 4.2 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 176.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 179.23 -69.61 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.728 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.21 175.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.8 Cg_endo -98.06 12.04 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.627 0 CA-C-N 120.634 1.262 . . . . 0.0 111.497 -178.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.4 131.37 3.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.844 -178.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 90.9 m -82.17 119.87 24.61 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.307 -0.861 . . . . 0.0 108.758 178.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 48.3 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.696 -178.049 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.629 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 5.9 m . . . . . 0 N--CA 1.456 -0.169 0 CA-C-O 121.237 0.542 . . . . 0.0 109.951 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.43 23.16 75.13 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 31.9 tt0 -122.13 148.58 44.73 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.281 -0.46 . . . . 0.0 110.144 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.541 HG22 ' O ' ' A' ' 21' ' ' PRO . 63.2 p -107.8 142.8 37.28 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.205 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -116.66 41.76 2.61 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.337 0.589 . . . . 0.0 110.385 178.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.6 t -54.85 -22.31 9.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.394 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.47 25.78 23.55 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.808 -0.71 . . . . 0.0 111.403 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.15 37.07 91.2 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.584 -0.308 . . . . 0.0 112.43 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.64 140.24 21.6 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 76.0 m -128.95 133.69 47.92 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.296 178.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.436 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.4 m-80 -81.21 -33.17 33.09 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 179.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.39 114.26 22.72 Favored Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.316 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -61.85 -46.05 14.85 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.982 2.455 . . . . 0.0 113.991 -177.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.36 2.7 Favored Glycine 0 CA--C 1.508 -0.355 0 C-N-CA 120.306 -0.949 . . . . 0.0 111.938 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 77.3 m -142.62 132.38 24.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.176 0.513 . . . . 0.0 112.147 -178.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.47 HG22 ' O ' ' A' ' 24' ' ' THR . 15.4 t -89.71 -162.19 0.86 Allowed 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 177.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 18.1 t -148.86 129.29 13.87 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 119.887 -0.725 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 m -89.8 -52.69 4.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.85 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.695 0 CA-C-N 113.877 -1.511 . . . . 0.0 110.363 175.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.2 Cg_endo -98.41 9.8 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.664 0 CA-C-N 120.524 1.223 . . . . 0.0 111.792 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.9 m -152.67 132.23 3.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -178.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.8 m -93.38 136.24 33.84 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 176.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.629 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.8 t . . . . . 0 C--N 1.323 -0.554 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.384 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.968 0.414 . . . . 0.0 109.95 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.5 24.97 71.24 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -111.57 154.44 24.82 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.017 -0.591 . . . . 0.0 110.163 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.594 HG22 ' O ' ' A' ' 21' ' ' PRO . 81.4 p -113.25 143.77 43.85 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -122.95 43.41 2.94 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.384 0.611 . . . . 0.0 110.315 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.4 t -53.72 -22.39 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 114.702 -1.135 . . . . 0.0 110.823 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.08 23.19 25.93 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.692 -0.766 . . . . 0.0 111.606 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.72 36.28 93.08 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 112.345 -0.302 . . . . 0.0 112.345 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.4 p -141.98 134.06 27.54 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 99.2 m -127.34 132.8 50.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.964 177.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -83.1 -37.72 23.42 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.732 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.3 m -67.3 115.25 24.28 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -60.4 -47.92 12.93 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.936 2.424 . . . . 0.0 113.77 -178.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.27 39.84 2.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.971 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 97.7 m -141.88 133.2 26.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.313 0.578 . . . . 0.0 112.134 -179.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.8 t -89.89 -154.58 0.33 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.3 t -155.86 129.44 8.39 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 121.702 -0.624 . . . . 0.0 112.41 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.9 m -91.76 -53.32 4.34 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.614 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.8 t90 179.01 -69.85 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.754 0 CA-C-N 113.826 -1.534 . . . . 0.0 110.241 175.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -97.62 11.4 1.02 Allowed 'Trans proline' 0 N--CA 1.44 -1.652 0 CA-C-N 120.671 1.275 . . . . 0.0 111.392 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.7 m -152.82 131.58 2.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.825 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 95.3 m -76.38 122.1 23.99 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.1 m . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.324 -177.359 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.1 m . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.973 0.415 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.05 21.6 71.82 Favored Glycine 0 C--N 1.333 0.398 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.949 179.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.407 ' HB3' ' HB2' ' A' ' 23' ' ' CYS . 87.4 tt0 -97.6 160.0 14.58 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.831 -0.685 . . . . 0.0 109.481 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 21' ' ' PRO . 73.8 p -113.67 141.69 46.92 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.539 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.7 p -117.92 42.85 2.55 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.304 0.573 . . . . 0.0 110.458 178.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -54.95 -22.41 10.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.367 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.38 25.88 23.38 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.441 178.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.5 37.0 87.35 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.432 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.6 140.76 22.17 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.539 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 73.8 m -127.18 131.49 50.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.258 178.438 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -78.99 -38.35 36.99 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 m -75.27 116.06 50.97 Favored Pre-proline 0 N--CA 1.45 -0.461 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.988 179.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -61.46 -38.15 65.68 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 123.182 2.588 . . . . 0.0 113.852 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.89 35.19 1.44 Allowed Glycine 0 C--O 1.228 -0.253 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.651 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 4.3 m -151.0 135.74 17.24 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.056 0.455 . . . . 0.0 111.957 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.489 HG22 ' O ' ' A' ' 24' ' ' THR . 13.7 t -89.29 -157.54 0.46 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.3 t -146.55 128.02 15.01 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 119.575 -0.85 . . . . 0.0 113.124 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.6 m -89.83 -52.83 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.641 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.9 t90 178.62 -69.9 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.717 0 CA-C-N 113.742 -1.572 . . . . 0.0 110.082 175.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.641 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.87 12.07 0.72 Allowed 'Trans proline' 0 N--CA 1.44 -1.668 0 CA-C-N 120.55 1.232 . . . . 0.0 111.573 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.405 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.29 132.82 4.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.668 0.747 . . . . 0.0 112.928 -178.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 83.9 m -96.57 124.99 40.73 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.809 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.489 ' O ' HG22 ' A' ' 17' ' ' THR . 9.1 t . . . . . 0 C--N 1.324 -0.533 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.288 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.654 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 9.3 m . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 121.235 0.54 . . . . 0.0 109.939 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 69.31 22.3 76.2 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.875 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.437 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 33.1 tt0 -123.07 149.82 43.94 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.265 -0.467 . . . . 0.0 110.222 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.9 p -110.38 144.3 39.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.294 -0.412 . . . . 0.0 109.892 178.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.65 41.97 2.72 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.384 0.611 . . . . 0.0 110.33 178.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 t -55.17 -22.59 11.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.304 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.64 25.46 25.6 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.464 178.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.95 36.7 89.22 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.529 -0.336 . . . . 0.0 112.577 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 140.72 22.0 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.5 m -128.88 133.66 48.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.355 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . 0.437 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.3 m-80 -81.49 -33.08 32.13 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.13 114.35 22.88 Favored Pre-proline 0 CA--C 1.535 0.377 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.227 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -62.08 -45.98 14.38 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.952 2.435 . . . . 0.0 114.002 -177.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.08 2.67 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.951 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.7 m -142.93 132.17 23.29 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.198 0.523 . . . . 0.0 112.088 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.467 HG22 ' O ' ' A' ' 24' ' ' THR . 15.2 t -89.73 -161.51 0.79 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 17.1 t -149.14 129.47 13.77 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 119.873 -0.731 . . . . 0.0 112.798 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.4 m -89.85 -52.57 4.91 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.628 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.75 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.66 0 CA-C-N 113.821 -1.536 . . . . 0.0 110.274 175.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.628 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.9 Cg_endo -98.69 10.81 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.676 0 CA-C-N 120.502 1.215 . . . . 0.0 111.805 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.8 m -153.14 133.46 4.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.444 0.64 . . . . 0.0 112.669 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.4 m -95.07 136.3 35.56 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 176.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.654 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.1 t . . . . . 0 C--N 1.323 -0.549 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.394 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 m . . . . . 0 N--CA 1.456 -0.156 0 CA-C-O 121.078 0.466 . . . . 0.0 109.824 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.83 28.17 73.05 Favored Glycine 0 C--N 1.334 0.431 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.813 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -122.44 150.08 42.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.13 -0.535 . . . . 0.0 109.976 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.558 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.0 p -109.37 143.46 38.89 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.381 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.632 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.4 p -117.78 41.13 2.94 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.359 0.6 . . . . 0.0 110.562 178.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.3 t -54.76 -21.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.587 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.2 25.33 23.86 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.476 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 61.2 36.83 93.0 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.572 -0.314 . . . . 0.0 112.348 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.62 142.48 23.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.235 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.632 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.6 m -133.1 130.6 39.51 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -78.33 -30.39 48.18 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.748 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.6 OUTLIER -77.68 113.99 37.16 Favored Pre-proline 0 N--CA 1.45 -0.452 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 177.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -63.91 -45.06 11.32 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 123.074 2.516 . . . . 0.0 114.593 -177.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.17 45.72 2.6 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.468 -0.873 . . . . 0.0 112.498 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.748 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 56.7 m -136.89 127.64 27.22 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.324 0.583 . . . . 0.0 112.545 -178.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.6 p -89.71 114.64 26.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.264 178.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.6 t -77.24 127.3 32.37 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 m -93.19 -52.46 4.54 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 179.14 -69.21 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.734 0 CA-C-N 113.965 -1.47 . . . . 0.0 110.451 175.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.9 Cg_endo -97.94 8.48 1.15 Allowed 'Trans proline' 0 N--CA 1.439 -1.692 0 CA-C-N 120.443 1.194 . . . . 0.0 111.653 -178.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.1 m -152.36 134.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.583 0.706 . . . . 0.0 112.309 -178.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 67.5 m -89.85 100.4 13.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.431 ' OG1' ' HA ' ' A' ' 16' ' ' CYS . 90.9 m . . . . . 0 N--CA 1.464 0.25 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.868 -177.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 121.298 0.571 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 66.44 23.53 71.93 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.307 -0.86 . . . . 0.0 112.352 179.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -113.56 153.85 28.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 ' O ' ' A' ' 21' ' ' PRO . 58.2 p -113.6 142.83 45.5 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.579 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 6.3 p -119.25 43.99 2.46 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.186 0.517 . . . . 0.0 110.475 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.1 t -52.89 -21.73 3.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.96 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -111.52 25.06 14.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.697 -0.764 . . . . 0.0 111.671 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.46 36.01 92.53 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.619 -0.291 . . . . 0.0 112.444 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.7 p -140.53 134.75 31.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.579 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.6 m -129.97 130.38 44.98 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.556 177.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.7 m-80 -80.4 -40.05 27.17 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.251 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.797 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.9 OUTLIER -72.61 116.81 53.5 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.59 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -63.68 -45.67 10.65 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.209 2.606 . . . . 0.0 114.901 -176.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.72 44.95 2.61 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.388 -0.91 . . . . 0.0 112.368 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.797 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 20.0 m -139.48 129.63 25.19 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.855 0.359 . . . . 0.0 111.947 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -93.07 141.38 28.47 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 39.7 t -95.02 125.18 39.51 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 m -93.51 -52.88 4.29 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 176.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.02 -70.92 0.0 OUTLIER Pre-proline 0 C--O 1.213 -0.831 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.963 175.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.9 Cg_endo -98.49 12.92 0.74 Allowed 'Trans proline' 0 N--CA 1.44 -1.625 0 CA-C-N 120.738 1.299 . . . . 0.0 111.348 -178.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.412 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.5 133.09 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-O 121.453 0.644 . . . . 0.0 112.417 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.553 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 78.2 m -90.72 57.79 3.68 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.044 177.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 21.4 m . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 121.242 0.544 . . . . 0.0 111.474 -178.865 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 32.6 m . . . . . 0 N--CA 1.456 -0.171 0 CA-C-O 120.742 0.306 . . . . 0.0 110.338 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.11 33.38 87.1 Favored Glycine 0 C--N 1.333 0.38 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.456 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 3.2 tp10 -127.28 151.96 48.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.804 -0.698 . . . . 0.0 110.0 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.57 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -113.79 144.59 42.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.385 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.4 p -119.39 40.66 3.29 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.289 0.566 . . . . 0.0 110.319 178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.6 t -55.61 -21.93 11.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.227 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.81 26.25 21.58 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.519 178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.01 36.59 89.05 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.661 -0.27 . . . . 0.0 112.482 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.55 140.86 22.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.0 m -124.99 123.87 40.78 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.178 178.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -73.59 -35.02 65.35 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.109 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.619 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -71.45 116.69 49.98 Favored Pre-proline 0 C--O 1.234 0.261 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.438 179.61 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.86 119.83 6.08 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.443 2.095 . . . . 0.0 112.948 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.06 -8.29 31.27 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.916 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.619 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.3 m -88.92 130.89 35.35 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.977 0.418 . . . . 0.0 111.518 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -88.11 144.93 26.21 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 36.5 t -103.17 132.01 49.76 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 113.731 1.011 . . . . 0.0 113.731 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 m -95.97 -52.66 3.96 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 176.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.5 t90 178.99 -69.63 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.667 0 CA-C-N 113.708 -1.587 . . . . 0.0 110.467 175.423 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.1 9.94 1.02 Allowed 'Trans proline' 0 N--CA 1.442 -1.544 0 CA-C-N 120.567 1.238 . . . . 0.0 111.615 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.8 m -152.39 135.18 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.62 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.506 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 84.7 m -90.04 37.74 0.9 Allowed 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.277 178.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 25.8 m . . . . . 0 C--O 1.238 0.468 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.525 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 82.7 m . . . . . 0 N--CA 1.456 -0.13 0 CA-C-O 120.906 0.384 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.23 28.87 74.06 Favored Glycine 0 C--N 1.334 0.418 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.112 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -112.12 147.78 35.37 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.653 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.561 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.8 p -101.73 142.62 32.79 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 120.688 0.28 . . . . 0.0 110.44 179.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.507 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.1 p -119.72 42.7 2.84 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 121.313 0.578 . . . . 0.0 110.198 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.7 t -52.51 -21.96 3.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.93 -1.032 . . . . 0.0 111.136 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -109.74 24.62 19.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.549 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.67 36.31 93.09 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 112.235 -0.346 . . . . 0.0 112.235 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.2 p -142.04 133.85 27.13 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -179.036 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.507 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.5 m -126.58 129.09 47.88 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 177.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 -81.21 -34.53 32.19 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.41 ' HA ' ' HD2' ' A' ' 14' ' ' PRO . 0.2 OUTLIER -77.59 117.31 64.79 Favored Pre-proline 0 N--CA 1.447 -0.589 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.862 179.245 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 13' ' ' THR . 24.5 Cg_endo -63.38 -39.53 36.64 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 123.169 2.579 . . . . 0.0 113.878 -178.46 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.69 33.6 1.2 Allowed Glycine 0 C--N 1.321 -0.28 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.815 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 11.0 m -150.9 135.04 16.8 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.957 0.408 . . . . 0.0 111.816 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.9 t -89.12 -161.22 0.74 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 35.1 t -144.29 130.78 19.92 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.951 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.7 t -93.35 -52.81 4.35 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 176.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.634 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.7 t90 179.3 -70.16 0.0 OUTLIER Pre-proline 0 C--O 1.214 -0.781 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.407 175.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.634 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.76 9.42 1.13 Allowed 'Trans proline' 0 N--CA 1.441 -1.598 0 CA-C-N 120.742 1.301 . . . . 0.0 111.711 -178.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.8 m -151.81 129.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.595 0.712 . . . . 0.0 112.396 -178.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.413 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 82.4 m -83.34 72.32 10.21 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.215 177.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.315 -178.876 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.466 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 29.0 m . . . . . 0 CA--C 1.521 -0.14 0 CA-C-O 120.97 0.414 . . . . 0.0 110.132 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.46 31.08 73.45 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.831 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -133.27 154.03 51.04 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 21' ' ' PRO . 62.8 p -106.91 148.06 29.05 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.947 0.403 . . . . 0.0 110.736 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' SG ' ' A' ' 23' ' ' CYS . 4.1 p -121.97 39.02 3.98 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.514 0.673 . . . . 0.0 110.02 178.18 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.451 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.0 t -56.32 -21.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.226 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.63 25.91 22.94 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.55 178.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.44 38.71 93.89 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.399 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.18 140.16 21.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 18' ' ' CYS . 91.9 m -123.4 127.34 48.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.556 178.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -77.45 -38.52 49.27 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.759 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.761 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -70.65 118.31 63.63 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.388 179.671 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -70.74 119.18 6.13 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.342 2.028 . . . . 0.0 112.711 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.19 -4.43 33.53 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.831 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.761 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 89.9 m -88.5 131.52 34.87 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.219 0.533 . . . . 0.0 111.596 -179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.44 142.76 27.45 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.443 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 31.0 t -103.04 130.11 50.04 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 113.072 0.768 . . . . 0.0 113.072 -178.048 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.14 -52.5 4.8 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.63 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.58 -68.52 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.656 0 CA-C-N 113.648 -1.615 . . . . 0.0 110.396 175.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.63 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.4 Cg_endo -98.05 6.66 1.22 Allowed 'Trans proline' 0 N--CA 1.44 -1.673 0 CA-C-N 120.24 1.121 . . . . 0.0 112.126 -178.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.5 m -152.33 133.74 5.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.8 m -93.36 130.83 39.0 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.102 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.466 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 11.6 t . . . . . 0 C--N 1.326 -0.454 0 C-N-CA 121.08 -0.248 . . . . 0.0 111.222 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.455 -0.218 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 58.27 28.97 62.39 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.051 -0.977 . . . . 0.0 113.309 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -124.77 153.28 42.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.7 0.286 . . . . 0.0 110.524 -179.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' O ' ' A' ' 21' ' ' PRO . 67.4 p -105.79 147.47 28.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.249 179.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.7 p -118.62 41.69 2.93 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.487 0.66 . . . . 0.0 110.085 178.162 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.8 t -56.25 -22.7 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.139 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -102.57 24.47 30.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.411 178.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.81 33.59 73.89 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.5 -0.35 . . . . 0.0 112.354 -179.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.48 140.22 21.73 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.4 m -122.27 138.33 54.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.295 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -74.2 -46.51 41.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.879 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.5 OUTLIER -76.17 118.79 73.83 Favored Pre-proline 0 N--CA 1.449 -0.49 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.304 178.742 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -64.67 -44.19 11.33 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 123.075 2.517 . . . . 0.0 114.061 -177.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.32 46.6 2.79 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.314 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.879 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.4 m -135.57 131.89 36.5 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.121 0.486 . . . . 0.0 111.907 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -88.39 127.36 35.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.829 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.8 t -93.96 127.59 39.82 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -93.57 -52.74 4.35 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 177.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 179.01 -68.9 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.706 0 CA-C-N 113.657 -1.61 . . . . 0.0 109.866 175.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -98.52 12.95 0.73 Allowed 'Trans proline' 0 N--CA 1.438 -1.735 0 CA-C-N 120.471 1.204 . . . . 0.0 111.386 -178.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -153.14 134.08 4.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.178 0.513 . . . . 0.0 111.978 -178.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.563 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 70.9 m -91.62 34.61 0.97 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.366 -0.833 . . . . 0.0 110.125 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 87.9 m . . . . . 0 C--O 1.237 0.435 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.087 -179.27 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.6 m . . . . . 0 N--CA 1.456 -0.165 0 CA-C-O 120.744 0.307 . . . . 0.0 110.594 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.25 26.51 70.57 Favored Glycine 0 C--N 1.334 0.464 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.846 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -103.58 155.34 18.61 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.676 -0.762 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.551 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.3 p -107.15 144.1 34.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.848 0.356 . . . . 0.0 110.196 178.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.2 p -121.1 39.09 3.9 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.398 0.618 . . . . 0.0 110.279 178.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.427 HG23 ' HB ' ' A' ' 5' ' ' THR . 21.8 t -55.35 -22.14 10.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.157 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.55 25.31 27.21 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.502 178.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.29 36.18 87.83 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.407 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 139.97 21.25 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.9 m -124.23 120.96 33.74 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.579 177.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -67.49 -38.65 84.68 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.393 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 m -82.18 120.79 77.97 Favored Pre-proline 0 N--CA 1.451 -0.408 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.91 -37.58 26.36 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 123.099 2.532 . . . . 0.0 113.965 -178.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.42 34.42 0.97 Allowed Glycine 0 CA--C 1.518 0.265 0 C-N-CA 121.22 -0.514 . . . . 0.0 114.033 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.5 m -151.15 142.0 22.89 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.95 0.405 . . . . 0.0 111.247 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.5 t -89.39 -156.29 0.39 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.1 t -153.38 129.27 10.22 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.247 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.3 p -93.13 -53.12 4.25 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 176.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 5.8 t90 179.21 -66.85 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.37 175.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.6 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.8 Cg_endo -97.34 2.78 1.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.791 0 CA-C-N 120.285 1.137 . . . . 0.0 112.383 -178.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 m -151.15 129.88 2.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.765 0.793 . . . . 0.0 112.658 -178.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 81.5 m -82.24 81.41 8.14 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 114.504 -1.225 . . . . 0.0 109.391 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.8 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-O 121.041 0.448 . . . . 0.0 111.852 -179.036 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.0 m . . . . . 0 N--CA 1.454 -0.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.387 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.06 28.62 73.84 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.581 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 5' ' ' THR . 3.3 tp10 -128.06 150.79 49.8 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.005 -0.597 . . . . 0.0 110.144 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.555 HG22 ' O ' ' A' ' 21' ' ' PRO . 75.8 p -112.96 143.04 44.92 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 178.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.518 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.0 p -118.18 40.45 3.17 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.345 0.593 . . . . 0.0 110.571 178.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 t -55.04 -22.19 10.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.319 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.9 26.73 18.43 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.477 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 37.48 91.75 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.632 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.66 140.03 21.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.518 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.6 m -126.14 125.17 42.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.064 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 70.5 m-80 -77.07 -32.58 56.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.3 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.471 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -66.72 116.94 40.01 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.722 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 10.1 Cg_exo -71.66 118.84 5.85 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.51 2.14 . . . . 0.0 112.598 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.25 -12.56 33.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.748 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.471 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 94.9 m -88.71 136.47 32.98 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.958 0.408 . . . . 0.0 111.418 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.5 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 12.9 t -89.09 -161.48 0.77 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 19.3 t -152.99 132.67 13.09 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 36.6 t -94.77 -52.64 4.18 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.623 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.9 t90 179.22 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.638 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.875 175.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.623 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.5 Cg_endo -97.57 7.34 1.31 Allowed 'Trans proline' 0 N--CA 1.441 -1.58 0 CA-C-N 120.635 1.263 . . . . 0.0 111.996 -178.127 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.0 m -152.37 133.12 4.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.222 0.534 . . . . 0.0 111.789 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 84.1 m -86.73 115.92 24.49 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.447 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . 0.5 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 6.5 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.045 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.456 -0.147 0 CA-C-O 121.03 0.443 . . . . 0.0 110.035 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.13 25.76 71.15 Favored Glycine 0 C--O 1.227 -0.328 0 CA-C-N 115.466 -0.788 . . . . 0.0 113.193 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -122.53 152.54 40.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.525 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -106.84 146.89 30.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.581 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.498 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.3 p -119.7 39.52 3.61 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.56 0.695 . . . . 0.0 110.056 178.193 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -56.49 -21.85 13.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.253 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.96 25.6 24.86 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.828 -0.701 . . . . 0.0 111.551 178.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.61 37.93 92.98 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.591 -0.338 . . . . 0.0 112.321 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.21 139.02 20.84 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 66.1 m -123.48 133.85 53.98 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.027 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -80.98 -42.78 20.66 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.615 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.647 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.7 OUTLIER -72.22 119.03 72.43 Favored Pre-proline 0 C--N 1.327 -0.373 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.175 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.04 -47.3 12.93 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.986 2.457 . . . . 0.0 113.834 -178.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.34 41.04 2.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.188 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.647 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 74.3 m -140.78 133.57 28.94 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.963 0.411 . . . . 0.0 111.403 -178.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.5 t -89.4 -159.0 0.54 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.5 t -153.63 129.54 10.22 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.161 -0.616 . . . . 0.0 112.442 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.7 m -91.97 -52.84 4.53 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.021 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.89 -68.44 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.691 0 CA-C-N 113.899 -1.501 . . . . 0.0 110.451 175.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.89 9.76 1.08 Allowed 'Trans proline' 0 N--CA 1.441 -1.583 0 CA-C-N 120.402 1.179 . . . . 0.0 111.717 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.2 m -152.84 133.17 4.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 0.0 111.896 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 80.3 m -85.78 35.8 0.64 Allowed 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.5 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.8 p . . . . . 0 C--O 1.238 0.469 0 C-N-CA 123.035 0.534 . . . . 0.0 112.056 -179.639 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 8.0 m . . . . . 0 CA--C 1.52 -0.195 0 CA-C-O 120.868 0.366 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 62.82 31.62 80.97 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.475 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 4.4 tp10 -128.04 150.2 50.04 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.858 -0.671 . . . . 0.0 110.407 -178.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.554 HG22 ' O ' ' A' ' 21' ' ' PRO . 70.4 p -113.61 145.09 41.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.336 178.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.3 p -120.18 40.0 3.56 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.354 0.597 . . . . 0.0 110.17 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.7 t -54.35 -21.94 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.633 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.04 23.48 25.34 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.672 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 63.58 34.97 91.37 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.571 -0.315 . . . . 0.0 112.45 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.8 p -143.34 132.95 23.66 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 61.2 m -122.4 119.86 32.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.244 177.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -71.5 -34.78 70.43 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.854 -1.067 . . . . 0.0 109.977 179.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.5 115.11 40.41 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.93 -45.76 9.85 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.879 2.386 . . . . 0.0 113.826 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.01 40.87 2.55 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.235 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -142.06 140.11 32.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.106 0.479 . . . . 0.0 111.729 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.3 t -89.04 -156.87 0.41 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.7 t -160.04 130.21 5.45 Favored 'General case' 0 C--N 1.322 -0.592 0 O-C-N 121.963 -0.46 . . . . 0.0 111.876 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -98.46 -52.12 3.74 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.601 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.98 -68.28 0.0 OUTLIER Pre-proline 0 C--O 1.218 -0.602 0 CA-C-N 114.24 -1.345 . . . . 0.0 111.028 175.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.601 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.0 Cg_endo -97.11 6.98 1.46 Allowed 'Trans proline' 0 N--CA 1.439 -1.69 0 CA-C-N 120.786 1.317 . . . . 0.0 112.06 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.0 m -152.15 135.0 6.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.093 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.475 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 90.3 m -77.76 53.31 1.11 Allowed 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.187 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.911 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 120.856 0.36 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.91 31.93 81.11 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.659 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 2.4 tp10 -132.97 152.42 51.94 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.545 -0.828 . . . . 0.0 109.778 -178.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.2 p -116.3 142.8 46.37 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.036 0.446 . . . . 0.0 110.769 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.9 p -117.5 41.54 2.8 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.265 0.555 . . . . 0.0 110.378 178.32 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.0 t -54.7 -21.96 8.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.15 22.77 26.66 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.598 178.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 64.41 30.54 78.13 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.624 -0.288 . . . . 0.0 112.596 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -146.87 134.7 21.25 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 122.678 -0.307 . . . . 0.0 111.524 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.9 m -115.34 128.68 56.25 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.818 178.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -73.65 -34.42 64.96 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.89 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.539 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -68.83 117.45 51.31 Favored Pre-proline 0 C--O 1.232 0.182 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.676 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 7.5 Cg_exo -73.27 119.52 6.05 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 122.441 2.094 . . . . 0.0 112.855 -179.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.35 -7.19 36.91 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.987 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.539 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 90.4 m -89.02 142.3 27.75 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.934 0.397 . . . . 0.0 111.627 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.7 t -88.53 -162.83 0.89 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.7 t -155.97 132.1 10.0 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -179.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.1 m -96.83 -51.88 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.1 t90 179.17 -70.27 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 114.156 -1.384 . . . . 0.0 110.721 175.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.2 Cg_endo -98.12 10.39 0.98 Allowed 'Trans proline' 0 N--CA 1.441 -1.603 0 CA-C-N 120.603 1.251 . . . . 0.0 111.606 -178.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.7 m -152.6 135.68 7.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.37 -178.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . 0.659 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 75.5 m -90.11 115.06 27.08 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.495 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 16.4 m . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.909 -178.404 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.522 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 35.2 m . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.804 0.335 . . . . 0.0 110.27 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.39 20.6 71.69 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.993 178.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 7.3 tp10 -97.05 157.23 16.01 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.545 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -100.61 144.86 29.09 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.054 0.454 . . . . 0.0 110.504 178.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.4 p -120.77 41.57 3.25 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.602 0.715 . . . . 0.0 109.906 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.9 t -56.06 -22.75 14.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.272 179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.32 23.43 35.3 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.351 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.31 32.48 72.38 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.504 -0.348 . . . . 0.0 112.321 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.85 139.54 20.7 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.6 m -118.63 137.39 53.31 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.295 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -76.53 -43.89 37.33 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.919 0.39 . . . . 0.0 110.07 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -78.58 122.05 84.41 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.121 179.209 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -65.6 -37.15 30.23 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 123.047 2.498 . . . . 0.0 113.692 -178.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.74 35.9 1.02 Allowed Glycine 0 C--N 1.321 -0.28 0 CA-C-N 115.991 -0.549 . . . . 0.0 113.899 -178.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -150.73 140.74 22.02 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.967 0.413 . . . . 0.0 111.258 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.8 t -89.57 -151.61 0.23 Allowed 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.3 t -158.06 128.91 6.4 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 119.996 -0.682 . . . . 0.0 112.569 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.2 m -90.69 -51.87 5.16 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 176.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TRP . . . . . 0.627 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 178.62 -69.36 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.632 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.108 175.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.627 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.3 Cg_endo -97.76 10.5 1.06 Allowed 'Trans proline' 0 N--CA 1.44 -1.632 0 CA-C-N 120.421 1.186 . . . . 0.0 111.45 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.33 129.42 2.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.509 0.671 . . . . 0.0 112.457 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 73.7 m -82.09 78.25 8.8 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.038 177.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.214 -178.684 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 44.4 t . . . . . 0 CA--C 1.521 -0.171 0 CA-C-O 121.394 0.616 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m -78.99 -20.56 48.79 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-N 115.091 -0.959 . . . . 0.0 109.463 179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.58 24.25 67.69 Favored Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.725 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -116.9 152.02 35.38 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 115.266 -0.467 . . . . 0.0 110.608 -179.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.568 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.4 p -111.89 142.61 44.07 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 178.283 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.1 p -118.58 42.32 2.78 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.463 0.649 . . . . 0.0 110.403 178.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -55.58 -22.57 12.55 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.261 179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.86 24.85 28.32 Favored Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 120.821 -0.704 . . . . 0.0 111.412 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.51 37.28 88.14 Favored Glycine 0 N--CA 1.451 -0.319 0 CA-C-N 115.582 -0.309 . . . . 0.0 112.378 -179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.57 140.44 21.87 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 90.1 m -128.83 135.06 48.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.237 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 62.4 m-80 -82.42 -38.13 24.49 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.602 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.1 m -66.9 114.9 20.09 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.571 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_exo -61.36 -45.06 19.87 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 122.968 2.446 . . . . 0.0 113.789 -177.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.09 39.32 2.6 Favored Glycine 0 N--CA 1.449 -0.439 0 C-N-CA 120.38 -0.914 . . . . 0.0 112.087 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 89.6 m -143.37 131.39 21.72 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.128 0.489 . . . . 0.0 111.779 -178.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.527 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 9.2 t -89.79 -153.34 0.28 Allowed 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 21.0 t -154.61 131.67 10.96 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -179.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.7 m -91.59 -53.24 4.39 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 176.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.619 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 178.96 -69.74 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.671 0 CA-C-N 113.818 -1.537 . . . . 0.0 110.393 175.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.619 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.3 Cg_endo -97.99 11.36 0.94 Allowed 'Trans proline' 0 N--CA 1.44 -1.619 0 CA-C-N 120.546 1.231 . . . . 0.0 111.482 -178.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.415 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.49 130.63 2.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.691 0 CA-C-O 121.188 0.518 . . . . 0.0 111.881 -178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.5 m -81.47 113.39 19.5 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.527 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 1.5 m . . . . . 0 C--N 1.323 -0.576 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.337 -178.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.9 m . . . . . 0 CA--C 1.526 0.042 0 CA-C-O 121.4 0.619 . . . . 0.0 110.522 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 71.1 m -83.86 -12.84 54.95 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.36 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 71.01 13.07 72.32 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.245 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 29.8 tt0 -98.09 151.7 20.09 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.104 -0.548 . . . . 0.0 109.748 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -105.97 143.83 33.56 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.849 0.357 . . . . 0.0 110.133 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.0 p -119.38 42.29 2.89 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.367 0.603 . . . . 0.0 110.203 178.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.6 t -54.94 -22.53 10.63 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.324 179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.78 25.2 26.27 Favored Glycine 0 N--CA 1.448 -0.509 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.463 178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.94 36.74 89.35 Favored Glycine 0 N--CA 1.451 -0.36 0 CA-C-N 115.524 -0.338 . . . . 0.0 112.417 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.69 140.45 21.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.2 m -127.13 132.61 50.53 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.162 178.3 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 68.1 m-80 -81.65 -34.7 30.65 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -76.48 115.33 46.61 Favored Pre-proline 0 N--CA 1.449 -0.476 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.914 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -62.11 -37.9 60.3 Favored 'Trans proline' 0 C--N 1.344 0.336 0 C-N-CA 123.11 2.54 . . . . 0.0 113.858 -178.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.99 33.93 1.47 Allowed Glycine 0 C--N 1.322 -0.202 0 C-N-CA 120.92 -0.657 . . . . 0.0 113.801 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 10.0 m -150.71 140.29 21.59 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.123 0.487 . . . . 0.0 112.002 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.0 t -90.08 -149.38 0.2 Allowed 'General case' 0 N--CA 1.447 -0.604 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 177.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.2 t -156.82 128.37 7.07 Favored 'General case' 0 C--N 1.321 -0.666 0 C-N-CA 120.051 -0.659 . . . . 0.0 112.519 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 12.5 m -92.13 -52.13 4.85 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 177.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.631 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 178.77 -70.04 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.703 0 CA-C-N 113.825 -1.534 . . . . 0.0 110.121 175.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.631 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.8 Cg_endo -97.99 11.17 0.96 Allowed 'Trans proline' 0 N--CA 1.439 -1.733 0 CA-C-N 120.632 1.261 . . . . 0.0 111.51 -178.75 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.54 130.73 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.613 0 CA-C-O 121.45 0.643 . . . . 0.0 112.335 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 72.7 m -84.67 80.57 9.2 Favored 'General case' 0 C--N 1.312 -1.054 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.651 177.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.325 -0.492 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.113 -178.402 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.579 HG22 ' H ' ' A' ' 3' ' ' GLY . 14.4 p . . . . . 0 N--CA 1.454 -0.244 0 CA-C-O 120.776 0.322 . . . . 0.0 110.256 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 19.5 m -78.77 -28.32 44.72 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.343 -179.114 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.579 ' H ' HG22 ' A' ' 1' ' ' VAL . . . 62.74 23.85 65.75 Favored Glycine 0 C--N 1.334 0.44 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -94.71 155.35 16.88 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 114.717 -0.742 . . . . 0.0 110.28 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.569 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.2 p -108.85 142.55 39.27 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.572 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.7 p -119.95 42.28 2.97 Favored 'General case' 0 C--N 1.313 -1.02 0 CA-C-O 121.324 0.583 . . . . 0.0 110.352 178.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.5 t -54.24 -22.55 8.41 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.402 179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.55 24.95 27.28 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.446 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.96 36.41 87.95 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.478 -0.361 . . . . 0.0 112.475 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.76 140.45 21.71 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 112.748 0.647 . . . . 0.0 112.748 -179.006 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.572 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 98.2 m -126.56 132.41 51.33 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.598 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.5 m-80 -80.18 -40.06 28.0 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.776 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.5 m -76.08 116.71 58.27 Favored Pre-proline 0 N--CA 1.45 -0.451 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.171 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_exo -62.1 -37.3 64.73 Favored 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 123.23 2.62 . . . . 0.0 113.734 -178.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.31 35.46 1.32 Allowed Glycine 0 CA--C 1.517 0.195 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.781 -179.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.7 m -150.82 141.01 22.21 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.107 0.479 . . . . 0.0 111.635 179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -88.69 -145.78 0.15 Allowed 'General case' 0 N--CA 1.449 -0.52 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.6 t -166.45 133.06 2.49 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.348 -0.541 . . . . 0.0 111.867 179.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 2.2 p -103.48 -53.01 2.88 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 107.562 -1.274 . . . . 0.0 107.562 177.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.611 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.8 t90 -177.87 -69.46 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.731 0 CA-C-N 114.329 -1.305 . . . . 0.0 111.013 175.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.611 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 41.6 Cg_endo -97.39 9.5 1.22 Allowed 'Trans proline' 0 N--CA 1.439 -1.702 0 CA-C-N 121.104 1.43 . . . . 0.0 111.727 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.403 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.9 m -151.35 132.91 5.07 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-O 121.531 0.682 . . . . 0.0 111.063 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 66.6 m -76.87 59.29 1.59 Allowed 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 114.75 -1.113 . . . . 0.0 110.739 179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 9.0 t . . . . . 0 C--N 1.326 -0.435 0 CA-C-N 115.718 -0.673 . . . . 0.0 109.977 -179.774 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.228 -0.072 0 CA-C-O 121.106 0.479 . . . . 0.0 110.631 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 7.2 m -79.28 -21.75 45.61 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.548 -0.751 . . . . 0.0 109.693 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.99 24.02 75.9 Favored Glycine 0 N--CA 1.448 -0.552 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.531 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -118.02 152.06 36.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.158 -0.521 . . . . 0.0 110.194 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.55 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.5 p -110.72 142.13 43.07 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 178.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.564 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.78 42.77 2.55 Favored 'General case' 0 C--N 1.311 -1.09 0 CA-C-O 121.37 0.605 . . . . 0.0 110.452 178.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.3 t -54.96 -22.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.388 179.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.27 25.09 27.16 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.815 -0.707 . . . . 0.0 111.442 178.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.23 37.04 85.54 Favored Glycine 0 N--CA 1.451 -0.327 0 CA-C-N 115.489 -0.355 . . . . 0.0 112.522 -179.609 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.54 140.46 21.92 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.393 0.516 . . . . 0.0 112.393 -179.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.564 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.6 m -126.96 134.56 50.37 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.233 178.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.4 m-80 -86.68 -37.22 18.19 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.685 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.545 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 2.6 m -61.77 116.89 23.57 Favored Pre-proline 0 C--O 1.236 0.344 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.504 -179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 15.9 Cg_exo -68.52 114.78 3.6 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 122.597 2.198 . . . . 0.0 112.887 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 111.61 -8.71 28.15 Favored Glycine 0 N--CA 1.446 -0.639 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.469 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.545 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 86.0 m -89.0 134.69 33.89 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.71 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.5 t -88.94 -159.71 0.59 Allowed 'General case' 0 N--CA 1.45 -0.463 0 N-CA-C 108.393 -0.966 . . . . 0.0 108.393 178.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 26.2 t -156.38 131.62 9.29 Favored 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 119.922 -0.711 . . . . 0.0 112.907 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.9 t -93.74 -53.01 4.2 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 176.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.2 t90 179.23 -69.61 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.728 0 CA-C-N 113.964 -1.471 . . . . 0.0 110.21 175.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.8 Cg_endo -98.06 12.04 0.87 Allowed 'Trans proline' 0 N--CA 1.44 -1.627 0 CA-C-N 120.634 1.262 . . . . 0.0 111.497 -178.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.4 131.37 3.07 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.844 -178.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 90.9 m -82.17 119.87 24.61 Favored 'General case' 0 C--N 1.314 -0.95 0 CA-C-N 115.307 -0.861 . . . . 0.0 108.758 178.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 48.3 m . . . . . 0 C--N 1.329 -0.298 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.696 -178.049 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 26.9 m . . . . . 0 N--CA 1.46 0.073 0 CA-C-O 121.234 0.54 . . . . 0.0 110.602 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.629 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 5.9 m -79.84 -20.37 46.18 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.951 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.43 23.16 75.13 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.96 179.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 31.9 tt0 -122.13 148.58 44.73 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.281 -0.46 . . . . 0.0 110.144 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.541 HG22 ' O ' ' A' ' 21' ' ' PRO . 63.2 p -107.8 142.8 37.28 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.205 178.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.606 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -116.66 41.76 2.61 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-O 121.337 0.589 . . . . 0.0 110.385 178.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.6 t -54.85 -22.31 9.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.394 179.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.47 25.78 23.55 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.808 -0.71 . . . . 0.0 111.403 178.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.15 37.07 91.2 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.584 -0.308 . . . . 0.0 112.43 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.64 140.24 21.6 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 112.507 0.558 . . . . 0.0 112.507 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.606 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 76.0 m -128.95 133.69 47.92 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.296 178.358 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.436 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.4 m-80 -81.21 -33.17 33.09 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 179.125 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.39 114.26 22.72 Favored Pre-proline 0 CA--C 1.535 0.374 0 CA-C-N 115.643 -0.708 . . . . 0.0 109.316 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -61.85 -46.05 14.85 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.982 2.455 . . . . 0.0 113.991 -177.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.36 2.7 Favored Glycine 0 CA--C 1.508 -0.355 0 C-N-CA 120.306 -0.949 . . . . 0.0 111.938 179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 77.3 m -142.62 132.38 24.07 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-O 121.176 0.513 . . . . 0.0 112.147 -178.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.47 HG22 ' O ' ' A' ' 24' ' ' THR . 15.4 t -89.71 -162.19 0.86 Allowed 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 177.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 18.1 t -148.86 129.29 13.87 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 119.887 -0.725 . . . . 0.0 112.839 -179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.5 m -89.8 -52.69 4.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.633 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.85 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.695 0 CA-C-N 113.877 -1.511 . . . . 0.0 110.363 175.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.633 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.2 Cg_endo -98.41 9.8 0.95 Allowed 'Trans proline' 0 N--CA 1.44 -1.664 0 CA-C-N 120.524 1.223 . . . . 0.0 111.792 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.9 m -152.67 132.23 3.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -178.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.8 m -93.38 136.24 33.84 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 176.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.629 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.8 t . . . . . 0 C--N 1.323 -0.554 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.384 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 CA--C 1.524 -0.024 0 CA-C-O 121.38 0.609 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -79.2 -31.39 43.76 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.95 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.5 24.97 71.24 Favored Glycine 0 C--N 1.334 0.424 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -111.57 154.44 24.82 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.017 -0.591 . . . . 0.0 110.163 -179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.594 HG22 ' O ' ' A' ' 21' ' ' PRO . 81.4 p -113.25 143.77 43.85 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.529 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.1 p -122.95 43.41 2.94 Favored 'General case' 0 C--N 1.312 -1.047 0 CA-C-O 121.384 0.611 . . . . 0.0 110.315 179.175 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.4 t -53.72 -22.39 6.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 114.702 -1.135 . . . . 0.0 110.823 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.08 23.19 25.93 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.692 -0.766 . . . . 0.0 111.606 178.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.72 36.28 93.08 Favored Glycine 0 N--CA 1.449 -0.475 0 N-CA-C 112.345 -0.302 . . . . 0.0 112.345 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.4 p -141.98 134.06 27.54 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 112.378 0.51 . . . . 0.0 112.378 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.529 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 99.2 m -127.34 132.8 50.16 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.964 177.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.5 m-80 -83.1 -37.72 23.42 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.732 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.3 m -67.3 115.25 24.28 Favored Pre-proline 0 CA--C 1.534 0.362 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -60.4 -47.92 12.93 Favored 'Trans proline' 0 C--N 1.346 0.435 0 C-N-CA 122.936 2.424 . . . . 0.0 113.77 -178.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -80.27 39.84 2.32 Favored Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.559 -0.829 . . . . 0.0 111.971 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 97.7 m -141.88 133.2 26.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 121.313 0.578 . . . . 0.0 112.134 -179.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.8 t -89.89 -154.58 0.33 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.3 t -155.86 129.44 8.39 Favored 'General case' 0 C--N 1.323 -0.579 0 O-C-N 121.702 -0.624 . . . . 0.0 112.41 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.9 m -91.76 -53.32 4.34 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 177.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.614 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.8 t90 179.01 -69.85 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.754 0 CA-C-N 113.826 -1.534 . . . . 0.0 110.241 175.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -97.62 11.4 1.02 Allowed 'Trans proline' 0 N--CA 1.44 -1.652 0 CA-C-N 120.671 1.275 . . . . 0.0 111.392 -178.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.7 m -152.82 131.58 2.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.825 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 95.3 m -76.38 122.1 23.99 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 177.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 97.1 m . . . . . 0 C--N 1.329 -0.287 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.324 -177.359 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 3' ' ' GLY . 37.8 t . . . . . 0 N--CA 1.454 -0.242 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.1 m -79.27 -26.16 42.39 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.973 0.415 . . . . 0.0 110.338 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.508 ' H ' HG12 ' A' ' 1' ' ' VAL . . . 67.05 21.6 71.82 Favored Glycine 0 C--N 1.333 0.398 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.949 179.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.407 ' HB3' ' HB2' ' A' ' 23' ' ' CYS . 87.4 tt0 -97.6 160.0 14.58 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.831 -0.685 . . . . 0.0 109.481 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.559 HG22 ' O ' ' A' ' 21' ' ' PRO . 73.8 p -113.67 141.69 46.92 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 178.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.539 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.7 p -117.92 42.85 2.55 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.304 0.573 . . . . 0.0 110.458 178.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -54.95 -22.41 10.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.367 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.38 25.88 23.38 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.854 -0.689 . . . . 0.0 111.441 178.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.5 37.0 87.35 Favored Glycine 0 N--CA 1.452 -0.292 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.432 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -150.6 140.76 22.17 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 -179.052 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.539 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 73.8 m -127.18 131.49 50.69 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.258 178.438 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -78.99 -38.35 36.99 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.4 m -75.27 116.06 50.97 Favored Pre-proline 0 N--CA 1.45 -0.461 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.988 179.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -61.46 -38.15 65.68 Favored 'Trans proline' 0 C--N 1.345 0.35 0 C-N-CA 123.182 2.588 . . . . 0.0 113.852 -178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -76.89 35.19 1.44 Allowed Glycine 0 C--O 1.228 -0.253 0 C-N-CA 120.982 -0.628 . . . . 0.0 113.651 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 4.3 m -151.0 135.74 17.24 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-O 121.056 0.455 . . . . 0.0 111.957 179.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.489 HG22 ' O ' ' A' ' 24' ' ' THR . 13.7 t -89.29 -157.54 0.46 Allowed 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 177.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 32.3 t -146.55 128.02 15.01 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 119.575 -0.85 . . . . 0.0 113.124 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.6 m -89.83 -52.83 4.78 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.641 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.9 t90 178.62 -69.9 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.717 0 CA-C-N 113.742 -1.572 . . . . 0.0 110.082 175.536 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.641 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.87 12.07 0.72 Allowed 'Trans proline' 0 N--CA 1.44 -1.668 0 CA-C-N 120.55 1.232 . . . . 0.0 111.573 -178.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.405 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -152.29 132.82 4.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.668 0.747 . . . . 0.0 112.928 -178.328 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.423 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 83.9 m -96.57 124.99 40.73 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.522 -1.217 . . . . 0.0 107.809 177.13 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.489 ' O ' HG22 ' A' ' 17' ' ' THR . 9.1 t . . . . . 0 C--N 1.324 -0.533 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.288 -179.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 N--CA 1.46 0.075 0 CA-C-O 121.229 0.538 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.654 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 9.3 m -80.76 -18.57 47.27 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.939 179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 69.31 22.3 76.2 Favored Glycine 0 N--CA 1.45 -0.381 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.875 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.437 ' CD ' ' H ' ' A' ' 12' ' ' ASN . 33.1 tt0 -123.07 149.82 43.94 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.265 -0.467 . . . . 0.0 110.222 -179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.548 HG22 ' O ' ' A' ' 21' ' ' PRO . 59.9 p -110.38 144.3 39.34 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.294 -0.412 . . . . 0.0 109.892 178.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.594 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.6 p -117.65 41.97 2.72 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-O 121.384 0.611 . . . . 0.0 110.33 178.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.4 t -55.17 -22.59 11.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 114.813 -1.085 . . . . 0.0 110.304 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.64 25.46 25.6 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.843 -0.694 . . . . 0.0 111.464 178.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.95 36.7 89.22 Favored Glycine 0 N--CA 1.451 -0.361 0 CA-C-N 115.529 -0.336 . . . . 0.0 112.577 -179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 140.72 22.0 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -179.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.5 m -128.88 133.66 48.01 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.355 178.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . 0.437 ' H ' ' CD ' ' A' ' 4' ' ' GLU . 66.3 m-80 -81.49 -33.08 32.13 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.2 m -69.13 114.35 22.88 Favored Pre-proline 0 CA--C 1.535 0.377 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.227 178.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_exo -62.08 -45.98 14.38 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.952 2.435 . . . . 0.0 114.002 -177.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.69 41.08 2.67 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.359 -0.924 . . . . 0.0 111.951 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.7 m -142.93 132.17 23.29 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 121.198 0.523 . . . . 0.0 112.088 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.467 HG22 ' O ' ' A' ' 24' ' ' THR . 15.2 t -89.73 -161.51 0.79 Allowed 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 17.1 t -149.14 129.47 13.77 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 119.873 -0.731 . . . . 0.0 112.798 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.4 m -89.85 -52.57 4.91 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 176.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.628 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.75 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.66 0 CA-C-N 113.821 -1.536 . . . . 0.0 110.274 175.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.628 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.9 Cg_endo -98.69 10.81 0.83 Allowed 'Trans proline' 0 N--CA 1.44 -1.676 0 CA-C-N 120.502 1.215 . . . . 0.0 111.805 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.8 m -153.14 133.46 4.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-O 121.444 0.64 . . . . 0.0 112.669 -178.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 58.4 m -95.07 136.3 35.56 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 176.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.654 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 13.1 t . . . . . 0 C--N 1.323 -0.549 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.394 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 34.3 m . . . . . 0 N--CA 1.461 0.077 0 CA-C-O 121.029 0.442 . . . . 0.0 110.709 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 6.6 m -78.87 -24.43 44.29 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.655 -0.702 . . . . 0.0 109.824 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 64.83 28.17 73.05 Favored Glycine 0 C--N 1.334 0.431 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.813 179.558 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -122.44 150.08 42.97 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-N 115.13 -0.535 . . . . 0.0 109.976 -179.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.558 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.0 p -109.37 143.46 38.89 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.381 179.32 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.632 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.4 p -117.78 41.13 2.94 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-O 121.359 0.6 . . . . 0.0 110.562 178.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.3 t -54.76 -21.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.587 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.2 25.33 23.86 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.765 -0.731 . . . . 0.0 111.476 178.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 61.2 36.83 93.0 Favored Glycine 0 N--CA 1.45 -0.37 0 CA-C-N 115.572 -0.314 . . . . 0.0 112.348 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.62 142.48 23.82 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 112.563 0.579 . . . . 0.0 112.563 -179.235 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.632 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 71.6 m -133.1 130.6 39.51 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 177.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -78.33 -30.39 48.18 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.748 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.6 OUTLIER -77.68 113.99 37.16 Favored Pre-proline 0 N--CA 1.45 -0.452 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 177.977 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -63.91 -45.06 11.32 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 123.074 2.516 . . . . 0.0 114.593 -177.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.17 45.72 2.6 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.468 -0.873 . . . . 0.0 112.498 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.748 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 56.7 m -136.89 127.64 27.22 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 121.324 0.583 . . . . 0.0 112.545 -178.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.6 p -89.71 114.64 26.33 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.264 178.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.6 t -77.24 127.3 32.37 Favored 'General case' 0 C--N 1.317 -0.809 0 N-CA-C 112.714 0.635 . . . . 0.0 112.714 -178.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.0 m -93.19 -52.46 4.54 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 176.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.1 t90 179.14 -69.21 0.0 OUTLIER Pre-proline 0 C--O 1.215 -0.734 0 CA-C-N 113.965 -1.47 . . . . 0.0 110.451 175.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 40.9 Cg_endo -97.94 8.48 1.15 Allowed 'Trans proline' 0 N--CA 1.439 -1.692 0 CA-C-N 120.443 1.194 . . . . 0.0 111.653 -178.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.1 m -152.36 134.62 6.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-O 121.583 0.706 . . . . 0.0 112.309 -178.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 67.5 m -89.85 100.4 13.22 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 107.751 -1.203 . . . . 0.0 107.751 177.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.431 ' OG1' ' HA ' ' A' ' 16' ' ' CYS . 90.9 m . . . . . 0 N--CA 1.464 0.25 0 CA-C-N 115.899 -0.592 . . . . 0.0 110.868 -177.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 7.3 p . . . . . 0 CA--C 1.527 0.084 0 CA-C-O 121.183 0.516 . . . . 0.0 110.468 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 21.3 m -79.66 -18.62 51.0 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.723 179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 66.44 23.53 71.93 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.307 -0.86 . . . . 0.0 112.352 179.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -113.56 153.85 28.12 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 ' O ' ' A' ' 21' ' ' PRO . 58.2 p -113.6 142.83 45.5 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 178.619 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.579 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 6.3 p -119.25 43.99 2.46 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-O 121.186 0.517 . . . . 0.0 110.475 178.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.1 t -52.89 -21.73 3.39 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.96 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -111.52 25.06 14.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.697 -0.764 . . . . 0.0 111.671 178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.46 36.01 92.53 Favored Glycine 0 N--CA 1.449 -0.47 0 CA-C-N 115.619 -0.291 . . . . 0.0 112.444 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 21.7 p -140.53 134.75 31.06 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.274 0.472 . . . . 0.0 112.274 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.579 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.6 m -129.97 130.38 44.98 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.556 177.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 60.7 m-80 -80.4 -40.05 27.17 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.679 -0.692 . . . . 0.0 109.251 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.797 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.9 OUTLIER -72.61 116.81 53.5 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.59 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -63.68 -45.67 10.65 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.209 2.606 . . . . 0.0 114.901 -176.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.72 44.95 2.61 Favored Glycine 0 N--CA 1.453 -0.206 0 C-N-CA 120.388 -0.91 . . . . 0.0 112.368 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.797 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 20.0 m -139.48 129.63 25.19 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.855 0.359 . . . . 0.0 111.947 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.7 t -93.07 141.38 28.47 Favored 'General case' 0 C--N 1.323 -0.577 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 39.7 t -95.02 125.18 39.51 Favored 'General case' 0 C--N 1.309 -1.191 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.1 m -93.51 -52.88 4.29 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.152 -1.425 . . . . 0.0 107.152 176.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.639 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.02 -70.92 0.0 OUTLIER Pre-proline 0 C--O 1.213 -0.831 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.963 175.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.639 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.9 Cg_endo -98.49 12.92 0.74 Allowed 'Trans proline' 0 N--CA 1.44 -1.625 0 CA-C-N 120.738 1.299 . . . . 0.0 111.348 -178.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.412 HG22 ' HD2' ' A' ' 21' ' ' PRO . 3.6 m -152.5 133.09 4.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.66 0 CA-C-O 121.453 0.644 . . . . 0.0 112.417 -178.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.553 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 78.2 m -90.72 57.79 3.68 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.044 177.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 21.4 m . . . . . 0 C--N 1.324 -0.521 0 CA-C-O 121.242 0.544 . . . . 0.0 111.474 -178.865 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 N--CA 1.458 -0.062 0 CA-C-O 121.321 0.581 . . . . 0.0 110.72 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 32.6 m -79.63 -24.67 41.76 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.338 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 63.11 33.38 87.1 Favored Glycine 0 C--N 1.333 0.38 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.456 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 3.2 tp10 -127.28 151.96 48.06 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 114.804 -0.698 . . . . 0.0 110.0 -178.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.57 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -113.79 144.59 42.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.385 178.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.5 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.4 p -119.39 40.66 3.29 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-O 121.289 0.566 . . . . 0.0 110.319 178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.401 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.6 t -55.61 -21.93 11.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.227 179.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.81 26.25 21.58 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.776 -0.726 . . . . 0.0 111.519 178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.01 36.59 89.05 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.661 -0.27 . . . . 0.0 112.482 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.55 140.86 22.3 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.5 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 89.0 m -124.99 123.87 40.78 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.178 178.489 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 69.0 m-80 -73.59 -35.02 65.35 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.109 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.619 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -71.45 116.69 49.98 Favored Pre-proline 0 C--O 1.234 0.261 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.438 179.61 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_exo -73.86 119.83 6.08 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 122.443 2.095 . . . . 0.0 112.948 -179.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 110.06 -8.29 31.27 Favored Glycine 0 N--CA 1.45 -0.414 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.916 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.619 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.3 m -88.92 130.89 35.35 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.977 0.418 . . . . 0.0 111.518 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.5 t -88.11 144.93 26.21 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 178.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 36.5 t -103.17 132.01 49.76 Favored 'General case' 0 C--N 1.312 -1.062 0 N-CA-C 113.731 1.011 . . . . 0.0 113.731 -177.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.3 m -95.97 -52.66 3.96 Favored 'General case' 0 C--N 1.329 -0.312 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 176.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.5 t90 178.99 -69.63 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.667 0 CA-C-N 113.708 -1.587 . . . . 0.0 110.467 175.423 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.0 Cg_endo -98.1 9.94 1.02 Allowed 'Trans proline' 0 N--CA 1.442 -1.544 0 CA-C-N 120.567 1.238 . . . . 0.0 111.615 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.41 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.8 m -152.39 135.18 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.699 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.62 -178.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.506 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 84.7 m -90.04 37.74 0.9 Allowed 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.277 178.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 25.8 m . . . . . 0 C--O 1.238 0.468 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.525 179.98 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 27.5 m . . . . . 0 N--CA 1.454 -0.262 0 CA-C-O 120.655 0.264 . . . . 0.0 110.741 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 82.7 m -79.42 -21.49 45.49 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.409 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.23 28.87 74.06 Favored Glycine 0 C--N 1.334 0.418 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.112 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 27.3 tt0 -112.12 147.78 35.37 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.653 -179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.561 HG22 ' O ' ' A' ' 21' ' ' PRO . 78.8 p -101.73 142.62 32.79 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 120.688 0.28 . . . . 0.0 110.44 179.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.507 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.1 p -119.72 42.7 2.84 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 121.313 0.578 . . . . 0.0 110.198 178.471 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.7 t -52.51 -21.96 3.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 114.93 -1.032 . . . . 0.0 111.136 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -109.74 24.62 19.08 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.658 -0.782 . . . . 0.0 111.549 178.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 62.67 36.31 93.09 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 112.235 -0.346 . . . . 0.0 112.235 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 19.2 p -142.04 133.85 27.13 Favored 'General case' 0 C--N 1.33 -0.259 0 N-CA-C 112.645 0.609 . . . . 0.0 112.645 -179.036 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.507 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.5 m -126.58 129.09 47.88 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 177.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.0 m-80 -81.21 -34.53 32.19 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.41 ' HA ' ' HD2' ' A' ' 14' ' ' PRO . 0.2 OUTLIER -77.59 117.31 64.79 Favored Pre-proline 0 N--CA 1.447 -0.589 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.862 179.245 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 13' ' ' THR . 24.5 Cg_endo -63.38 -39.53 36.64 Favored 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 123.169 2.579 . . . . 0.0 113.878 -178.46 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -75.69 33.6 1.2 Allowed Glycine 0 C--N 1.321 -0.28 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.815 -178.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 11.0 m -150.9 135.04 16.8 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-O 120.957 0.408 . . . . 0.0 111.816 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.9 t -89.12 -161.22 0.74 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 107.645 -1.243 . . . . 0.0 107.645 177.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 35.1 t -144.29 130.78 19.92 Favored 'General case' 0 C--N 1.321 -0.656 0 C-N-CA 119.759 -0.776 . . . . 0.0 112.951 -179.694 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 35.7 t -93.35 -52.81 4.35 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 176.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.634 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.7 t90 179.3 -70.16 0.0 OUTLIER Pre-proline 0 C--O 1.214 -0.781 0 CA-C-N 114.005 -1.452 . . . . 0.0 110.407 175.829 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.634 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.76 9.42 1.13 Allowed 'Trans proline' 0 N--CA 1.441 -1.598 0 CA-C-N 120.742 1.301 . . . . 0.0 111.711 -178.526 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.8 m -151.81 129.28 2.31 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.595 0.712 . . . . 0.0 112.396 -178.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.413 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 82.4 m -83.34 72.32 10.21 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.215 177.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 8.9 m . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.315 -178.876 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 N--CA 1.455 -0.175 0 CA-C-O 120.803 0.335 . . . . 0.0 110.77 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.466 ' SG ' ' HA ' ' A' ' 24' ' ' THR . 29.0 m -79.36 -27.34 41.96 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.132 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 68.46 31.08 73.45 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.555 -0.748 . . . . 0.0 112.831 179.299 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 10.9 tp10 -133.27 154.03 51.04 Favored 'General case' 0 C--N 1.32 -0.675 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.654 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 21' ' ' PRO . 62.8 p -106.91 148.06 29.05 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 120.947 0.403 . . . . 0.0 110.736 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.437 ' HB3' ' SG ' ' A' ' 23' ' ' CYS . 4.1 p -121.97 39.02 3.98 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.514 0.673 . . . . 0.0 110.02 178.18 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.451 HG23 ' HB ' ' A' ' 5' ' ' THR . 23.0 t -56.32 -21.24 11.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.226 179.567 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -105.63 25.91 22.94 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.814 -0.708 . . . . 0.0 111.55 178.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.44 38.71 93.89 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 121.682 -0.294 . . . . 0.0 112.399 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.18 140.16 21.96 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.35 0.5 . . . . 0.0 112.35 -179.117 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 18' ' ' CYS . 91.9 m -123.4 127.34 48.31 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.556 178.028 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -77.45 -38.52 49.27 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-N 115.127 -0.942 . . . . 0.0 110.759 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.761 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -70.65 118.31 63.63 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.388 179.671 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 11.9 Cg_exo -70.74 119.18 6.13 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.342 2.028 . . . . 0.0 112.711 -179.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 108.19 -4.43 33.53 Favored Glycine 0 N--CA 1.449 -0.456 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.831 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.761 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 89.9 m -88.5 131.52 34.87 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.219 0.533 . . . . 0.0 111.596 -179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -88.44 142.76 27.45 Favored 'General case' 0 N--CA 1.447 -0.59 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 178.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.443 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 31.0 t -103.04 130.11 50.04 Favored 'General case' 0 C--N 1.315 -0.909 0 N-CA-C 113.072 0.768 . . . . 0.0 113.072 -178.048 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.14 -52.5 4.8 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 106.562 -1.644 . . . . 0.0 106.562 176.2 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.63 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.7 t90 178.58 -68.52 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.656 0 CA-C-N 113.648 -1.615 . . . . 0.0 110.396 175.399 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.63 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.4 Cg_endo -98.05 6.66 1.22 Allowed 'Trans proline' 0 N--CA 1.44 -1.673 0 CA-C-N 120.24 1.121 . . . . 0.0 112.126 -178.194 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.5 m -152.33 133.74 5.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 -178.563 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.437 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.8 m -93.36 130.83 39.0 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.102 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.466 ' HA ' ' SG ' ' A' ' 2' ' ' CYS . 11.6 t . . . . . 0 C--N 1.326 -0.454 0 C-N-CA 121.08 -0.248 . . . . 0.0 111.222 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 43.2 t . . . . . 0 CA--C 1.52 -0.183 0 CA-C-O 121.268 0.556 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.5 m -78.87 -22.3 46.22 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.433 179.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 58.27 28.97 62.39 Favored Glycine 0 C--N 1.334 0.465 0 CA-C-N 115.051 -0.977 . . . . 0.0 113.309 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -124.77 153.28 42.69 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 120.7 0.286 . . . . 0.0 110.524 -179.669 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.522 HG22 ' O ' ' A' ' 21' ' ' PRO . 67.4 p -105.79 147.47 28.6 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.249 179.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.574 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.7 p -118.62 41.69 2.93 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-O 121.487 0.66 . . . . 0.0 110.085 178.162 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 27.8 t -56.25 -22.7 14.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 114.651 -1.159 . . . . 0.0 110.139 179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -102.57 24.47 30.76 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.752 -0.737 . . . . 0.0 111.411 178.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 58.81 33.59 73.89 Favored Glycine 0 N--CA 1.449 -0.435 0 CA-C-N 115.5 -0.35 . . . . 0.0 112.354 -179.582 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.48 140.22 21.73 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.574 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.4 m -122.27 138.33 54.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.295 179.173 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -74.2 -46.51 41.47 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.879 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.5 OUTLIER -76.17 118.79 73.83 Favored Pre-proline 0 N--CA 1.449 -0.49 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.304 178.742 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -64.67 -44.19 11.33 Favored 'Trans proline' 0 C--N 1.344 0.33 0 C-N-CA 123.075 2.517 . . . . 0.0 114.061 -177.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -78.32 46.6 2.79 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.314 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.879 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 73.4 m -135.57 131.89 36.5 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.121 0.486 . . . . 0.0 111.907 -178.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -88.39 127.36 35.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.829 179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 25.8 t -93.96 127.59 39.82 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 112.436 0.532 . . . . 0.0 112.436 -178.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 7.1 m -93.57 -52.74 4.35 Favored 'General case' 0 C--N 1.325 -0.469 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 177.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.622 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 179.01 -68.9 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.706 0 CA-C-N 113.657 -1.61 . . . . 0.0 109.866 175.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.622 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 39.4 Cg_endo -98.52 12.95 0.73 Allowed 'Trans proline' 0 N--CA 1.438 -1.735 0 CA-C-N 120.471 1.204 . . . . 0.0 111.386 -178.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.42 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 3.6 m -153.14 134.08 4.72 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.178 0.513 . . . . 0.0 111.978 -178.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.563 ' O ' ' HB3' ' A' ' 16' ' ' CYS . 70.9 m -91.62 34.61 0.97 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.366 -0.833 . . . . 0.0 110.125 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 87.9 m . . . . . 0 C--O 1.237 0.435 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.087 -179.27 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.617 HG22 ' H ' ' A' ' 3' ' ' GLY . 12.0 p . . . . . 0 N--CA 1.455 -0.205 0 CA-C-O 120.756 0.312 . . . . 0.0 110.321 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 61.6 m -79.23 -26.55 42.49 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.594 -179.299 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.617 ' H ' HG22 ' A' ' 1' ' ' VAL . . . 64.25 26.51 70.57 Favored Glycine 0 C--N 1.334 0.464 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.846 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -103.58 155.34 18.61 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 114.676 -0.762 . . . . 0.0 109.939 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.551 HG22 ' O ' ' A' ' 21' ' ' PRO . 82.3 p -107.15 144.1 34.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.848 0.356 . . . . 0.0 110.196 178.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.513 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 4.2 p -121.1 39.09 3.9 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-O 121.398 0.618 . . . . 0.0 110.279 178.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.427 HG23 ' HB ' ' A' ' 5' ' ' THR . 21.8 t -55.35 -22.14 10.84 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 114.671 -1.149 . . . . 0.0 110.157 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -103.55 25.31 27.21 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.502 178.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.29 36.18 87.83 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.407 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.73 139.97 21.25 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.513 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 93.9 m -124.23 120.96 33.74 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.579 177.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.8 m-80 -67.49 -38.65 84.68 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.393 179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 1.1 m -82.18 120.79 77.97 Favored Pre-proline 0 N--CA 1.451 -0.408 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.91 -37.58 26.36 Favored 'Trans proline' 0 N--CA 1.472 0.248 0 C-N-CA 123.099 2.532 . . . . 0.0 113.965 -178.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.42 34.42 0.97 Allowed Glycine 0 CA--C 1.518 0.265 0 C-N-CA 121.22 -0.514 . . . . 0.0 114.033 -178.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 16.5 m -151.15 142.0 22.89 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 120.95 0.405 . . . . 0.0 111.247 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.5 t -89.39 -156.29 0.39 Allowed 'General case' 0 N--CA 1.449 -0.521 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 22.1 t -153.38 129.27 10.22 Favored 'General case' 0 C--N 1.321 -0.633 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.247 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 6.3 p -93.13 -53.12 4.25 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 176.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.6 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 5.8 t90 179.21 -66.85 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 113.585 -1.643 . . . . 0.0 110.37 175.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.6 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 44.8 Cg_endo -97.34 2.78 1.61 Allowed 'Trans proline' 0 N--CA 1.438 -1.791 0 CA-C-N 120.285 1.137 . . . . 0.0 112.383 -178.072 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.4 m -151.15 129.88 2.94 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.765 0.793 . . . . 0.0 112.658 -178.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 81.5 m -82.24 81.41 8.14 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 114.504 -1.225 . . . . 0.0 109.391 178.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.8 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-O 121.041 0.448 . . . . 0.0 111.852 -179.036 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.306 0.575 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 57.0 m -80.16 -17.59 52.03 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.387 179.855 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 67.06 28.62 73.84 Favored Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.581 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.436 ' HG3' ' N ' ' A' ' 5' ' ' THR . 3.3 tp10 -128.06 150.79 49.8 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.005 -0.597 . . . . 0.0 110.144 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.555 HG22 ' O ' ' A' ' 21' ' ' PRO . 75.8 p -112.96 143.04 44.92 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 178.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.518 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.0 p -118.18 40.45 3.17 Favored 'General case' 0 C--N 1.31 -1.12 0 CA-C-O 121.345 0.593 . . . . 0.0 110.571 178.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 22.9 t -55.04 -22.19 10.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.319 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.9 26.73 18.43 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.895 -0.669 . . . . 0.0 111.477 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.13 37.48 91.75 Favored Glycine 0 N--CA 1.45 -0.388 0 CA-C-N 115.576 -0.312 . . . . 0.0 112.632 -179.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.66 140.03 21.37 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -179.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.518 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 75.6 m -126.14 125.17 42.06 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.064 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 70.5 m-80 -77.07 -32.58 56.86 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.3 179.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.471 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -66.72 116.94 40.01 Favored Pre-proline 0 C--N 1.331 -0.212 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.722 179.963 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 10.1 Cg_exo -71.66 118.84 5.85 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 122.51 2.14 . . . . 0.0 112.598 -179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 109.25 -12.56 33.77 Favored Glycine 0 N--CA 1.449 -0.483 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.748 179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.471 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 94.9 m -88.71 136.47 32.98 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.958 0.408 . . . . 0.0 111.418 -179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.5 ' CG2' ' HB ' ' A' ' 24' ' ' THR . 12.9 t -89.09 -161.48 0.77 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 19.3 t -152.99 132.67 13.09 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 113.068 0.766 . . . . 0.0 113.068 -179.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 36.6 t -94.77 -52.64 4.18 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.623 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.9 t90 179.22 -69.23 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.638 0 CA-C-N 114.069 -1.423 . . . . 0.0 110.875 175.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.623 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.5 Cg_endo -97.57 7.34 1.31 Allowed 'Trans proline' 0 N--CA 1.441 -1.58 0 CA-C-N 120.635 1.263 . . . . 0.0 111.996 -178.127 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 5.0 m -152.37 133.12 4.41 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.222 0.534 . . . . 0.0 111.789 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 84.1 m -86.73 115.92 24.49 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.251 -0.886 . . . . 0.0 109.447 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . 0.5 ' HB ' ' CG2' ' A' ' 17' ' ' THR . 6.5 m . . . . . 0 C--N 1.323 -0.557 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.045 -179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 3.8 t . . . . . 0 CA--C 1.528 0.132 0 CA-C-O 121.669 0.747 . . . . 0.0 109.645 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 4.2 m -79.65 -26.87 40.96 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.035 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.13 25.76 71.15 Favored Glycine 0 C--O 1.227 -0.328 0 CA-C-N 115.466 -0.788 . . . . 0.0 113.193 178.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 11.1 tp10 -122.53 152.54 40.26 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.525 HG22 ' O ' ' A' ' 21' ' ' PRO . 68.3 p -106.84 146.89 30.39 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.581 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.498 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.3 p -119.7 39.52 3.61 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.56 0.695 . . . . 0.0 110.056 178.193 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.44 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.7 t -56.49 -21.85 13.67 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 114.646 -1.161 . . . . 0.0 110.253 179.69 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.96 25.6 24.86 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.828 -0.701 . . . . 0.0 111.551 178.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.61 37.93 92.98 Favored Glycine 0 N--CA 1.449 -0.466 0 C-N-CA 121.591 -0.338 . . . . 0.0 112.321 -179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.21 139.02 20.84 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.146 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.498 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 66.1 m -123.48 133.85 53.98 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.384 -0.825 . . . . 0.0 110.027 178.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 61.2 m-80 -80.98 -42.78 20.66 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.615 -179.61 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.647 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.7 OUTLIER -72.22 119.03 72.43 Favored Pre-proline 0 C--N 1.327 -0.373 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 179.175 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.04 -47.3 12.93 Favored 'Trans proline' 0 C--N 1.346 0.442 0 C-N-CA 122.986 2.457 . . . . 0.0 113.834 -178.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -79.34 41.04 2.23 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.564 -0.827 . . . . 0.0 112.188 179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.647 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 74.3 m -140.78 133.57 28.94 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 120.963 0.411 . . . . 0.0 111.403 -178.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 12.5 t -89.4 -159.0 0.54 Allowed 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.441 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.5 t -153.63 129.54 10.22 Favored 'General case' 0 C--N 1.32 -0.679 0 C-N-CA 120.161 -0.616 . . . . 0.0 112.442 -179.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 8.7 m -91.97 -52.84 4.53 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 177.021 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.629 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.0 t90 178.89 -68.44 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.691 0 CA-C-N 113.899 -1.501 . . . . 0.0 110.451 175.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.629 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 43.4 Cg_endo -97.89 9.76 1.08 Allowed 'Trans proline' 0 N--CA 1.441 -1.583 0 CA-C-N 120.402 1.179 . . . . 0.0 111.717 -178.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 4.2 m -152.84 133.17 4.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.099 0.476 . . . . 0.0 111.896 -178.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 80.3 m -85.78 35.8 0.64 Allowed 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.5 178.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 44.8 p . . . . . 0 C--O 1.238 0.469 0 C-N-CA 123.035 0.534 . . . . 0.0 112.056 -179.639 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.498 HG12 ' H ' ' A' ' 3' ' ' GLY . 37.5 t . . . . . 0 N--CA 1.455 -0.197 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 8.0 m -79.39 -25.28 42.18 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.333 -179.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.498 ' H ' HG12 ' A' ' 1' ' ' VAL . . . 62.82 31.62 80.97 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.475 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 4.4 tp10 -128.04 150.2 50.04 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-N 114.858 -0.671 . . . . 0.0 110.407 -178.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.554 HG22 ' O ' ' A' ' 21' ' ' PRO . 70.4 p -113.61 145.09 41.82 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.336 178.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.533 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 3.3 p -120.18 40.0 3.56 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-O 121.354 0.597 . . . . 0.0 110.17 178.429 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.7 t -54.35 -21.94 7.48 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.633 179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.04 23.48 25.34 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.666 -0.778 . . . . 0.0 111.672 178.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 63.58 34.97 91.37 Favored Glycine 0 N--CA 1.449 -0.484 0 CA-C-N 115.571 -0.315 . . . . 0.0 112.45 -179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 15.8 p -143.34 132.95 23.66 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.533 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 61.2 m -122.4 119.86 32.26 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.244 177.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 67.2 m-80 -71.5 -34.78 70.43 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 114.854 -1.067 . . . . 0.0 109.977 179.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -74.5 115.11 40.41 Favored Pre-proline 0 CA--C 1.535 0.369 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_exo -63.93 -45.76 9.85 Favored 'Trans proline' 0 C--N 1.346 0.424 0 C-N-CA 122.879 2.386 . . . . 0.0 113.826 -177.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -81.01 40.87 2.55 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.235 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 76.4 m -142.06 140.11 32.48 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.106 0.479 . . . . 0.0 111.729 -178.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.3 t -89.04 -156.87 0.41 Allowed 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 178.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.436 ' HB2' ' SG ' ' A' ' 11' ' ' CYS . 15.7 t -160.04 130.21 5.45 Favored 'General case' 0 C--N 1.322 -0.592 0 O-C-N 121.963 -0.46 . . . . 0.0 111.876 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 3.3 p -98.46 -52.12 3.74 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.601 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 7.8 t90 179.98 -68.28 0.0 OUTLIER Pre-proline 0 C--O 1.218 -0.602 0 CA-C-N 114.24 -1.345 . . . . 0.0 111.028 175.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.601 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.0 Cg_endo -97.11 6.98 1.46 Allowed 'Trans proline' 0 N--CA 1.439 -1.69 0 CA-C-N 120.786 1.317 . . . . 0.0 112.06 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.429 ' HA ' ' HA ' ' A' ' 5' ' ' THR . 5.0 m -152.15 135.0 6.84 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.76 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.093 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.475 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 90.3 m -77.76 53.31 1.11 Allowed 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.404 -0.816 . . . . 0.0 111.187 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 10.3 t . . . . . 0 C--N 1.327 -0.386 0 CA-C-N 115.772 -0.649 . . . . 0.0 109.911 -179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.228 -0.072 0 CA-C-O 121.184 0.516 . . . . 0.0 110.652 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m -79.87 -14.74 58.43 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.179 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . 65.91 31.93 81.11 Favored Glycine 0 N--CA 1.449 -0.46 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.659 ' HG3' ' SG ' ' A' ' 23' ' ' CYS . 2.4 tp10 -132.97 152.42 51.94 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 114.545 -0.828 . . . . 0.0 109.778 -178.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.564 HG22 ' O ' ' A' ' 21' ' ' PRO . 72.2 p -116.3 142.8 46.37 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-O 121.036 0.446 . . . . 0.0 110.769 179.655 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.9 p -117.5 41.54 2.8 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.265 0.555 . . . . 0.0 110.378 178.32 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 24.0 t -54.7 -21.96 8.49 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.617 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -108.15 22.77 26.66 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.598 178.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 64.41 30.54 78.13 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.624 -0.288 . . . . 0.0 112.596 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.5 p -146.87 134.7 21.25 Favored 'General case' 0 C--N 1.332 -0.19 0 O-C-N 122.678 -0.307 . . . . 0.0 111.524 -179.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 74.9 m -115.34 128.68 56.25 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.818 178.813 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 1.9 m120 -73.65 -34.42 64.96 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.89 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.539 ' HB ' ' SG ' ' A' ' 16' ' ' CYS . 0.2 OUTLIER -68.83 117.45 51.31 Favored Pre-proline 0 C--O 1.232 0.182 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.676 179.842 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 13' ' ' THR . 7.5 Cg_exo -73.27 119.52 6.05 Favored 'Trans proline' 0 N--CA 1.458 -0.563 0 C-N-CA 122.441 2.094 . . . . 0.0 112.855 -179.469 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 107.35 -7.19 36.91 Favored Glycine 0 N--CA 1.45 -0.408 0 CA-C-N 115.791 -0.64 . . . . 0.0 111.987 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.539 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 90.4 m -89.02 142.3 27.75 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 120.934 0.397 . . . . 0.0 111.627 -179.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.7 t -88.53 -162.83 0.89 Allowed 'General case' 0 N--CA 1.45 -0.457 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 23.7 t -155.97 132.1 10.0 Favored 'General case' 0 C--N 1.322 -0.602 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -179.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.1 m -96.83 -51.88 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.62 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 8.1 t90 179.17 -70.27 0.0 OUTLIER Pre-proline 0 C--O 1.216 -0.697 0 CA-C-N 114.156 -1.384 . . . . 0.0 110.721 175.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.62 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 37.2 Cg_endo -98.12 10.39 0.98 Allowed 'Trans proline' 0 N--CA 1.441 -1.603 0 CA-C-N 120.603 1.251 . . . . 0.0 111.606 -178.395 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.7 m -152.6 135.68 7.32 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.37 -178.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . 0.659 ' SG ' ' HG3' ' A' ' 4' ' ' GLU . 75.5 m -90.11 115.06 27.08 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 115.261 -0.882 . . . . 0.0 109.495 178.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 16.4 m . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.909 -178.404 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.4 HG12 ' H ' ' A' ' 3' ' ' GLY . 35.6 t . . . . . 0 N--CA 1.454 -0.273 0 N-CA-C 110.222 -0.288 . . . . 0.0 110.222 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.522 ' SG ' ' HB ' ' A' ' 13' ' ' THR . 35.2 m -78.65 -31.69 46.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.27 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.4 ' H ' HG12 ' A' ' 1' ' ' VAL . . . 67.39 20.6 71.69 Favored Glycine 0 C--N 1.332 0.339 0 CA-C-N 115.94 -0.573 . . . . 0.0 112.993 178.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 7.3 tp10 -97.05 157.23 16.01 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 179.483 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.545 HG22 ' O ' ' A' ' 21' ' ' PRO . 64.7 p -100.61 144.86 29.09 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-O 121.054 0.454 . . . . 0.0 110.504 178.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.562 ' HB3' ' SG ' ' A' ' 11' ' ' CYS . 2.4 p -120.77 41.57 3.25 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.602 0.715 . . . . 0.0 109.906 178.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.42 HG23 ' HB ' ' A' ' 5' ' ' THR . 24.9 t -56.06 -22.75 14.29 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.272 179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.32 23.43 35.3 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.722 -0.751 . . . . 0.0 111.351 178.752 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 59.31 32.48 72.38 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.504 -0.348 . . . . 0.0 112.321 -179.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.85 139.54 20.7 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 112.133 0.42 . . . . 0.0 112.133 -179.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' CYS . . . . . 0.562 ' SG ' ' HB3' ' A' ' 6' ' ' CYS . 86.6 m -118.63 137.39 53.31 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.295 179.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -76.53 -43.89 37.33 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.919 0.39 . . . . 0.0 110.07 179.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 2' ' ' CYS . 0.2 OUTLIER -78.58 122.05 84.41 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.121 179.209 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_endo -65.6 -37.15 30.23 Favored 'Trans proline' 0 N--CA 1.472 0.249 0 C-N-CA 123.047 2.498 . . . . 0.0 113.692 -178.653 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -74.74 35.9 1.02 Allowed Glycine 0 C--N 1.321 -0.28 0 CA-C-N 115.991 -0.549 . . . . 0.0 113.899 -178.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 15.2 m -150.73 140.74 22.02 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 120.967 0.413 . . . . 0.0 111.258 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.8 t -89.57 -151.61 0.23 Allowed 'General case' 0 N--CA 1.447 -0.584 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 178.057 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 29.3 t -158.06 128.91 6.4 Favored 'General case' 0 C--N 1.321 -0.651 0 C-N-CA 119.996 -0.682 . . . . 0.0 112.569 179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.2 m -90.69 -51.87 5.16 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 176.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TRP . . . . . 0.627 ' HB3' ' HD3' ' A' ' 21' ' ' PRO . 6.6 t90 178.62 -69.36 0.0 OUTLIER Pre-proline 0 C--O 1.217 -0.632 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.108 175.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.627 ' HD3' ' HB3' ' A' ' 20' ' ' TRP . 42.3 Cg_endo -97.76 10.5 1.06 Allowed 'Trans proline' 0 N--CA 1.44 -1.632 0 CA-C-N 120.421 1.186 . . . . 0.0 111.45 -178.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.6 m -152.33 129.42 2.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.509 0.671 . . . . 0.0 112.457 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' CYS . . . . . . . . . . . . . 73.7 m -82.09 78.25 8.8 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.038 177.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' THR . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.325 -0.499 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.214 -178.684 . . . . . . . . 0 0 . 1 stop_ save_